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ABSTRACT 
 
Most of the load-bearing demand placed on the human body is transduced by skeletal 
tissue, and the capacity of the skeleton to articulate in various opposing directions is 
essential for body movement and locomotion. Consequently, cartilage and bone defects 
due to trauma, disease, and developmental abnormalities result in disabling pain and 
immobility for millions of people worldwide. A novel way of promoting cartilage and 
bone regeneration is through the incorporation of either primary cells or multipotent 
progenitor cells in a three-dimensional (3D) biomaterial scaffold, and/or the addition of 
exogenous growth and differentiation factors. The first part of this study reports a 
protocol for using freshly isolated mature chondrocytes seeded in a 3D hydrogel 
biomaterial scaffold, developed to explore mechanotransduction of engineered cartilage 
constructs cultured in a designed bioreactor. The bioreactor was designed to allow the 
application of physiological mechanical forces (compression and fluid flow), as well as a 
non-invasive/non-destructive method for analyzing regenerating tissue in real time 
through ultrasound transducers and a computerized monitoring system. In the second part 
of this study, an engineered immortalized osteoprecursor cell line, designated OPC1 
(osteoblastic precursor cell line 1), was used as a culture model system for exploring the 
effects of exogenous growth and differentiation factors, mainly vitamin D, on early bone 
development. OPC1 was previously designed to provide a consistent reproducible culture 
system for direct comparisons of engineered bone constructs, evaluating bone 
development and cell/biomaterial interactions, and for investigating putative bone 
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differentiating factors. One of the objectives of this research effort was to explore tissue 
development and regeneration by culturing OPC1 in the presence of vitamin D 
metabolites vitaD3 and 1,25OH2D3, while assaying the concomitant biological response. 
Results indicate that OPC1 is capable of metabolizing the parental metabolite vitaD3, and 
thus 25OHD3, to the active vitamin D form 1,25OH2D3. The metabolism of vita3 resulted 
in an anti-proliferative and pro-differentiative influence on OPC-1 . These results support 
the hypothesis that extra-endocrine synthesis of 1,25OH2D3 functions in a tissue specific 
manner to regulate growth and differentiation, in addition to the classic calcimic actions 
of the vitamin D endocrine pathway. Understanding the influence of vitamin D on bone 
development will have significant implications on healthy aging, including the 
susceptibility to skeletal disorders involved in development and aging, such as 
osteoarthritis (OA) and osteoporosis.  
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deposition in comparison with the treatment groups. By week three of culture, there was a 
significant (P<0.01) amount of calcium deposition detected by ARS in cells treated with 
either vitaD3 or 1,25OH2D3 compared to that of the ethanol control. There was a 
significant (P<0.001) amount of calcium deposition compared to all BM- groups (see 
Figure 6-2). [p. 169].  
 
Figure 6-5. Induced mRNA expression of (A) CYP27A1, (B) CYP27B1, (C) CYP24A1, 
and (D) VDR in OPC1 by vitaD3 and 1,25OH2D3 in standard bone medium (BM-) and 
medium containing osteogenic factors (BM+ and BMP+). Total RNA was isolated and 
examined by quantitative RT-PCR. Data was normalized to GAPDH. [p. 171].  
 
Figure 6-6. Induced mRNA expression of (A) proColI, (B) OC, and (C) OP mRNA in 
OPC1 cultures containing vitaD3 or 1,25OH2D3 and/or osteogenic factor (BM+ or 
BMP+). Total RNA was isolated and examined by quantitative RT-PCR. Data was 
normalized to GAPDH. [p. 173].  
 
Figure A-1. OPC-1 Aggregate Data, cell population over time. [p.207].  
 
Figure A-2. OPC-1 Isolated Test Group Data, cell population over time. [p. 207].  
 
Figure A-3. MC3T3-E1 Aggregate Data, cell population over time. [p. 208].  
 
Figure A-4. MC3T3-E1 Isolated Test Group Data, cell population over time. [p. 208].  
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Figure A-5. Dissection of cartilage from the bovine metacarpophalangeal joint. (A) The 
skin is removed, exposing the outer joint capsule. (B) An incision through the anterior 
surface of the join capsule is made which spares the cartilage within. (C) After the joint 
has been opened and exposed, a scalpel is used to excise articular cartilage by shaving 
along the curved surface of the exposed joint. (D) The same joint with some of the 
cartilage removed, revealing the underlying bone [Liebman and Goldberg, 2001].  [p. 
213].  
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2D   Two-dimensional 
3D   Three-dimensional 
7-DHC  provitamin D3 D7-dehydrocholesterol 
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ACT   Autologous chondrocyte transplantation     
ALP   Alkaline phosphatase 
ARS   Alizarin red stain 
BGLAP  Bone gamma carboxyglutamate protein, osteocalcin 
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BM+   Standard bone medium containing common osteogenic factors 
BMP   Bone morphogenetic protein, see rhBMP-2 
BMSC   Bone marrow stromal cell 
BSPI   Bone Sialoprotein I 
ColI   Collagen Type I 
ColII   Collagen Type II 
ColX   Collagen Type X 
CYP   Cytochrome P450 oxidase 
CYP24A1  vitamin D 24-hydroxylase 
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DBD   DNA binding domain 
DBP   Vitamin D binding protein 
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Chapter I. INTRODUCTION 
 
Section 1.01 Tissue Engineering 
Cartilage and bone defects are one of the most common causes of long-term 
disability world-wide, an economic burden with an annual cost that exceeds 28 billion 
dollars in orthopedic repair each year in the United States alone, and the number 
continues to increase with an aging population suffering from bone and cartilage defects 
caused by deterioration, disease, and trauma [Chao et al., 2007; Mason et al., 2011]. 
Tissue engineering (TE) and regenerative medicine are multidisciplinary fields that 
integrate the principles of engineering (material sciences and biomedical engineering) 
and life sciences (biochemistry, genetics, cellular and molecular biology) to develop 
biological cellular/tissue/organ replacements that can repair, restore, maintain or improve 
tissue function [Brockbank, 2000], and provides a promising solution for cellular and 
tissue replacement therapies as well as an alternative for animal models used in clinical 
research. 
TE has two applications: therapeutic and diagnostic. Therapeutic applications 
involve growing tissue either in vivo or ex vivo for subsequent transplantation, while 
diagnostic applications involve growing tissue in vitro and using the tissue to study 
biological mechanisms such as drug metabolism, uptake, and toxicity.  The foundation 
for most TE strategies, whether therapeutic or diagnostic, encompasses living cells 
combined with a biomaterial scaffolds capable of mimicking the tissue-specific ECM, 
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signaling factors that promote growth and differentiation, and/or specialized culture 
devices or bioreactor that can facilitate growth and differentiation by creating physical 
conditions that closely resembles the native environment [Tortelli & Cancedda, 2009; 
Mason et al., 2011; Chao et al., 2007].  In addition, for diagnostic application of studying 
metabolism of tissue growth and development, mathematical and computational 
modeling can be used to characterize biological phenomena.  
In the case of skeletal tissue, the key to long-term success of cell-based tissue 
engineered constructs, depends largely on its ability to function mechanically and to 
appropriately respond to biological and biomechanical signals [Freed et al., 2006; Haj et 
al., 2005]. In native tissue, the forces created by the environment provides important 
mechanical cues in directing cellular process, including adhesion, spreading, migration, 
cytoskeletal organization, growth, differentiation, apoptosis, and tissue morphogenesis 
[Cheung et al., 2009]. Mechanotransduction, the process of cells transducing mechanical 
signals into chemical signals, is known to play an essential role in bone tissue remodeling 
and repair; for example, dynamic mechanical loading at physiological magnitudes has 
been shown to initiate bone deposition and remodeling in animal models and in organ 
cultures, while the lack of mechanical load results in tissue atrophy and bone loss  [Haj et 
al., 2005].  
There are several factors that need to be taken into consideration for TE 
experimental design, such as cell source and acquisition, and appropriate signaling 
molecules. For example, TE for bone regeneration generally utilizes a combination of 
biomaterial scaffolding with either an osteoblast or precursor cell source and growth 
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factors such as bone morphogenetic proteins (BMPs) [Winn et al., 1999], while many 
studies have indicated that a primary cell culture from mature functional articular 
cartilage, is a logical cell choice for cartilage TE [Hardingham, Tew, & Murdoch, 2002]. 
Each cell source has its benefit and challenge. One of the major challenges of using 
mesenchymal stem cells (MSCs)/progenitor cells for in vitro and in vivo studies is the 
isolation sufficiency and expansion for possible clinical applications [Huang et al., 2012]. 
MSCs and progenitor cells from bone marrow can differentiate into bone, cartilage, fat, 
and fibrous connective tissue when guided by appropriate growth factors, however 
isolates are typically heterogenous and limited by variability in their phenotypes, 
including proliferation capacity, differentiation, expression of cell surface markers and 
ability to secrete cytokines [Pevsner-Fischer, Levin, & Zipori, 2011]. Tissue-specific 
differentiated cells isolated from mature tissue are also limited by the ability to isolate a 
sufficient number of cells and maintain phenotypic stability. Primary cell cultures can 
become senescent or dedifferentiate during the culture period [Fodor, 2003], which 
causes them to loose phenotypic structure and function. In addition, repeated isolations of 
primary human osteoblasts and chondrocytes have been reported to result in cellular 
preparations that have variable differentiation potential and proliferative capacity during 
expansion [Otero et al., 2012; Winn et al., 1999]. The incorporation of growth and 
differentiation factors can facilitate proliferation and differentiation, however cannot 
entirely control for phenotypic variability. Therefore, an established cell line with a 
reproducible stable phenotype is most desirable for the diagnostic application of tissue 
engineering. In the following studies, a primary cell culture protocol was established and 
  
 
 
4
used for cartilage tissue constructs, while an engineered osteoblast precursor cell line 
(OPC1) was used for early bone tissue development.  
 
Section 1.02 Three-Dimensional Culture System 
While there have been rapid advancements in TE, to date, the properties and 
structure of native cartilage and bone tissue have not been entirely mimicked by 
engineered tissues. Limitations of current tissue replacement therapies, such as 
autologous transplantation (the patient receives their own cells/tissue), include difficulty 
in obtaining a required amount of cells for a TE construct, dedifferentiation during 
cellular expansion, degeneration at the donor site, and long-term success rate. 
Reconstruction of skeletal tissue can be accomplished by using an appropriate cell 
source, biomaterial scaffold, and growth factors; however recreating the unique structure 
of ECM and mechanical properties of load-bearing tissue is a major challenge in TE. 
In healthy connective tissue, structural protein fibers such as collagen and elastin 
fibers, which make up the ECM, entangle to form a nonwoven mesh that provides tensile 
strength and elasticity [Zuwei, et al., 2005]. Cells embedded within the tissue are 
responsible for the synthesis and maintenance of the tissue-specific ECM, thus they are 
the true “tissue engineers.” It is the unique make-up of the ECM that allows mechanical 
movement of the body. In order to successfully engineer load bearing connective tissue, 
the distinctive structure and function that gives the tissue the capability of bearing 
mechanical loads during daily activities has to be mimicked. It has been demonstrated 
that cells often exhibit unnatural behavior when they are excised from their native 3D 
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environment and confined to a two-dimensional (2D) monolayer. A 2D monolayer 
environment allows cells to attach to the bottom of culture vessels and gradually spread, 
which causes them to lose their spherical morphology and acquire an elongated 
fibroblast-like phenotype. Morphological alterations acquired in 2D culture are 
accompanied by critical biochemical changes, which change the functionality of the cell.  
 
(i) Biomaterial Scaffolds 
In order to enhance cell and tissue growth, and maintain phenotype in vitro, 
many studies have indicated the usefulness in employing a biomaterial scaffold as 
a vehicle for growing tissue constructs [Tellisi & Nureddin, 2007]. Biomaterial 
scaffolds can be used to recreate the native 3D environment and mimic the 
physical structure, biological function, and biochemical nature of ECM 
[Villanueva, Weigal, & Bryant, 2009]. In order for a biomaterial to function as an 
ECM-like scaffold, a number of considerations and criteria have to be met, 
depending on the TE application, such as biocompatibility, biodegradability, and 
mechanical property.  
Native ECM is a physical substrate that doesn’t just provide physical 
support for cells and tissue, but also contains specific ligands for cell adhesion 
and migration, as well as signaling factors that regulates and facilitates cellular 
proliferation, differentiation, and function [Zuwei, et al., 2005]. Cartilage and 
bone regenerative therapeutics under clinical development, have utilized 
  
 
 
6
biomaterials as scaffolds to provide an anchor for attachment and differentiation 
of endogenous migratory precursor cells [Winn, et al., 1999]. Cells must adhere, 
migrate, proliferate, function, and secrete ECM macromolecules within the 
provided space of the scaffold. Therefore, the scaffold has to be porous and 
biocompatible, and for therapeutic TE constructs, it has to be non-immunogenic 
and biocompatible with the body. 
The overall purpose of the scaffold is to serve as a temporary support for 
growing cells and new tissue formation, therefore it must be biodegradable in a 
such a way that the scaffold degrades at a complimentary rate to the cellular 
proliferation and ECM development, ultimately resulting in a TE construct that 
consists entirely of newly formed tissue. During healthy balanced tissue 
development and regulation, growth factors stimulate the anabolic synthesis of 
ECM macromolecules, a process that is complimented by the catabolic 
degradation of ECM during tissue remodeling and repair [Saha & Kohles, 2010; 
Saha & Kohles, 2011].  In order for this process to take place in vitro, the 
biomaterial scaffold needs to degrade at a rate that compliments the synthesis of 
neotissue, be responsive to the local biological environment, and provide the 
appropriate physical cues [Bahney, et al., 2011].  
In addition to facilitating permeation, attachment, proliferation, 
differenitation, and ECM turnover, the architecture of the scaffold has to mimic 
the mechanical strength of native tissue. One of the greatest challenges of 
engineering load-bearing tissue like cartilage and bone is producing a scaffold 
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with adequate mechanical properties [O'Brien, 2011]. A scaffold needs to have 
sufficient mechanical integrity to function from the time cells are seeded within it 
to the completion of tissue remodeling. Therefore, the scaffold needs to maintain 
its mechanical property as it degrades and is replaced with tissue-specific ECM.  
             
(ii) Mechanical stimulation using a bioreactor 
Conventional tissue culture methods are limited in their ability to replicate the 
physiological anabolic and catabolic environment of the body. Normal cells and 
tissue are continuously exposed to various forms of physiological stresses and 
stimuli. Cells extracted from a 3D environment and expanded in a 2D monolayer 
tend to dedifferentiate as they adhere and spread along the surface of the culture 
vessel. Dedifferentiated cells that have been expanded in a 2D monolayer have 
the capacity to redifferentiate if they are transferred into a 3D environment that 
supports their native morphology; however, their original phenotype may not be 
fully re-acquired if the in vitro environment does not mimic the physical native 
environment [Barbero & Martina, 2007]. When 3D cellular constructs are grown 
in static culture, cells on the outer surface of the constructs are typically viable 
and proliferate, while cells within the construct may be less active or necrotic 
[Cartnmell, et al., 2003].  
3D culture techniques that encompass biomaterials allow spherical cells to 
remain round, yielding cells that continue to express tissue specific genes, but are 
limited relative to proliferation capacity and lack the ECM molecules found in 
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native tissue [Choi, et al., 2007]. Mechanical stimulation (fluid, solid, thermal, 
etc.) of 3D constructs consisting of cells, biomaterials, and growth factors have 
shown promising results in the production of viable load-bearing tissues such as 
cartilage and bone [Kohles, Wilson, & Bonassar, 2007]. The transduction of 
mechanical signals  to chemical signals from cell-cell and cell-ECM interactions 
determines the formation of healthy tissue morphology. Thus, preserving these 
interactions is essential in recreating the native tissue.  
A bioreactor is a tissue-culture device that provides a controllable, 
physically active environment that can be used to study and potentially improve 
engineered tissue structure and properties [Freed, et al., 2006]. For the cultivation 
of engineered tissues, bioreactors can improve construct shape and size, cell and 
ECM density and molecular composition, and can permit the studies of (i) mass 
transport of oxygen and signaling factors, (ii) hydrodynamic conditions, and (iii) 
mechanotransduction [Freed, et al., 2006], as well (iv) the study of drug 
metabolism, intake and toxicity. Utilizing a bioreactor can help recreate the native 
physiological mechanical environment and facilitate tissue development.  
A novel bioreactor has been fabricated by Portland State University’s 
Regenerative Bioengineering Laboratory, capable of providing mechanical 
stimulation (compressive loading and fluid perfusion), real-time mechanical 
characterization, optical inspection, and non-destructive ultrasonic assessment of 
ECM-biomaterial content (Figure 1-1). The device combines a linear actuator 
(Electro Force, Bose, Eden Prairie, MN) connected to five load transducers 
  
 
 
9
(1,000g, +/- 0.15 to 0.25%, Model 31 Mid, Sensotec/Honeywell, Golden Valley, 
MN) connected to solid platens that contact specimens from above and apply 
compressive solid mechanical loads. The actuator can be controlled via 
displacement (+/- 2.5 mm) or force (20 N) to apply a variety of waveforms (Win 
Test, Bose) for dynamic stimulation of five concurrent cube-shaped test samples. 
Access for a digital video microscope and ultrasound transducers facilitates the 
minimally invasive assessment of cultured tissue constructs. The entire bioreactor 
can fit inside an incubator (Galaxy R Series Incubator, New Brunswick, Edison, 
NJ) with sensor control of the internal environment chemistry, carbon dioxide 
(CO2), oxygen (O2), and nitrogen (N2). The bioreactor is capable of controlled 
monitoring of biological, chemical, and mechanical components associated with 
engineered tissue constructs, which includes cells, biomaterials, growth 
stimulants/inhibitors, and the developing neotissue in order to address the 
complexities of developing native tissue.  
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Figure 1-1: The fabricated, novel multiphysics bioreactor with five culture wells. The high-
resolution, copper-colored load-cells measure the dynamic loads transferred via the load-rods 
through the square load-platens into the culture-well designs (upper right) and onto the cell-
biomaterial constructs (pink cube, lower right) [Mason et al., 2011; Kohles et al., 2011]. 
 
 
(iii) Nondestructive techniques to assess 3D tissue constructs 
Most mechanical and biochemical assessment of engineered tissue constructs 
require destructive endpoint-testing and/or compromise the sterility of the 
bioreactor environment used during construct formation [Walker, et al., 2011]. 
Ultrasonic imaging is a standard clinical diagnostic tool that is based on 
propagating high-frequency (HF) sound waves and offers a technology for tissue 
characterization and stimulation in a noninvasive and nondestructive manner. The 
response to mechanical stimulation induced in passive tissues by external sources 
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such as low to high frequency vibration or compression can be used to analyze 
tissue elasticity as a metric for tissue health [Hein & O'Brien, 1993]. Recently, it 
has been shown that ultrasonic assessment can predict the process of native 
cartilage regeneration and engineered cartilage histology [Hattori, et al., 2005].   
The bioreactor described in the previous section has the capability of 
providing ultrasonic assessment of 3D engineered tissue constructs. As a 
ultrasonic wave passes through a specimen, the speed of attenuation provides a 
metric associated with the density of accumulated matrix molecules, while the 
speed of sound is associated with Young’s Modulus or elasticity (stress-strain) 
[Kohles, Bowers, Vailas, & Vanderbery, 1997]. When a sound wave travels 
through a medium, its amplitude decreases with distance. In homogenous 
materials, the amplitude of sound waves are only reduced by the spreading of the 
wave, however, in natural heterogenous materials, objects within the medium 
(such as cells in tissue) weakens the amplitude which results from scattering (the 
reflection of the sound waves in other directions) and absorption (the conversion 
of sound energy to other energy forms) of the sound wave. Ultrasonic attenuation, 
the decay rate of the wave as it propagates through the material, can be used to 
explain physical or chemical phenomenon that decreases ultrasonic intensity, 
while the speed of sound, which is related to elastic property and material density, 
can be used to describe the mechanical property.  Therefore, ultrasound provides a 
nondestructive means to assess the mechanical properties of growing engineered 
tissue in real time 
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Section 1.03 Cartilage Tissue Engineering 
Cartilage disease and injury affects more than 15% (approximately 40 million people) 
of the US population and with more than 250,000 knee and hip replacements performed 
each year, exceeds an annual cost of $60 billion per year [Chung & Burdick, 2008; 
Steward, Liu, & Wagner, 2011]. With an aging population suffering from defects or 
deterioration of articular cartilage by OA and trauma, the number continues to increase. 
Articular cartilage provides a unique challenge for tissue engineering in that its structure 
appears simple and it only contains one cell type, the chondrocyte, however the ECM is 
highly organized and complex [Hardingham, et al., 2002]. Articular cartilage is not 
innervated and avasculature so normal mechanisms involving the recruitment of cells 
from blood or bone marrow to a wound site, can not occur, limiting the capacity of self-
repair [Vinatier, et al., 2009; Hardingham, et al., 2002]. In cases of cartilage damage 
caused by trauma, severe injuries are frequently followed by degeneration [Appleman, et 
al., 2009]. Because chondrocytes do not sustain a healing response on their own, tissue 
engineering has the potential to provide functional cartilage tissue to help the millions of 
people who suffer from degenerated, diseased, or damaged articular cartilage.  
There have been rapid advancements in cell-based therapies, which include the in 
vitro engineering of functional tissue substitutes for subsequent in vitro transplantation 
[Chung & Burdick, 2008]. To date, however, the properties and structure of native 
cartilage tissue have not been entirely mimicked by engineered tissue. Limitations of the 
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current solutions such as autologous chondrocyte transplantation (ACT) include difficulty 
in obtaining a required amount of cells for a construct and cellular dedifferentiation 
during expansion, as well as degeneration at the donor site. Although recorded success 
rates of ACT are between 60-90% depending on the localization of the injury [Yilmaz, et 
al., 2010], long-term success rates are considerably lower.  
Articular cartilage is a highly specialized tissue that reduces joint friction at the 
extremities of long bones, and helps absorb mechanical load. Articular cartilage consists 
of chondrocytes and ECM that is composed of a network of collagens, particular type II 
collagen (ColII), which gives the tissue its shape and strength, and proteoglycans, which 
give resistance to mechanical stress and compression [Vinatier, et al, 2009; Hardingham, 
et al., 2002]. Although only about 10% by volume, the immobilized chondrocytes 
embedded within the ECM are responsible for the synthesis, organization, and 
maintenance of ECM macromolecules [Pazanno, et al., 2000; Lanza, Langer, & Vacanti, 
2007; Hardingham, Tew, & Murdoch, 2002]. The continuous remodeling of cartilage 
ECM in response to exogenous mechanical stimuli occurs through biokinetic anabolic 
and catabolic reactions of ECM macromolecules [Saha & Kohles, 2011; Saha & Kohles, 
2010a; Saha & Kohles, 2010b], which allow the tissue to respond to the physiological 
environment and protect the underlying bone.  
The structural integrity of cartilage is derived from the fibrous network formed by 
the cartilage-specific collagen type II (ColII), which is immersed in a gelatin formed by 
proteoglycans rich in sulfated glycosaminoglycans (GAG). Because it is abundant in 
sulfate and carboxyl groups, GAG is negatively charged which draws water into the 
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tissue with such high affinity that it makes up ~70% of the total weight creating a large 
osmotic swelling pressure [Wilson, et al., 2002; Hardingham, et al., 2002]. This hydration 
permits the diffusion of water-soluble molecules throughout the tissue. GAG is too large 
and immoble to redistribute itself, therefore swells and expands the ECM, placing the 
collagen network under tension. Equilibrium in the tissue is reached when the tension 
from the collagen network balances the swelling pressure. It is this unique molecular 
combination that allows low friction movement of joint surfaces. In return, joint loading 
from body movement induces fluid flow within the tissue, which maintains ion 
movement, and nutrient/waste exchange, therefore reducing the need for vascularization. 
Recreating this dynamic is a major challenge in TE.  
Because chondrocytes from mature articular cartilage are capable of producing 
ColII and GAG ECM macromolecules, it has been suggested that isolates from adult 
articular cartilage is a logical cell choice for cartilage TE [Hardingham, et al., 2002]. 
Although chondrocytes have been widely used in cartilage repair, they have been shown 
to be unstable when cultured in a standard 2D monolayer. In the body, cells exist, 
proliferate, and differentiate, within a 3D environment, but when chondrocytes are 
cultured in a 2D environment, they tend to lose their overall hyaline structure and 
functional elasticity, thus their overall differentiated phenotype. In vitro expansion of 
static monolayer cultures are associated with cellular dedifferentiation and reduced or 
total loss of the ability to produce ECM and redifferentiate [Barbero & Martina, 2007; 
Barlic & Kregar-Velikonja, 2008; Ando, et al., 2009]. Many authors have described a 
fibrocartilaginous quality observed in chondrocytes prepared in monolayer [Ando, et al., 
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2009]. A 2D environment allows chondrocytes to attach and gradually spread, which 
causes them to lose their spherical morphology and acquire an elongated fibroblast-like 
phenotype. Morphological alterations acquired in monolayer are accompanied by critical 
biochemical changes. Loss of the hyaline morphology is associated with the expression 
or total loss of aggrecan and ColII synthesis, and an increase in the expression of 
fibrocartillage associated ECM molecules collagen type I (ColI) and versican [Barbero & 
Martina, 2007; Barlic & Kregar-Velikonja, 2008].  
Chondrocytes that have dedifferentiated have the capacity to redifferentiate if they 
are transferred to a 3D environment that supports their native spherical morphology; 
however, their original phenotype may not fully be re-acquired [Barbero & Martina, 
2007]. Because cartilage-specific ECM macromolecules bind to water with such high 
affinity, hydrated biomaterials (hydrogels) can be used to recreate the native 3D 
environment and mimic the physical structure, biological function, and biochemical 
nature of cartilage ECM. Natural or synthetic polymers such as proteoglycan aggrecans 
and collagen have been found to provide 3D support, induce chondrocyte proliferation 
and improve their synthetic function [Tellisi & Nureddin, 2007]. Recent studies have 
indicated that bioabsorbable polymers such as polyglycolic acid (PGA), enhances 
proteoglycan synthesis, while collagen scaffolds stimulate collagen synthesis [Atala & 
Lanza, 2002]. It has been shown that 3D cultures, such as those grown in with alginate or 
agarose allows chondrocytes to remain round and supports cartilage-specific gene 
expression [Hardingham, Tew, & Murdoch, 2002], but may be limited relative to 
proliferation capacity and lack the zonal distribution of cells and ECM molecules found 
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in native tissue [Choi, et al., 2007]. Part of the challenge of engineering cartilage is 
providing the essential cells and signals that will establish cartilage ECM and recapitulate 
the molecular organization that forms the basis for the essential mechanical properties of 
the tissue [Hardingham, et al., 2002].  
Although cartilage is made up of only one cell type, it is characterized by zonal 
differences in architecture and distribution of ECM components. There are four 
histologically distinct zones (superficial tangential or resting zone, proliferative of middle 
zone, hypertrophic or deep zone, and the calcified zone) characterized by orientation and 
density of ECM molecules, morphology, and biochemistry [Kohles et al. 2012; Atala & 
Lanza, 2002]. Because of the depth-dependent structural arrangement of chondrocytes 
and ECM macromolecules, articular cartilage is a heterogenous and mechanically 
anisotropic material. Assessing the mechanical properties of cartilage constructs in real-
time via ultrasound while tissue is developing may elucidate the physical interactions and 
localized biomechanics (stresse, strain, and elastic property) between cell-cell and cell 
ECM that occurs within and between zones.  
Healthy chondrocytes undergo hydrostatic, compressive, tensile, and shear forces 
within a physiological environment, which act to maintain the phenotype and promote 
production of new cartilage tissue [Ramage, et al., 2009]. Abnormal mechanical forces, 
such as those sustained in traumatic skeletal injuries, can alter chondrocyte behavior, 
regulating in degradation of cartilage from increased catabolic activity and apoptosis. In 
order to engineer a cartilage construct ex vivo an environment that supports chondrocyte 
development into functional cartilage needs to be recreated, including the appropriate 
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scaffold bioactivity and mechanical stimulation [Appleman, et al., 2009]. Since normal 
cartilage is continuously exposed to various forms of physiological stresses, diffusion-
based nutrient supply is believed to be a vital mechanism for the maintenance of cartilage 
homeostasis, along with the concurrent physiological stimulations [Park, et al., 2007]. 
Utilizing a multi-scale bioreactor as previously described, can recreate native 
biomechanical and biochemical stimuli, facilitate cartilage development investigations, 
and validate ongoing biokinetic modeling. 
Section 1.04 Engineering Bone Development 
Imbalances between osteoblastic bone formation and osteoclastic bone resorption 
can result in a net bone loss and osteoporosis [Hens, et al., 2005]. While many therapies 
aim to inhibit bone resorption, in order to cure skeletal diseases associated with bone loss, 
new bone formation is essential. Bone formation in the embryo or during adult bone 
repair or remodeling involves the progeny of MSCs (osteoprecursors) [Bruder, et al., 
1994]. MSCs are multipotent cells that continuously replicate while a portion become 
committed to the mesenchymal cell lineage such as bone, cartilage, tendon, ligament and 
muscle (see Figure 1-2). Bone regeneration is based on the hypothesis that healthy 
progenitor cells, either recruited or delivered to a bone defect, can regenerate damaged or 
degenerated tissue [Shea, et al., 2000]. Culturing osteogenic cells in an enviornment that 
supports bone formation is a possible solution for the treatment of extensive bone defects 
and osteoprosis. A source of human cells that can be produced in large numbers and can 
predictably differentiate into bone is critical for the therapeutic application of engineering 
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human bone replacements [Marolt, et al.,  2010], and for the diagnostic application of 
studying bone formation in vitro.  
The differentiation of MSCs and progenitor cells within each specialized celular 
lineage is a complex multistep pathway involving discrete cellular transitions that depend 
on the presence of specific signaling factors, nutrients, and environmental cues. An 
important aspect of bone biology is to experimentally address the regulatory events 
related to the commitment of progenitor cells into the developmental pathway and 
elucidating the regulatory factors that influence bone formation, remodeling, and 
regeneration [Lian & Stein, 1995]. While human-derived immortalized and conditionally 
immortalized osteogenic cell lines that have been used as model systems to develop bone 
constructs, a human derived cell-line that exhibits a consistent differentiation pattern and 
is stable over generations is essential for modeling bone development, and for studying 
biomaterial-cellular interactions necessary for optimizing bone regenerative therapies.  
   
  
 
 
 
 
(i) Engineered Osteoprecursor Cell Culture System
Advancements in the design of biomedical engineering technologies, especially 
those supporting regenerative medicine through cell and tissue engineering, 
include the use of precursor cell lines
develop neotissue. A
human fetal bone tissue from the periosteum and femur, was originally 
Figure 1-2. MSC bone developmental pathway. An important aspect of bone biology is to address the 
regulatory events related to commitment of pluri
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, which can consistently be manipulated to 
n osteoblastic precursor cell line (OPC1), derived from 
potent progenitor cells into the developmental pathway that 
 Lian & Stein, 1992]. 
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established to provide a consistent and reproducible culture system for evaluating 
bone development and cell/biomaterial interactions, and for screening putative 
differentiating factors in a culture system that would be applicable to a clinical 
situation [Winn, et al., 1999]. In addition, OPC1 can be used to study the growth 
and differentiation of osteoprogenitors and offers the possibility of examining 
events associated with stem cell differentiation to osteoblasts. Because OPC1 is a 
stable osteoblast precursor that has displayed consistent reproducible cultures, and 
may be useful for elucidating bone differentiation patterns during bone 
development and evaluating putative differentiating factors, it is an ideal culture 
system to study the effects of vitamin D on bone development.  
 
(ii) In vitro bone development  
Several osteoblast culture systems have demonstrated that cells undergo a 
temporal developmental sequence that starts with a proliferation phase and results 
in fully mature osteocyte-like cells embedded in mineralized ECM [Pockwinse et 
al., 1995; Owen et al., 1991]. There are three stages of in vitro bone development 
that have been characterized by morphology and gene expression: (1) a 
proliferation and ECM biosynthesis stage, (2) an ECM development and 
maturation stage noted by an increase in ALP activity, and (3) a final stage of 
ECM mineralization in which hydroxyapetite is organized and deposited (see 
Figure 1-3) [Pockwinse et al., 1995; Owen et al., 1991; Lian & Stein, 1995].  
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In the first stage, following initial cell-seeding, the cells actively proliferate 
for the first 10 to 12 days of culture and several genes associated with ECM 
formation, including procollagen type I (proColI) and osteopontin (OP), are 
actively expressed then gradually decline as proliferation rate decreases and ECM 
maturation begins (see Figure 1-3). Immediately following the decrease in 
proliferation, ALP activity is greatly increased. This post-proliferative period 
occurs between days 12 and 18, and it is during this time that the ECM matures 
and becomes competent for mineralization [Pockwinse et al., 1995; Lian & Stein, 
1995]. ALP expression is used as a marker for osteoblast phenotype, however its 
function still remains unclear. It has been postulated to increase concentration of 
inorganic phosphate, a concept known as the “booster hypothesis” [Golub & 
Boesze-Battaglia, 2007]. During the third stage of bone development, ALP 
expression decreases and other genes associated with bone mineralization are 
expressed at maximal level [Owen et al., 1991; Lian & Stein, 1995; Golub & 
Boesze-Battaglia, 2007], which include OP and osteocalcin (OC) and are known 
to interact with the mineralized ECM in vivo [Lian & Stein, 1995]. OP is 
expressed in both the proliferation and mineralization periods, and down-
regulated post-proliferatively during matrix maturation; however, during 
proliferation, OP expression reaches only about 25% of its maximal level which 
peaks between days 16 and 20 during mineralization. In contrast, OC, the calcium 
binding protein that binds to hydroxyapatite, is expressed only post-proliferatively 
 with the onset of nodule formation, and is expresse
mineralization in vivo 
 
 
 
 
 
Figure 1-3. Temporal expression of cell growth and
formation of bone tissue. This figure is
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d maximally with ECM 
 and in vitro [Lian & Stein, 1995]. 
 osteoblast phenotype during
 based on studies conducted by Lian & Stein, 1995.   
 
 in vitro 
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Section 1.05 Vitamin D 
Vitamin D, also known as calciferol, refers to a collective group of fat-soluble 
pluripotent, seco-steroid metabolites that together carry out the known vitamin D-related 
functions. The classic understanding of vitamin D stems from the essential role it plays in 
the regulation and maintenance of calcium and phosphorous homeostasis and bone 
metabolism. Elucidating the steps required for the metabolism of vitamin D precursors, 
vitaD3 (cholecalciferol) and 25OHD3 (calcidiol), to the active hormone 1,25OH2D3 
(calcitriol) led to the discovery of regulatory cytochrome P-450 (CYP) hydroxylases 
involved in the activation and inactivation of vitamin D, and the nuclear vitamin D 
receptor (VDR) and its interactions with transcriptional machinery inside vitamin D 
target cells [Jones, et al., 1998]. 1,25OH2D3 directly influences osteoblasts, by binding to 
VDR, which consequently elicits nuclear and extra-nuclear cellular responses related to 
the production and maintenance of the skeleton [Biswas & Zanello, 2009].  
Once it was demonstrated that VDR and vitamin D regulatory CYPs were present 
in multiple tissues and cells not involved in the classic endocrine actions of vitamin D, it 
was acknowledged that its functions extended far beyond mineral homeostasis and bone 
metabolism. It is now recognized that vitamin D is associated with the regulation of many 
cellular process including proliferation, differentiation, and apoptosis in multiple tissues 
in an autocrine/paracrine manner [Brannon, 2012; Hobaus et al., 2013; Jones et al., 
1998]. However, because there are few detailed reports of the extrarenal synthesis of 
1,25OH2D3, and limited reporting on the extrahepatic metabolism of vitaD3, extra-
endocrine vitamin D metabolism is not widely recognized.   
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(i) Photosynthesis of Vitamin D 
Vitamin D is one of the oldest prohormes that has been produced by almost all 
life forms for over 750 million years [Hollick, 2003]. The production of vitaD3 
begins with the photosynthesis of the subcutaneous pro-vitamin D 7-
dehydrocholesterol (7-DHC) in the basal and suprabasal layers of the skin when it 
is exposed to ultraviolet (UVB) light (See Figure 1-4) [Hollick et al., 2008; Jones 
et al., 1998; Lehman, 2008]. Once 7-DHC is photochemically transformed to 
previtamin D3 (previtaD3), then it undergoes thermal-isomerization to vitaD3 
[Kumar, 1990; Lehman, 2008; MacLaughlin et al., 1982]. During prolonged 
exposure to the sun, both previtaD3 and vitaD3, undergo reversible 
photoisomerization reactions to biologically inert sterols, including lumisterol and 
tachysterol [Lehman, 2008]. Consequently, this prohibits vitamin D toxicity from 
prolonged sun exposure because it limits vitaD3 formation. PrevitaD3 is also 
subject to reversal leading to the regeneration of 7-DHC [Lehman, 2008]. There 
are several intrinsic and extrinsic factors that influence the conversion of 7-DHC 
to previtaD3, including pigmentation, age, percent of body-fat, latitude, season, 
time of day, and the usage of sunscreen [Lehman, 2008].  
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Figure 1-4. Schematic of photosynthesis, metabolism, and regulation of vitamin D metabolites. Vitamin D 
precursors and metabolites are in black, and metabolic enzymes are in blue.  
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(ii) Vitamin D Metabolism and Regulation 
After vitaD3 is endogenously made from cholesterol via themerisomerization of 
previtaD3, it passively diffuses into the blood and slowly transfers to the vitamin 
D binding protein (DBP), a highly polymorphic glycoprotein that is a member of 
a gene family including albumin and α-fetoprotein [Berg, 1999; Kumar, 1990; 
Ahmed and Shoker, 2010]. Alternatively vitamin D can be acquired by diet in 
either the vitaD3 (derived from animals) or vitaD2 (derived from plants) form. 
VitaD3, the metabolic precursor to 25OHD3, itself is biologically inert, or 
inactive, in that it does not directly increase the active transport of calcium or 
mediate any of the other vitamin D-related activities in physiological 
concentrations unless it its metabolized to a more polar compound (Kumar, 1990).  
There are many metabolites or isomers of vitamin D. The active metabolite, 
1,25OH2D3, and the immediate metabolic precursor to the active metabolite, 
25OHD3, are among the most studied. In the classic endocrine metabolic pathway 
of vitamin D, both endogenous and dietary vitaD3, are transloacted by DBP to the 
liver and kidney, sequentially for bioactivation. Generally, the first stop for 
circulation vitaD3 is the liver, where it is hydroxylated to the major circulating 
form, 25OHD3, by CYP-related 25-hydroxylases CYP2R1 (microsomal) or by 
CYP27A1 (mitochondrial) [Ahmed & Shoker 2010; Norman, 1998; Jones et al. 
1998]. Circulating 25OHD3 from the liver is transported via DBP to the kidney, 
where it is metabolized by the biologically active form 1,25OH2D3 by 25-
hydroxyvitaminD3-1α-hydroxylase (CYP27B1) in the kidneys [Ahmed & Shoker 
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2010; Norman, 1998; Jones et al. 1998]. CYP27B1 is a mixed function oxidase 
comprised of a ferredoxin and an iron sulfur protein, and is regulated by several 
factors that work in concert to maintain normal concentrations of plasma calcium 
and phosphorous [Kumar 1990]. During states of calcium or phosphorus demand, 
1,25OH2D3 is readily converted from the circulating 25OHD3 metabolite; 
conversely, during states of calcium and phosphate homeostatic balance, 25OHD3 
is metabolized to the inactive 24R,25OH2D3 metabolite [Kumar, 1990], which is 
excreted from the endocrine system.  
While early data suggested that the liver is the only significant site of 25-
hydroxylation in vivo, there have been occasional reports of extrahepatic 25-
hydroxylation of vitamin D3 [Jones et al., 1998; Hollick, 2010]. Recently 
extrarenal metabolism of 25OHD3 to 1,25OH2D3 has been demonstrated [Zhou et 
al., 2012; Hobaus et al., 2013]. In vitro, many non-renal cells, including MSCs, 
bone, cartilage, keratinocytes, placenta, prostrate, macrophages, lymphocytes, 
dendritic cells, and several cancer cell lines can convert 25OHD3 to 1,25OH2D3 
[Zhou et al., 2012]. Several of these cell types have been shown to express both 
CYP27A1 and CYP27B1, which may explain the occasional reports of 
extrahepatic 25-hydroxylation of vitaD3 [Lehman, 2008; Hollick, 2010; Jones et 
al.,1998]. Besides the local renal activity of 1,25OH2D3, the hormonally active 
vitamin D metabolite is translocated by DBP to other target tissues that express 
VDR to operate in a genomic or nongenomic manner [Lehman, 2008]. 
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The action of vitamin D is limited by the catabolic enzyme 24-hydroxylase 
(CYP24A1), which results in a compound that is more soluble and has a 
substantially lower affinity for VDR [Trump, et al., 2010; Ahmed & Shoker, 
2010; Ambrecht, et al.,1998]. CYP24A1 has been shown to hydroxylate both 
25OHD3 and 1,25OH2D3 to form 24,25OH2D3 and 1,24,25OH3D3, respectively 
[Flanagan, et al., 2006]. The main function of CYP24A1 is to regulate the 
circulating concentration of vitamin D metabolites. 1,25OH2D3 induces and 
mediates CYP24A1 via an autocatalytic loop through vitamin D response 
elements (VDRE) located in the promoter region of the CYP24 gene [Chen et al., 
2011]. Generally, basal expression of CYP24 is extremely low but the gene is 
highly induced by 1,25OH2D3 [Geng, et al., 2011; Atkins, et al., 2007]. Thus, the 
synthesis and degradation of 1,25OH2D3 is highly regulated, and the concentration 
is controlled at the cellular level.  
 
(iii) Signal Transduction and Gene Expression.  
The molecular effects of vitamin D are mediated through the intra-nuclear 
receptor VDR, which acts as a ligand-activated transcription factor for target 
genes when bound to 1,25OH2D3 [Seiffert et al., 2004]. VDR is a member of the 
superfamily of nuclear hormone receptors, and like other members of the nuclear 
receptor family, is composed of distinct structural domains within the protein that 
include a ligand binding domain (LBD) and DNA binding domain (DBD) 
[Ahmed & Shoker, 2010]. LBD is responsible for hormone binding, strong 
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receptor dimerization and interaction with co-repressors and co-activators, which 
are all essential for the regulation of VDR transcriptional activities.  
VDR has a high affinity for 1,25OH2D3, and following 1,25OH2D3 binding 
forms a heterodimer with the retinoid X receptor, which allows it to bind to the 
response/receptor element (VDRE) in the promoter regions of target genes 
[Flanagan et al., 2006; Brannon, 2012; Geng et al., 2011]. VDR heterodimers and 
associated factors binding to the VDRE of vitamin D responsive genes increases 
the rate of transcription of vitamin D associated genes by RNA polymerase II 
(RNAPII) [Adorini et al., 2007]. Responsive genes include those associated with 
calcium homeostasis, immune response and maintenance of immune cells, 
cellular growth, differentiation, cell cycle arrest, apoptosis, and the enzymes 
required for vitamin D metabolism (Figure 1-5) [Chen et al., 2011; Flanagan et 
al., 2006; Boyan et al., 2009; Geng et al., 2011]. VDR is nearly ubiquitously 
expressed, and almost all cells are genetically regulated by 1,25OH2D3 [Bouillon, 
et al., 2008]. In summary, VDR has been reported to regulate a large range of 
genes (200-3065) and has been estimated to modulate 5-10% of the human 
genome [Morris & Anderson, 2010; Flanagan et al., 2006; Hollick, 2010; 
Norman, 1998; Naeem, 2010]. 
                           
 
(iv) Nongenomic
the word is typically used
It has previously been shown that the nongenotropic actions of 1,25OH
level of the plasma membrane leads
induction of regulated exocytosis in osteoblasts
be related to the bone anabolic functions of the vitamin D 
2009]. In osteoblasts, 1,25OH
opening calcium-
depleting internal Ca
rapid membrane-
binding protein PDIA3 (protein disulfide isomerase, family A, member 3) 
Figure 1-5. The active metabolite of vitaD3, 1,25OH
homeostasis and bone health through its classic hormonal actions in concert with its nuclear 
transcriptional factor, VDR, on ta
 
 
 
30
[not sure what you mean by nongenomic – but this is not 
] Effects of Vitamin D.  
 to the activation of ion channels and the 
. These activities are predicted to 
[Biswas & Zanello, 
2D3 increases intracellular calcium concentration by 
permeating channels present in the plasma membrane and 
2+
 stores [Biswas & Zanello, 2009]. 1,25OH
associated signaling pathways via the 1,25OH
2D3, regulates calciu
rget genes containing the VDRE [Brannon, 2012]
 
how 
2D3 at the 
2D3 initiates 
2D3 membrane 
[Boyan 
m-phosphorous 
. 
  
 
 
31
et al., 2012]. The mechanisms involved in membrane-associated 1,25OH2D3 
signal transduction include activation of voltage gated Ca2+ ion channels and Ca2+ 
influx, as well as activation of several kinase cascades including protein kinase C 
(PKC) [Boyan et al., 2012]. 1,25OH2D3 activates PKC signaling in both 
osteoblasts and chondrocytes via VDR and PDIA3 [Boyan et al., 2012; Olivares-
Navarrete et al., 2012]. 
 
(v) Free Hormones and Local Vitamin D Storage Pools 
The serum concentration of hormones depends on the concentration of their 
respective transport proteins, and only the concentration of free hormone is 
considered to be physiologically important [Boulion, et al.,1981], this concept is 
known as the “free hormone hypothesis”. Vitamin D metabolites are transported 
and circulated throughout the body by DBP, which is generally found in high 
concentrations in plasma. 25OHD3 is the main ligand for DBP, and therefore the 
major “circulating” form. While it was originally thought that there is no 
correlation between the serum concentration of 25OHD3 and DBP, an indication 
that the level of free 25OHD3 is not feedback regulated [Boulion et al., 1981], it 
was recently demonstrated that the amount of DBP inversely influenced the 
available free 25OHD3 in cultured human monocytes [Brannon 2012]. There has 
also been a significant positive correlation between the increase of 1,25OH2D3 
and DBP, which indicates that it is feedback regulated.  
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The binding affinity of vitamin D metabolites to DBP plays a large role in 
regulating vitamin D concentration. 25OHD3 has a very high binding affinity 
(Km) to DBP, and with the high concentrations of DBP seen in plasma (0.3-
0.5mg/ml; 5-6µmol/L) virtually all 25OHD3 molecules in the circulatory system 
are bound to DBP, and only ~0.03% are found in the free form [Ahmed & Shoker, 
2010; Lehman, 2008]. Although 1,25OH2D3 has lower affinity for DBP, 0.4%, 
approximately 6 x 10-13 M, of 1,25OH2D3 circulating in free form, a concentration 
that is approximately ten times lower than 25OHD3 [Lehman, 2008; Berg, 1999]. 
In a study conducted on the serum levels of DBP in pregnant and normal woman, 
it was found that there was a 10-fold difference in free concentrations of 
1,25OH2D3 over 25OHD3, while there was a 320-fold molar excess of total 
25OHD3 over 1,25OH2D3  [Boulion et al. 1981].  
Many studies have shown that antiproliferative effects of 1,25OH2D3 
requires unbound concentrations higher than 10-8 M, which is equivalent to a 
highly unphysiological concentration of approximately 2.5 x 10-6 M circulating in 
blood [Lehman, 2008], although it is believed that local vitamin D storage pools 
throughout the body that may account for this [Brannon , 2012]. According to the 
‘free hormone’ hypothesis, the sterols bound to DPB are a reservoir that can be 
made available to vitamin D receptors or enzymes that modify the sterols by 
dissociation from the DBP [Berg, 1999]. The ‘free hormone’ and ‘local vitamin D 
storage’ hypotheses change the traditional endocrine views of vitamin D 
metabolism, and explain paracrine and autocrine mechanisms of vitamin D 
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metabolism, involved in the regulation of proliferation and differentiation that 
have been observed in vitro in response to supraphysiological doses of 
1,25OH2D3 and 25OHD3 (Figure 1-6 and 1-7).  
DBP may also slow the release of 25OHD3 and regulate the level of free 
sterol available, as free 25OHD3 can diffuse across cell membranes, which 
appears to be nearly a ubiquitous mechanism of vitamin D uptake [Brannon , 
2012], preventing the rapid metabolism and excretion of vitamin D.  
 
  
Figure 1
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Figure 1-7. Traditional 
action (B) based on the ‘free hormone hypothesis’ and the theory of ‘local vitamin D storage 
pool’ [Brannon, 2012; and Berg, 1999]. 
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(vi) The Autocrine/Paracrine Vitamin D Paradigm 
In the early 1900’s vitamin D was the fourth identified essential vitamin, thus 
named vitamin “D” by convention. It wasn’t until 50 years later that it was 
realized that vitamin D is metabolized and acts as a steroid hormone in an 
endocrine manner, a paradigm that has dominated the classic thought of vitamin 
D function until the end of the 20th century [Morris & Anderson, 2010]. Recently, 
it has been demonstrated that number of organ systems are influenced by vitamin 
D in an autocrine manner, that is 1,25OH2D3 is being synthesized within those 
cells, and/or within adjacent cells (paracrine action) (see Figure 1-6 and 1-7). It 
has been hypothesized that local production of 1,25OH2D3 in extrarenal  tissues 
regulates cell growth, differentiation, and apoptosis, however there are few 
detailed reports and is still not widely recognized [Atkins, et al., 2007].  
 There has been reports of extra-endocrine CYP27 hydroxylase expression 
in the parathyroid gland, lymph nodes, macrophages, prostate cells,  skin, colon, 
adrenal medulla, dendritic cells, endothelial cells, brain, hypothalamus, and 
placenta [van Driel, et al., 2006]. Interestingly enough, the expression of the 
enzymes required to metabolize and activate vitamin D were reported in human 
bone cultures 25 years ago, but bone is still not identified as a vitamin D 
synthesizing tissue.  
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(vii)  Vitamin D and In Vitro Bone Development 
1,25OH2D3 influences many aspects of bone cell biology, and has been 
implicated in the regulation of both osteoblastic and osteoclastic activity 
affecting both resorptive and synthetic phases of bone remodeling [Atkins, et al., 
2007]. Bone remodeling is a dynamic process coordinated by osteoblasts (bone-
forming) and osteoclasts (bone-resorbing), in which resorption is followed by 
bone formation. An imbalance in this process can lead to bone density loss and 
osteoporosis. A typical feature of vitamin D deficiency is impairment of bone 
formation and mineralization. Paradoxically, 1,25OH2D3 has been demonstrated 
to indirectly simulate bone formation and mineralization by stimulating 
intestinal calcium absorption, and induce bone resorption by inducing calcium 
mobilization from bone  [Suda, et al., 2012].  
 Interestingly enough, the benefits of using vitamin D for bone 
development in vitro, is separate from the in vivo calcimic actions. 1,25OH2D3 
has been demonstrated to regulate osteoblast and chondrocyte gene 
transcription, proliferation, differentiation, and mineralization of ECM [Boyan 
et al., 2009; Atkins et al., 2007]. In addition, 1,25OH2D3 has been shown to 
stimulate the osteoblastogenesis of MSCs, which suggests that vitamin D 
metabolism may play an autocrine/paracrine role in osteoblast differentiation of 
MSCs  [Zhou et al., 2012].  
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Chapter II. OBJECTIVES 
 
Section 2.01 3D Cell Culture for Cartilage Tissue Engineering 
Previous studies focusing on engineering cartilage have indicated that a primary 
chondrocyte cell culture isolated and harvested from mature functional articular cartilage 
is a logical cell choice for cartilage constructs [Hardingham, et al., 2002]. Due to the 
avascular and hypoxic nature of cartilage, chondrocytes can be isolated from both post-
operative and post-mortem cartilage tissue, as well as from refrigerated stored tissue 
[Tew, et al., 2008]. The first objective for the present research was to develop a protocol 
for harvesting articular cartilage tissue and isolating chondrocytes from the 
metacarpophalangeal joints of freshly slaughtered bovine. These procedures are described 
in detail in Chapter 3.  
Successful engineered cartilage constructs require a combination of several 
components, including the appropriate cell type and a temporary artificial and/or 
molecular scaffold to provide structure for regenerating tissue [Steward, et al., 2011]. In 
vivo, chondrocytes exist, proliferate, and differentiate, within a 3D enviornment. When 
they are excised from their native enviornment, and placed in a 2D monolayer for 
expansion, the naturally round chondrocytes, attach and spread, causing them to lose their 
spherical morphology and acquire an elongated fibroblast-like phenotype. These 
morphological alterations are accompanied by critical biochemical changes associated 
with the loss of mechanical function. Because cartilage-specific GAG binds to water with 
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such high affinity, natural hydrated biomaterials can be used to recreate the 3D 
enviornment.  
Using agarose as a biomaterial scaffold has been shown to allow chondrocytes to 
remain round, promote chondrogenic induction, induce cartilage phenotype and support 
cartilage-specific gene expression [Hardingham, et al., 2002; Steward, et al., 2011]. 
While agarose has an advantage in its inherent biocompatiility, the mechanical properties 
of agarose can be a set back, as they have a compressive modulus that is about 15% of 
native cartilage tissue [Steward, Liu, & Wagner, 2011]. Photocrosslinkable hydrogels 
such as poly(ethylene glycol) (PEG) can be modified for photopolymerization, which 
enables spatial and temporal control of the gelation process, and has been shown to 
support MSC survival, differentiation, and accumulation of chondrogenic ECM. In the 
current study, 3D culture protocols using low-melting point agarose and PEG are 
described in Chapter 3 and Chapter 4 for maintaining cellular and biomolecular 
constituents within defined parameters.  
Mechanical and chemical signals are instrumental in the development, 
remodeling, and pathogenesis of load-bearing tissues through cellular 
mechanotransduction. In vivo, chondrocytes experience hydrostatic, compresive, tensile, 
and shear forces within a physiologic 3D environment which maintains the phenotype 
and production of regenerating cartilage tissue. Abnormal mechanical forces have been 
shown to alter chondrocyte behavior, resulting in pathological matrix synthesis, increased 
catabolic activity (degradation), and ultimately cell death.  Convential culture methods 
are limited in their ability to replicate the natural balance of anabolic and catabolic 
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reactions necessary for tissue remodeling and regeneration. A variety of designs have 
been applied to regenerative medicine through tissue engineering applications including 
rotating vessels [Pollack, et al., 2000], pressure combined with fluid perfusion 
[Cartnmell, et al., 2003], and direct perfusion [Pazanno, et al., 2000]. As an extension of 
these technologies, a bioreactor has been designed which provides compressive 
mechanical stimulation (solid and fluid), real-time mechanical characterization, optical 
inspection, and integrated ultrasonic assessment of ECM, that can fit on a shelf of a 
standard incubator (Figure 1-1). Preliminary validation of the bioreactor’s form and 
function, expected bioassays of the resulting matrix components, and application to 
biokietic models are described in Chapter 3.  
Non-destructive techniques characterising the mechanical properties of cells, 
tissues, and biomaterials provide baseline metrics for tissue engineering design. 
Ultrasonic wave propagation and attentuation has previously demonstrated the dynamics 
of ECM synthesis in chondrocyte-seeded hydrogel constructs in a non-invasive and non-
destructive manner [Kohles, et al., 2012]. In Chapter 4, an ultrasonic method to analyse 
two of the construct elements used to engineer articular cartilage in real-time, native 
cartilage explants and an agarose biomaterial is described.  
The overall objective of this project was to characterize biomechanical influence on 
the anabolic and catabolic behavior of chondrocytes cultured in a 3D enviornment, and to 
characterize the developing ECM response to mechanical stimuli. In addition, protocols 
which established the environment most effective in developing healthy adaptive cellular 
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responses such as cellular proliferation, cytoskeleton remodeling, induction of 
differentiation, and ECM regulation.  
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Section 2.02 OPC1 Bone Development and Vitamin D Metabolism 
A novel way of promoting cartilage and bone regeneration as a tissue development 
model is through the use of MSCs or multipotent progenitor cell lines. MSCs can expand 
rapidly in culture, but the rate of expansion and the yield of multipotential progenitors are 
inversely related to the plating density and incubation time of each passage [Sekiya, et 
al., 2002], which could lead to a heterogenous population of precursors of different 
potential over time. OPC1 is a multipotent progenitor cell line derived from human fetal 
bone tissue that provides a stable and reproducible culture system and represents a 
homogenous osteogenic cell line with the capacity to generate programmed 
differentiation [Winn, et al., 1999]. The specific objective of this project was to 
characterize the influence of vitamin D and other commonly used osteogenic factors on 
the programmed differentiation of OPC1 during early bone development.  
Because OPC1 is a homogenous, stable, and reproducible culture system, it 
provides a means to screen for putative growth and differentiation factors for bone 
development. While recent studies have shown extra-renal metabolism of 25OHD3 
[Zhou, et al., 2012], the immediate precursor to the active vitamin D hormone 
1,25OH2D3, there has been occasional reports of extrahepatic 25-hydroxylation of the 
parental precursor vitamin D3 [Jones, et al., 1998]. In the present study, the capacity for 
osteoblast precursors to convert parental vitamin D3 to 1,25OH2D3 in a dose-dependent 
manner was examined and described in Chapter 5. The objective of this study was to 
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investigate the potential of parental vitaD3 to induce 1,25OH2D3 bone-associated 
biological responses during early stages of bone development.  
One major goal of bone-tissue engineering is the ability to predictably enforce the 
osteoinductive program of stem and progenitor cells [De Kok, et al., 2006]. In addition to 
extrahepatic vitamin D metabolism, the influence of vitamin D metabolites in 
combination of commonly used osteogenic factors ascorbic acid, β-glycerophosphate, 
bone morphogenetic protein-2 (BMP-2), and the synthetic steroid, dexamethasone, on 
OPC1 ECM maturation and mineralization during bone development was explored. The 
objective of the study  described in Chapter 6 was to investigate the influence of vitamin 
D metabolites vitaD3 and 1,25OH2D3 with or without osteogenic factors on the temporal 
development stage sequences of early bone development in order to find the optimal 
chemical environment for ECM maturation and mineralization.  
The overall goal of the studies described in Chapter 5 and Chapter 6 were to 
establish a reproducible culture system for the in vitro osteogenic differentitation of 
human osteoblast precursor cells, and to characterize the capacity of osteoblast precursors 
to convert vitaD3 to 1,25OH2D3 and the potential of vitaD3 to induce 1,25OH2D3 
associated biological activities. In addition, to investigate the effects of vitamin D 
metabolites as ostegenic factors on the temporal development sequence of bone 
development which include proliferation, maturation, and mineralization. These studies 
will provide a 2D culture foundation for future 3D engineered tissue studies using the 
OPC1 cell line.  
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Section 3.01 Preface 
The chapter is comprised of material from a manuscript submitted to the Journal of 
Nanotechnology in Engineering and Medicine as a Design Innovation Paper (NANO-11-
1022) and published in March 2011. This paper encompasses protocols for 3D cartilage 
TE culture systems and mathematical modeling that characterizes the organization, 
mechanical properties, and physiologic response at multiple scales, from molecular to 
cellular, and to tissue and organ levels. 
 
Section 3.02 Authors Contributions 
The work presented here was carried out in collaboration between all authors. 
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the biological 
methods and experiments, while SSK and AKS designed the mathematical modeling and 
statistical analysis. SSM and SSK wrote the paper. All authors have contributed to, seen 
and approved the manuscript. 
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Section 3.03 Abstract 
There has been considerable progress in cellular and molecular engineering due to 
recent advances in multiscale TE technology. Such technologies allow controlled 
manipulation of physiochemical interactions among cells in tissue culture. In particular, a 
novel chemomechanical bioreactor has recently been designed for the study of bone and 
cartilage tissue development, with particular focus on extracellular matrix formation. The 
bioreactor is equally significant as a tool for validation of mathematical models that 
explore biokinetic regulatory thresholds [Saha and Kohles, 2010, J Nanotechnol Eng 
Med. 1(3):031005; Saha and Kohles, 2010, J Nanotechnol Eng Med. 1(4):041001]. In the 
current study, three-dimensional culture protocols are described for maintaining the 
cellular and biomolecular constituents within defined parameters. Preliminary validation 
of the bioreactor’s form and function, expected bioassays of the resulting matrix 
components, and application to biokinetic models are described. This approach provides 
a framework for future detailed explorations combining multiscale experimental and 
mathematical analyses, at nanoscale sensitivity, to describe cell and biomolecule 
dynamics in different environmental regimes. 
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Section 3.04 Introduction  
Cartilage and bone defects are a leading cause of disability, an economic burden 
that exceeds 28 billion dollars in orthopedic repair in the United States alone [Chao et al., 
2007]. More than 250,000 knee and hip replacements are performed each year [Chung, 
2008], and the number continues to increase with an aging population suffering from 
defects or deterioration of articular cartilage caused by osteoarthritis and trauma. Because 
cartilage is avascular, and has a limited capability for self-repair, it has been the focus of 
many bioengineering investigations in nanomedicine. TE is an evolving field that has the 
potential to provide functional cartilage tissue to help the millions of people who suffer 
from degenerated, diseased, or damaged articular cartilage. There have been rapid 
advancements in cell-based therapies, which includes the in vitro engineering of 
functional tissue substitutes for subsequent in vitro transplantation [Chung, 2008]. To 
date, however, the properties and structure of native cartilage tissue have not been 
entirely mimicked by engineered tissue (Figure 3-1). Limitations of the current solutions 
such as autologous chondrocyte transplantation (ACT) include difficulty in obtaining a 
required amount of cells for a construct and cellular dedifferentiation during expansion, 
as well as degeneration at the donor site. Although recorded success rates of ACT are 
between 60-90% depending on the localization of the injury [Yilmaz et al., 2010], long-
term success rates are considerably lower.  
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TE is the process of creating functional 3D tissues using cells combined with 
scaffolds, signaling factors, and devices that facilitate growth, organization and 
differentiation. The development of mathematical models based on the interaction 
Figure 3-1: Three-dimensional reconstruction 
via micro-computed tomography of a through-
thickness section of human articular cartilage 
[after Jadin and Sah, 2006]. The total transverse 
slice dimension is 1,500 mm representing the 
articular surface (top), three histologic zonal 
layers, and the bony osteochondral transition 
(bottom).  
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between cells and biomaterials can help understand the basic mechanisms of cartilage 
physiology [Tortelli & Cancedda, 2009]. In order to create an environment for tissue 
development, the mathematical models need to characterize the organization, mechanical 
properties, and physiologic response at multiple scales, from cellular to molecular to 
tissue levels. Harnessing nanobiotechnology, this approach can help design new drug 
development and delivery systems, regenerative medicine, and tissue remodeling 
procedures [Saha and Kohles, 2010a; 2010b; 2011].  
In healthy connective tissue, structural protein fibers such as collagen and elastin 
fibers have diameters ranging from several tens to several hundreds of nanometers. The 
nanoscale protein fibers entangle with each other to form a nonwoven mesh that provides 
tensile strength and elasticity for the connective tissue [Zuewei et al., 2005]. Articular 
cartilage is composed of immobilized chondrocytes which secret the cartilage specific 
biomolecules that make up the tissue’s ECM [Pazano et al. 2000; Lanza et al. 2007]. 
Physiological regulation, synthesis and maintenance of ECM are maintained by the 
chondrocytes (although only 10% of the volume) through biokinetic reactions [Saha and 
Kohles, 2010a; 2010b; 2011]. The structural integrity of cartilage is derived from the 
fibrous network formed by the cartilage-specific protein, collagen type II (ColII), which 
is immersed in a gelatin formed by proteoglycans rich in sulfated glycosaminoglycans 
(GAG), and water, which binds with such high affinity that it makes up ~70% of the total 
weight [Wilson et al., 2002]. It is this unique ECM that allows low friction movement of 
joint surfaces. In return, joint loading from body movement induces fluid velocities in the 
tissue that maintain waste and nutrient flow, as well as ion movement. Recreating the 
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unique mechanical properties that give cartilage tissue the capability of bearing 
compressive loads during daily activities is a major challenge in TE. 
 
(i)  Biomaterial Scaffolds and Three-Dimensional Culture 
Recent work has shown that cells often exhibit unnatural behavior when they are 
excised from their native 3D environment and confined to a 2D monolayer. The 
acute disparities in cellular function between 2D and 3D cultures warrant further 
biological examination [Tibbitt and Anseth, 2009]. When articular chondrocytes 
are cultured in a static 2D monolayer, they lose their overall hyaline structure and 
functional elasticity. In vitro expansion of such cultures is associated with cellular 
dedifferentiation and reduced or total loss of their ability to redifferentiate 
[Barbero and Martin, 2007; Barlic and Kregar-Velikonja, 2008]. A 2D 
environment allows chondrocytes to attach and gradually spread, which causes 
them to lose their spherical morphology and acquire an elongated fibroblast-like 
phenotype. In our current work, we observed morphological changes that occur 
within the first few days of cells cultured in a static monolayer, as the freshly 
isolated cells begin to adhere and spread along the culture vessel.  
Morphological alterations acquired in monolayer are accompanied by critical 
biochemical changes. Loss of the hyaline morphology is associated with the 
expression or total loss of aggrecan and ColII synthesis, and an increase in the 
expression of fibrocartillage associated ECM molecules collagen type I (ColI) and 
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versican [Barbero and Martin 2007; Barlic and Kregar-Velikonja 2008]. Hydrated 
biomaterials may recreate the native 3D environment and mimic the physical 
structure, biological function, and biochemical nature of ECM. Native ECM 
provides physical support for cells, as well as a substrate with specific ligands for 
cell adhesion and migration, and regulates cellular proliferation and function by 
providing growth factors [Zuewei et al., 2005]. During healthy balanced tissue 
regulation, growth factors stimulate the anabolic synthesis of essential ECM 
macromolecules, a process that is complemented by the catabolic degradation of 
ECM by proteinases during tissue remodeling and repair [Saha and Kohles, 
2010a; 2010b; 2011]. In order for this process to take place in vitro the 
biomaterial scaffold needs to degrade at a rate that compliments the synthesis of 
neotissue and be responsive to the local biological environment [Bahney et al., 
2011]. 
For the experimental design described herein, hydrated polymers (hydrogel) 
offer a biomaterial scaffold with customizable and biomimetic properties. This 
material is manipulated by photopolymerization for quick formation of the liquid 
mixture into gel when exposed to ultraviolet B (UVB) rays. Photopolymerization 
has been examined as a method to create scaffolds with specific nanoscale 
topography to promote control of cell migration and function [Elisseeff et al., 
2000].  
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(ii) Mechanical Stimulation and Biological Response  
Dedifferentiated chondrocytes have the capacity to redifferentiate if they are 
transferred into a 3D environment that supports a spherical morphology; however, 
their original phenotype may not be fully re-acquired [Barbero and Martin, 2007]. 
When 3D cellular constructs are grown in static culture, cells on the outer surface 
of the constructs are typically viable and proliferate, while cells within the 
construct may be less active or necrotic [Cartmell et al., 2003]. 3D culture 
techniques that encompass biomaterials and so allow chondrocytes to remain 
round yield cells that continue to express cartilage specific genes, but are limited 
relative to proliferation capacity and lack the zonal distribution of cells and ECM 
molecules found in native tissue [Choi et al., 2007]. Mechanical stimulation 
(fluid, solid, thermal, etc.) of 3D constructs consisting of cells, biomaterials, and 
growth stimulant inhibitors have shown promising results in the production of 
viable load-bearing tissues such as cartilage and bone [Kohles et al., 2007]. The 
transmission of biochemical and biomechanical signals from the cell-cell and cell-
ECM interactions determines the formation of healthy tissue morphology. Thus, 
preserving these interactions is essential in recreating the native tissue. 
In one cartilage engineering approach, it has been suggested that isolating 
cells from distinct histological zones and seeding the cells layer-wise within a 
scaffold may help to preserve the native zonal distribution that contributes to the 
function of absorbing compressive and tensile forces. Utilizing a multiscale 
bioreactor as described in this design innovation paper, that can recreate native 
  
 
 
53
biomechanical and biochemical stimuli, will facilitate tissue development 
investigations and validate ongoing biokinetic modeling. 
  
Section 3.05 Eng
(i) Bioreactor Design and Application
A chemomechanical bioreactor was recently designed [Quinn et al. 2009; Chiu 
et al., 2010] with the primary objectives of providing mechanical stimulus (solid 
and fluid), mechanical
assessment of engineered tissue development (Figure 3
cartilage is a thin layer of 0.5 to 5 mm thick hyd
Doran, 2005]; as such the 3D culture env
constructs 5-mm in height to mimic native cartilage geometry.
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ineering and Experimental Design Methods:
 
 characterization, optical inspection, and ultrasonic 
-2). In humans, articular 
rated soft tissue [Mahmoudifar &
ironment was designed to support 
 
 
Figure 3-2: A solid model of the 
assembled chemomechanical 
bioreactor for three
culture [after Quinn et al., 2009]. 
The image includes the upper 
electromechanical actuator applying 
high-resolution load
control to the ‘hat’ which distributes 
the mechanical stimulus to the five 
load arms and, as such, to the five
culture-wells below. The wells can 
be rotated into the view of single 
ultrasonic or digital imaging 
sensors. 
 
 
 
-dimensional 
-deformation 
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A prototype bioreactor has now been fabricated for stimulating and monitoring 
cell, ECM, and scaffold development of 3D engineered cartilage constructs 
(Figure 3-3). The device combines a linear actuator (ElectroForce, Bose, Eden 
Prairie, MN) connected to an array of five load transducers (1,000g, +/- 0.15 to 
0.25%, Model 31 Mid, Sensotec/Honeywell, Golden Valley, MN). The actuator 
can be controlled via displacement (+/- 2.5 mm) or force (20 N) to apply a variety 
of waveforms (WinTest, Bose) for dynamic stimulation of five concurrent cube-
shaped test samples (Figure 3-4). Access for a digital video microscope and 
ultrasound transducers facilitate minimally invasive construct assessment. The 
entire bioreactor is sized to fit inside an incubator (Galaxy R Series Incubator, 
New Brunswick, Edison, NJ) with sensor control of the internal environment 
chemistry, carbon dioxide (CO2), oxygen (O2), and nitrogen (N2).  
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Figure 3-3: The now-fabricated, novel chemomechanical bioreactor with five culture 
wells (on the left) and a load-train applying load-displacement for measuring exact loads 
(on the right). The high-resolution, copper-colored load-cells measure the dynamic loads 
transferred via the load-rods through the square load-platens into the culture-wells and 
onto the eventual cell-biomaterial constructs. 
 
Figure 3-4: Open-view (model) of a bioreactor test chamber for engineered tissue 
chemomechanical stimulation indicating the a) cell-biomaterial construct (125 mm3 
pink cube) and b) three current well designs for static and dynamic three-dimensional 
culture. The middle culture-well, which provides perfused flow and dynamic culture 
will be described in a future article [Kohles et al., 2011]. 
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Elastic moduli of 3D hydrogel-cell constructs are typically measured in 
compression after 2, 4, and 6 weeks of in vitro culture time. Samples are initially 
unloaded, then subjected to compressive strain at a rate of 0.5 mm/min [Rice et 
al., 2009]. The compression modulus will be determined by analyzing the linear 
regions of the stress versus strain curve on samples at low deformation (<15%). 
Initial mechanical stimulation will relate dynamic constituent masses with elastic 
properties applying a basic rule of mixtures. More complex spherical-composite 
models will eventually be applied [Kohles et al., 2007]. The modeled (and 
measured) scaffold and cell-ECM masses (mi) can be converted to constituent 
volumes (Vi) using density values (ri): 
Cell-ECM:               (totaled for multiple ECM constituents) 
Scaffold:            (1) 
 
The total porosity (P) of the construct can be calculated from constituent volumes 
estimated from the biomarkers and the current gross volume of the construct 
composite (Vo) using the relationship: 
 
           (2) 
 
V CE =
mCE
ρCE
V s =
ms
ρs
P =
V o − (V s +V CE )
V o
=1− (V s +V CE )
V o
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For constructs with distinct porosities, the elastic modulus of the cell-ECM-
scaffold composite structure (Estructure) may be characterized by the 
phenomenological relationship [Martin et al., 1998]:   
 
Estructure = Esolid (1-P) k           (3) 
 
Where k is a curve-fit parameter and Esolid can be defined by the cell-ECM (ECE) 
and polymeric scaffold (Es) moduli using the two-phase, Voigt model [Hashin and 
Shtrikman, 1963]:   
  
Esolid = vCEECE + vsEs            (4) 
 
Here, the solid volume of the engineered construct is defined by the volume 
fractions of the cell-ECM (vCE) and polymeric scaffold (vs), respectively: 
 
Cell-ECM:  
 
Scaffold:  where vCE + vs = 1                (5) 
 
This preliminary micromechanical arrangement assumes that the scaffold and 
neo-ECM experience equivalent deformation in response to an applied load 
vCE =
V CE
V s +V CE
vs =
V s
V s +V CE
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[Jones, 1999]. These metrics will provide a quantitative means of comparing the 
developing engineered tissues with native tissues as an approach for assessing the 
designed 3D culture environment. 
 
(ii) Cartilage Dissection and Disaggregation 
In the initial preparations of cell-scaffold constructs which will be developed 
into cell-ECM-scaffold constructs using the bioreactor, fresh tissue is excised 
from the chondylar surface cartilage of 6 month to 2 year old bovine 
metacarpophalangeal joints contributed by a local abattoir within 1 to 8 hours of 
death (Mark's Meat, Canby, OR). To decrease the chances of contamination, the 
joints are dissected in cold, sterile dissection solution containing a high 
concentration (5%) of antibiotic/antimycotic (AB/AM) solution (100x) stabilized 
(Sigma) in Dulbecco's phosphate buffered saline (DPBS; Sigma Aldrich Co., St. 
Louis, MO) to give a final concentration of 250 µg/mL or 0.625 µg/mL 
amphotericin B. The soft muscle and connective tissue is removed utilizing a 
sterile scalpel (sizes 11 and 23), and cartilage is carved from the bone utilizing a 
sterile scalpel (size 15) from the bone and separated from any remaining soft 
tissue. The excised tissue is rinsed several times with cold DPBS and 2.5% 
AB/AM solution through a 70-µm mesh filter (Cell Mirco Sieves TM, BioDesign 
Inc. of New York), weighed, and measured for ultrasonic propagation as 
described in Section vii. The resulting tissue fragments are mechanically 
disaggregated and finely minced with surgical scissors and opposing scalpels into 
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~1 mm3 pieces. The cells released from supporting matrix during disaggregation 
are centrifuged and resuspended in 5 ml of media containing Dulbecco's modified 
eagle medium mixture and Ham's F12 nutrient mixture (DMEM/F12 (1:1); 
Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, HyClone), 5% 
L-Glutamine (L-Glut Lonza-BioWhitaker), 1% AB/AM, and stored at 4°C until 
digestion is complete. To allow timely detection of microbial contamination, it 
has been suggested to incubate the fragments for 24 to 48 hrs before digestion 
[Harris, Graham, & Rickwood, 2006]. 
 
(iii) Enzymatic Digestion.  
The explanted tissue fragments are consecutively digested with 0.25% trypsin 
(BioWhittaker, Lonza, Basel, Switzerland) and 0.5% collagenase (Liberase 
Blendzyme III, Roche Diagnostics, Madison, WI) to release the chondrocytes 
from the ECM with a high cell count of ~5 x 106/ml per calf hoof. Warm 
trypsinization is carried out at 37°C on a hot-plate/magnetic stirrer for 1 hour in 
Hank's buffered salt solution (HBSS; Lonza) supplemented with 1% AB/AM 
solution. Culture media containing fetal bovine serum (FBS; Thermo Scientific 
HyClone, Logan, UT) is added to inhibit trypsin activity and the cell suspension 
obtained is filtered through a 70-µm sterile nylon filter to remove any tissue 
debris. Cells are collected by centrifugation at 1,500 rpm for 10 min and rinsed 
several times with culture media, which consisted of Dulbecco's modified Eagle's 
medium and Ham's F-12 nutrient mixture (DMEM/F12: Sigma), and resuspended 
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in 5 ml chondrocyte culture media containing DMEM/F12 supplemented with 
10% FBS, 5% L-Glutamine (Lonza), and 1% AB-AM and stored at 4°C until 
further digestion with collagenase is complete. The undigested tissue debris 
collected after trypsination, which appeared more gelatinous then solid, is 
digested overnight in 0.5% collagenase at 37°C for 16 to 24 h. Sterile disposable 
15 ml transfer pipets (VWR Int., Radnor, PA) are used to aspirate the fragments 
several times in order to release loosened cells from the gelatinous tissue debris. 
Digestion is continued in the samples that appeared to have tissue fragments still 
intact or a low cell count, at a higher concentration (0.75%) for an additional 
hour. Isolated viable chondrocytes from each collection set (i.e., cells from 
disaggregation, trypsin and collagenase digestion) were counted using a 
hemocytometer and trypan-blue exclusion dye (0.4% in DPBS). The sample 
collections having a cellular health viability of  >75% as indicated by a lack of 
trypan dye incorporation are resuspended in chondrocyte media at a concentration 
of ~5 x 106/ml. 
 
(iv) Cell-Seeding and Biomaterial Polymerization   
The hydrogel scaffold mixture, consisting of poly(ethylene oxide) (PEO), 
poly(ethylene glycol) dimethacrylate (PEGDM), and the photoinitiator, 1-
hydroxycyclohexyl phenyl ketone (Sigma Aldrich), is dissolved in sterile saline, 
penicillin G, and streptomycin to form a 20% (w/v) solution [Gibson and Kohles, 
2010]. The hydrogel constituents are combined in a 3:2 ratio (PEO:PEGDM). The 
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UV photoinitiator creates a final concentration of 0.05% [Elisseeff et al., 2000]. 
Individual 125-µl aliquots of chondrocyte suspension (5 x 106 cells/ml in growth 
media as applied previously [Wilson et al., 2002]) are added and polymerized 
layer-wise in cubic molds of 125-mm3 under 365-nm UV light for 3 min, a 
wavelength not harmful to the living cells [Fedorovich et al., 2009]. The resulting 
hydrogels (five per batch) are removed from the 125mm3 cubic molds using a 
sterile spatula, weighed, and measured for ultrasonic propagation (as input for 
equations 1 to 5) before being placed into each of the five culture wells fabricated 
for the bioreactor (Figures 3-3 and 3-4).  
 
(v) Biomolecular Assays 
Constituents representing the greatest total volume fraction and primary 
influence on cartilage biology and biomechanics will be monitored during 
cartilage development and biokinetic interactions. These are the chondrocytes, 
proteoglycan, and collagen content. Cell density can be measured through 
fluorometric assay as an indicator of proliferation or death overtime [Rice et al., 
2009]. The primary components of ECM are easily measured by colorimetric 
assay after construct digestion, and constituent distribution is assessed through 
histological staining of the neotissue sections. Specific proteoglycans and 
collagen isoforms, namely aggrecan and collagen type II, can be quantified 
through immunoassays or visualized by antibody staining [Rice et al., 2009]. 
Total GAG content is quantified utilizing dimethyl-methylene blue assay; total 
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collagen content is quantified by a hydroxyproline assay. DNA content can be 
measured by Hoeschst-33258 and related to cell number by dividing DNA content 
by 7.7 ρg per chondrocyte [Rice et al., 2009]. While these techniques provide 
useful information about the tissue grown in vitro, they require digestion and 
destroy the samples at specific end points. Ongoing design efforts are directed 
toward development of a bioreactor in which the quality of the neo-ECM and 
scaffold may be measured in real-time, utilizing digital imaging and ultrasonic 
sensors.  
 
(vi) Histochemical Staining 
At typical selected time points of 2, 4, and 6 weeks, constructs are removed 
from the chemomechanical culture environment, fixed in 10% formalin for 8 to 
24 h, dehydrated, paraffin-embedded, and partially sectioned (10-µm thick) using 
a microtome. Sections are then stained with fast green and safranin-O (GAGs 
stains red-orange), and Masson's trichrome method (collagen stains blue) (Figure 
3-5). Colorimetric assays will determine planar and volumetric densities of the 
assayed constituents as harvested time points. Remaining section geometries will 
be weighed and measured for ultrasonic propagation (as input for equations 1 to 
5). The biomolecular assays characterize the state of the ECM as assessment of 
the tissue development as well as input for validation of the biokinetic models 
(Table 3-1). The primary assays will characterize antibodies associated with 
immunohistochemistry and histochemical staining to include:  
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Type II Collagen as the predominant collagen in healthy articular 
cartilage. Type II collagen forms a three-dimensional fibrillar network 
essential for the tensile stiffness and strength of cartilage [Oesser and 
Seifert 2003].  
 
Aggrecan as the third major component of articular cartilage, constituting 
the majority of the proteoglycan-hyaluronic acid polymers. These large 
macromolecules are embedded within the fibrous network of collagen type 
II, providing the compressibility and elasticity of cartilage. During tissue 
turnover aggrecan and its fragments originating from the core protein part 
of aggrecan are released into the supernatant of cartilage explant cultures. 
The total aggrecan can be identified via an enzyme-immunoassay for the 
quantitative determination of aggrecan and its fragments containing the 
G1 and/or G2 domains that are released into the supernatant from articular 
cartilage explants [Oesser and Seifert 2003].  
 
Type I Collagen as an indicator of dedifferentiation of articular 
chondrocytes during expansion of cells grown in a monolayer and as an 
indicator for fibrocartilage. An assay kit is designed to quantify the 
amount of ColI from bovine cell and/or tissue cultures (Chondrex, Inc.). 
Type X Collagen (ColX) as an indicator of hypertrophic cartilage.  
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Biomarkers Assay Product Cell Secretion Rate (in vitro values) 
Type II Collagen  Rhuemera® Native Type II Collagen 
Capture* 
~1.5 to 3.0 µg per 106 chondrocytes 
(basal media) [Oesser and Seifet, 2003] 
Glycosaminoglycan 
(GAG) 
Rhuemera® Assay Kit for 
Proteoglycan*  
~55 to 105 mg per 106 chondrocytes 
(basal media) 
Type I Collagen  Rhuemera® Type I Collagen Kit*  ~10 to 15 ng per 106 fibroblasts  
Type X Collagen  Kit for Collagen Type X** ? µg per 106 chondrocytes 
Figure 3-5: Expected cell-matrix preparations [after Rice et al., 2009]. During matrix 
synthesis, cells will be distributed throughout the collagen (on the left, stained with Masson's 
Trichome) and aggrecan (on the right, stained with safranin-O/fast) constituents as are typical 
for this cell-scaffold arrangement. The solid dark circles each represent a single cell at ~20 mm 
in diameter. 
Table 3-1: Focal biomarkers and the assay products applied to evaluate the state of extracellular matrix 
biokinetics. The biomarkers and the listed typical secretion standards will be measured as boundary 
conditions characterizing the experimental progress of the engineered tissue development. These data will 
also provide input for model initiation and validation during statistical comparison. *Enzyme-linked 
immuno-sorbent assay (ELISA), Rhuemera and Immunodiagnostics System (Astarte Biologics, LLC, 
Redmond, WA). ** ELISA (Antibodies-online, Atlanta, GA). ***Sircol (Biocolor Life Science Assays, 
Carrickfergus, UK. 
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(vii) Ultrasound Analysis 
Ultrasound transmission velocities are measured in vitro with the objective of 
defining acute and post facto elasticity metrics for characterizing developing 
engineered cartilage constituents. Ultrasound analysis is non-destructive 
techniques that can assess macroscopic construct properties and constituent 
quality. Ultrasonic longitudinal (vii) and transverse (vij) wave propagation 
velocities are measured in three orthogonal orientations (planar and thickness 
directions) for 6 measurements per sample.  The test set-up includes a pulser-
receiver (Model 5058PR, Panametrics, Olympic Corp., Waltham, MA), a 
multichannel oscilloscope (Model TDS460A, Tektronix, Beaverton, OR), and an 
array of sending-receiving transducers: 5 MHz (Model V156), 10 MHz (Model 
V112), 50 kHz (Model X1021), and 100 kHz (Models X1020 and V1548) 
transducers (Panametrics) facilitating a total of at most 1,050 measurements. 
Aggregate cell-ECM-scaffold densities (r) of the samples are determined and 
system time delays are accounted for during each transducer arrangement. Bulk 
(K = rfvii2) and aggregate (Ha = rsvii2) moduli can be measured from separated 
fluid (f) and solid (s) ultrasound propagations, respectively [Shull, 2002], and 
used as input for equations 3 and 4. The measurement of intrinsic ultrasonic 
properties may indicate the structure and composition of the tissue under 
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investigation, as well as its mechanical and physical properties [Rice et al. 2005]. 
Initial cartilage pieces are excised as described earlier under aseptic conditions, 
sliced into 800-1000 µm sections with a microtome. Preliminary native cartilage 
testing confirmed density (r = 1,330 kg/m3) and propagation velocities similar to 
that reported in the literature (1,500 to 1,720 m/s) [Agemura et al., 1990]. 
 
(viii) Mathematical Model Input  
Previous mathematical frameworks characterized nanoscale biokinetic 
mechanisms as stimulated within the micromechanical environment of a single 
cell [Saha and Kohles, 2010a; 2010b; 2011]. The model results described the 
influence of mechanical stress on the anabolic and catabolic pathways including 
the interactions with cytokines (C) and growth factors (G), fundamental 
regulatory processes that lead to matrix homeostasis. The engineering and 
experimental designs presented here monitor the catabolic (negative influence) 
and anabolic (positive influence) effects of chemomechanical stimuli (T), C, and 
G on a multi-cellular level using the mathematical framework exploring these 
differential interactions through time (dt): 
 
 
         (6) 
d
dt
collagen +GAG( ) = f C,G,collagen+GAG,λ,δ( )
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This computational framework defines the secretion rates of C and G as functions 
(f) of the their current levels and associated rate constants derived from the tissue 
engineering literature (ai, bi, and Wi) and the bioreactor controls (ξi), for i = C or 
G, as previously described [Saha and Kohles, 2010a; 2010b; 2011]. The dynamic 
state of the C and G is then applied as a positive or negative influence on the 
accumulation rate of ECM, defined as the total amount of collagen plus GAG. 
Boundary conditions for these levels will be determined from the protocols 
described in Sections v and vi (Table 3-1). The dynamic state of the ECM is 
defined as a function of the matrix molecules themselves and rate constants (l and 
d) modified to optimize description of the model with the collected data. This is 
an iterative modeling process which will allow us to initiate an assumed 
biokinetic state and ‘back calculate’ the levels of C and G from the measured 
ECM abundance through multiple iterations. Combinations of positive and 
negative feedback/influences can be explored by varying the chemomechanical 
bioreactor control system. Iterative analyses of the biokinetic models (equation 6) 
are run through 5 x103 to 10 x105 normalized time steps using commercial 
software (MathCAD 14.0, Parametric Technology Corp., Needham, MA) at each 
sample harvest/collection period (Figure 3-6). Recreating the tissue in vitro by 
utilizing the bioreactor’s capability provides an approach to validate biokinetic 
models as a descriptor of dynamic inter- and intra-cellular interactions, necessary 
to promote tissue synthesis, regulation and maintenance of the resulting ECM. 
 Statistical validation and assessment of influencing variables will be conducted 
with multiple analyses of co
Concepts, Inc., Cary, NC).
 
 
 
 
 
 
 
Figure 3-6: Representative biokinetic
expected biomolecular accumulation data as gathered from the chemomechanical 
bioreactor (as boundary conditions and validation). Here the model is initially allowed to 
run as the ECM concentration (%, GAG and co
resources and then drops to a steady state level. A chemomechanical stimulus is then 
applied at 5 x105 relative time units, driving the accumulation upward in an anabolic 
response. 
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-variance (MANCOVA) techniques (JMP v9, SAS 
 
 modeling results (applying equation 6) from 
llagen) peaks in the response to local 
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Section 3.06 Discussion 
The successful large-scale production of engineered tissues requires an adequate 
source of healthy expandable cells, the optimization of biomaterial scaffolds, and the 
application of bioreactors, which mimic the in vivo environment of the body and are 
amenable to scale-up [Griffith and Naughton 2002]. The in vitro environment provided 
by the chemomechanical bioreactor described here provides an experimental platform to 
explore cell-cell and cell-matrix molecular communication associated with ECM 
synthesis and degradation as a nanomedicine application. The importance of static or 
dynamic chemical and/or mechanical stimulation as characterized in biokinetic models 
for cartilage has indicated mechanisms which increase proteoglycan and collagen 
expression, thus suggesting an active role in maintaining healthy chondrocytic phenotype 
[Tortelli and Cancedda, 2009].  
The engineering and experimental design innovation described here recreates the 
in vivo environment of load bearing articular cartilage on micro- to milli-scales (cells and 
scaffold architecture) by measuring/modeling nano-scale biomolecular interactions. As 
an approach to exploring highly resolved, intra-sample heterogeneity, distinct zonal 
distributions of ECM macromolecules and chondrocyte morphology in articular cartilage 
may be controlled through layer-wise construct fabrication. Articular cartilage is 
stratified in a depth-dependent manner with distinct layers (superficial, middle, and 
deep). Each distinct zone is well characterized by cellular shape, ECM ultra-structure, 
and material properties (Figure 3-1). The superficial region has a dense network of 
collagen fibers primarily aligned parallel to the joint surface, whereas collagen fiber 
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orientation is more random in the middle and perpendicular in the deepest zone 
[Vanderploeg et al., 2008]. Being avascular in nature, it is not a surprise that articular 
cartilage has reduced oxygen tension, and each zone has varying oxygen levels that 
decrease from superficial (~6% O2) to deep (~1% O2) zones [Fermor et al., 2007]. 
Oxygen tension can alter matrix synthesis, as well as the material properties of articular 
cartilage in vitro, which can be a testable explanation for the zonal distribution along the 
depth of the tissue. The bioreactor described here has the potential to test the influence of 
many such parameters including oxygen tension and offers a novel arrangement in 
comparison to current bioreactor designs [Cartmell et al., 2003; Lujan et al., 2011].  
Ongoing efforts are exploring the chemomechanical environments in support of 
dynamic cell and tissue culture. These efforts include optimizing the scaffold’s material 
and structural properties (local stiffness, porosity, etc.) in a manner that supports cell, 
nutrient, waste, and other biomolecular transport concomitant with controllable 
mechanical properties. Future capabilities will monitor and evaluate the developing 
neotissue in a nondestructive manner, accommodating real-time measurement. Utilizing a 
bioreactor that encompasses the ability to culture tissue as well as monitor matrix growth 
and maintenance may have a much broader scope then facilitating tissue development; it 
has the potential of replacing animal models in drug response studies, cellular and 
molecular engineering, and regenerative medicine. It may be possible to better 
understand the roles of specific mammalian genes involved with essential metabolic 
pathways without manipulating an animal model.  
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Section 4.01 Preface 
The following chapter encompasses material from a manuscript submitted to the 
International Journal of Biomedical Engineering and Technology as a Research Paper 
(IJBET) in February 2012, and published in April 2012. The application of ultrasound 
analysis presented here will be used to distinguish between the fluid and solid properties 
of engineered cartilage constructs, including the cell and matrix biokinetics as a non-
destructive means to evaluate growing tissue, as well as a validation of previous 
mathematical models described in Chapter 3.  
 
Section 4.02 Authors Contribution 
The work presented here was carried out in collaboration between all authors. SSM 
and SSK defined the research theme. SSM designed the biological methods and 
experiments, while SSK designed the engineering methods and mathematical modeling. 
SSM, APA, RJB, JB, FG, JR, and ISW carried out the laboratory experiments. SSM and 
SSK analyzed the data, interpreted the results and wrote the paper. AKS co-designed the 
mathematical modeling. All authors have contributed to, seen and approved the 
manuscript. 
 
Section 4.03 Hypothesis 
Using ultrasound as an application of acoustoelastic analysis, agarose, as a natural 
biomaterial scaffold, will have similar elastic and shear properties as cartilage explants. 
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Section 4.04 Abstract 
Nondestructive techniques characterizing the mechanical properties of cells, 
tissues, and biomaterials provide baseline metrics for tissue engineering design. 
Ultrasonic wave propagation and attenuation has previously demonstrated the dynamics 
of extracellular matrix synthesis in chondrocyte-seeded hydrogel constructs. In this paper, 
we describe an ultrasonic method to analyze two of the construct elements used to 
engineer articular cartilage in real-time, native cartilage explants and an agarose 
biomaterial. Results indicated a similarity in wave propagation velocity ranges for both 
longitudinal (1,500 to 1,745 m/s) and transverse (350 to 950 m/s) waveforms. Future 
work will apply an acoustoelastic analysis to distinguish between the fluid and solid 
properties including the cell and matrix biokinetics as a validation of previous 
mathematical models.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
81
Section 4.05 Introduction 
Cartilage tissue engineering (TE) is a promising solution for cellular and tissue 
replacement therapies as well as an alternative for animal models used in clinical 
research; however, many of the current TE approaches have not been fully validated. 
Most mechanical and biochemical assessment of TE constructs require destructive 
endpoint-testing and/or compromise the sterility of the bioreactor environment used 
during construct formation [Walker et al., 2011]. Ultrasonic imaging is a standard clinical 
diagnostic tool that is based on propagating sound waves and offers a technology for 
tissue characterization and stimulation in a noninvasive and nondestructive manner. The 
response to mechanical stimulation induced in passive tissues by external sources such as 
low to high frequency vibration or compression can be used to analyze tissue elasticity as 
a metric for tissue health [Hein et al., 1993]. Recently, it has been shown that ultrasonic 
assessment can predict the process of native cartilage regeneration and engineered 
cartilage histology [Hattori et al., 2005].  
Native articular cartilage is divided into four distinct histological zones 
(superficial tangential or resting zone; the proliferative or middle zone; the hypertrophic 
or deep zone; and the calcified zone) based on the preferential orientation of matrix 
molecules, cellular morphology, and biochemistry. Ultrastructural studies of adult 
cartilage have shown that the preferential orientation of collagen fibrils varies from the 
articular surface to the intermediate and deep zones [Agemura et al., 1990]. The depth-
dependent structural arrangement of chondrocytes and extracellular matrix (ECM) 
macromolecules, such as proteoglycans (PG) and fibrillar collagens, mainly collagen type 
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II (ColII), results in a structurally heterogeneous and mechanically anisotropic material. 
For example, at any given depth from the articular surface, PG concentration may change 
as a function of the distance from the chondrocytes [Jurvelin et al., 1997]. The zonal 
distribution of ECM molecules gives rise to the tissue’s unique poroelastic properties and 
ability to act as a load-bearing cushion in which mechanical forces transmitted through 
the joint to the underlying subchondral bone can be properly distributed [Waldman et al., 
2004].  
The localized biomechanics (stresses, strains, and elastic properties) of articular 
cartilage ECM is thought to be actively modulated by chondrocyte-matrix interaction 
driving biosynthesis regulation [Korhonen et al., 2008; Saha and Kohles, 2012]. 
Characterizing the mechanical properties of cartilage constituents including cells and 
ECM as a means to define constitutive relationships between stress and strain may 
elucidate their physical interactions and contribute to the understanding of cartilage 
development, adaptation, and degeneration [Kohles et al., 2007]. In addition, the distinct 
histologic zones within articular cartilage have exhibited distinct material properties at 
both the cell and tissue level [Ginat et al., 2006; Shieh and Athanasiou, 2006]. Selection 
of cells and replication of matrix organization based on zonal mimicry may provide 
strong design specifications when constructing regenerative or tissue replacement 
therapies. In this work, ultrasonic wave transmission was investigated as one of many 
baseline bioengineering design metrics with the objective of characterizing and 
comparing key engineered cartilage constituents. 
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Section 4.06 Methods 
(i) Articular Cartilage Harvest and Ultrasonic Testing 
Full-thickness articular cartilage was harvested from a two-year-old steer 
(Mark's Meat, Canby, OR) within 4 hours of slaughter. The cartilage was 
extracted from the metacarpophalangeal joint using a scalpel (Figure 4-2). Full-
thickness cartilage parallelepipeds (typically x = 4 mm, y = 4 mm, and z or t  = 
1.5 mm) were created from the tissue samples. Ultrasonic longitudinal (vii) and 
transverse (vij) wave propagation velocities were measured in three orthogonal 
orientations (planar and thickness directions indicated by i, j subscripts) for 6 
measurements per sample (Figure 4-1). The experimental test set-up included a 
pulser-receiver (Model 5058PR, Panametrics, Billerica, MA, USA), a 
multichannel oscilloscope (Model TDS460A, Tektronix, Beaverton, OR, USA), 
and an array of sending-receiving transducers: 5 MHz (Model V156), 10 MHz 
(Model V112), 50 kHz (Model X1021), and 100 kHz (Models X1020 and V1548) 
transducers (Panametrics) facilitating a total of 1,050 measurements. Aggregate 
tissue density (ρt) of the samples was determined and system time delays were 
accounted for during each transducer arrangement.  
  Figure 4-1: Schematics of explant anatomic orientation and propagating ultrasonic waveforms.
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Figure 4-2: Images of harvested bovine cartilage tissue (a) and fabricated agarose hydrogel 
scaffold cubes (b). 
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(ii) Hydrogel Scaffold Fabrication and Ultrasonic Testing 
An agarose hydrogel formulation has been widely accepted as a host-biomaterial 
for cartilage TE culture [Nicodemus & Bryant, 2008], providing an appropriate 
technology for the bioengineering of modern scaffolds [Mata, 2011; Morsi et al., 
2011]. Here, a 2% agarose solution was made by slowly adding low-melting 
agarose (Type VII, Sigma-Aldrich, St. Louis, MO, USA) to a beaker containing 
Dulbecco's phosphate buffered solution (DPBS, Sigma-Aldrich) while being 
stirred on a hot plate. The concentration change due to excessive heating was 
taken into consideration in order to maintain a 2% concentration by weighing the 
beaker and solution prior to heating. The solution was brought to a boil for 10 
minutes stirring continuously until the agarose was completely dissolved. Hot 
sterile water was added to return the contents to the original weight and mixed 
continuously. The mixture was allowed to cool to 45°C and casted in a 5mm x 
5mm x 5 mm mold, immediately being placed in a refrigerator at 4°C for 10 
minutes.  
 For an equal-weighted statistical comparison with the cartilage explants, 
35 agarose samples were prepared (Figure 4-2). Due to the homogeneity of the 
125-mm3 agarose cubes, ultrasonic longitudinal (vii) and transverse (vij) wave 
propagation velocities were only measured in the z-direction. Three 
measurements per sample from each of the five sending-receiving transducers, 
described above, were used facilitating a total of 525 measurements per sample. 
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Aggregate biomaterial density (ρb) of all of the samples was determined and 
system time delays were accounted for during each transducer arrangement.  
(iii) Elastic and Statistical Analysis 
The measured propagation velocities were examined as a distinguishing elastic 
feature between the cartilage/hydrogel structure (when wavelength, λ > t, 
typically at kHz) or the constituent matrix/polymer material (when λ < t, typically 
at MHz). Transverse isotropy was tested and confirmed in the cartilage samples, 
while full-isotropy was affirmed in the agarose samples. Generalized stiffness or 
moduli (as a Young’s and Shear Moduli variants) were calculated (ρvii2 and ρvij2) 
for both the cartilage explants and agarose samples. An analysis of variance was 
applied for all comparisons (JMP v5.0.1, SAS Institute, Inc., Cary, NC, USA). 
Means (+/- standard deviation, SD) are shown for graphical comparisons.
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Section 4.07 Results 
In this work, ultrasonic measurements analyzed an agarose hydrogel formulation as 
a scaffold substrate for cartilage TE in comparison with native cartilage samples. The 
analyzed cartilage samples confirmed an aggregate density (here ρt = 1,330 kg/m3) and 
both longitudinal and transverse propagation velocities similar to that reported in the 
literature (vii = 1,500 to 1,720 m/s) [Agemura et al., 1990] (Figure 4-3). The statistical 
influence of propagation orientation on longitudinal (p = 0.8763) and transverse (p = 
0.0006) wave velocities in the native cartilage samples was statistically inconsistent. 
However, the wavelength of propagating waves relative to the propagating distance as 
indicated by MHz (λ < t) versus kHz (λ > t) frequencies was statistically significant for 
both longitudinal (p = 0.0001) and transverse (p = 0.0001) waves within the cartilage 
samples. 
In comparison, the fabricated agarose cubes had a mean density of ρb = 1,110 
kg/m3. A longitudinal propagation velocity range of 1,595 to 1,745 m/s was also 
determined for the biomaterial indicating a statistical similarity (p > 0.05) with native 
cartilage (Figure 4-4). Overall, the basic calculation addressing the ultrasonic elastic and 
shear moduli for both the cartilage and hydrogel samples was dominated by similar 
density, propagation velocity measurements, and water content (nearly 80%) [D’Arrigo 
& Paparelli, 1988]. These influences produced statistically similar (p > 0.05) hydrated 
stiffness values having large magnitudes dominated by the incompressible nature of 
 water when assessed with both longitudinal and transverse wave propagation modes 
(Figure 4-5). 
 
Figure 4-3: Mean (+/- SD) longitudinal (a) and trans
gathered from through-thickness (anterior
medial-lateral) orientations of harvested cartilage explants.
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Figure 4-4. Comparison of mean (+/- SD) ultrasonic propagation velocities of n = 
35 agarose biomaterial samples as driven by longitudinal wave impulses at varying 
frequencies. 
 
Figure 4-5. Fluid-dominated stiffnesses of the agarose biomaterial scaffolds and 
cartilage explants as measured using the 100 kHz longitudinal and transverse wave 
transducers.  
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Section 4.08 Discussion  
The application of ultrasonic wave propagation was explored as a means to 
compare an agarose biomaterial as a scaffold for cartilage TE design. Here, the results 
provided baseline measurements for analyzing future neotissue growth in a 
nondestructive manner. It was found that 2% agarose constructs had an ultrasonic 
propagation velocity similar to that of native cartilage, and that this approach may be 
used to assess the integrity of agarose constructs seeded with chondrocytes while ECM 
macromolecules are being synthesized without destroying the engineered tissue. Due to 
the aqueous nature of both the articular cartilage explants and the agarose hydrogels, the 
reported propagation values are highly dominated by the mechanical wave transfer 
through the water constituent.  
As a limitation in this approach, the ultrasonic propagation velocities themselves 
may not provide critical information in assessing native or TE cartilage. However, the 
signal resolution may be tuned in a manner sufficient to identify cellular or molecular 
influences on wave propagation during chondrocyte and ECM biokinetics. The difference 
in ultrasonic signals when comparing isolated agarose with cell-seeded agarose, may be 
used to assess the elastic properties of chondrocytes and newly developing ECM. 
Mechanical loading of hydrated materials such as cartilage tissue has also been shown to 
influence ultrasonic propagation velocity measurements [Nieminen et al., 2007]. Tissue-
equivalent phantoms may eventually aid in standardizing the accuracy of developing cell-
biomaterial construct measurements [Singh et al., 2008]. Articular cartilage is a highly 
hydrated tissue due to the negatively charged PG that binds fluid within its matrix. The 
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mechanical performance of cartilage is dominated by these solid/fluid interactions. When 
the tissue degenerates through injury or disease, the PG and collagen network is 
disturbed, altering the load transfer to the subchondral bone. This cascade of degeneration 
ultimately compromises the tissue and joint mechanical properties, as recently assessed 
with ultrasound [Brown et al., 2007].  
Ultrasonic wave transmission offers a highly resolved technique for characterizing 
these subtle changes in the tissue properties. However, distinguishing the ultrasonic 
propagation through its water content (~1,482 m/s) from the composite solid components 
(ECM and cells) will be very challenging. Ongoing efforts will apply forward and reverse 
acoustoelastic analysis to decipher bulk (K = ρfvii2) and aggregate (Ha = ρsvii2) moduli, 
which can be measured from separated fluid (f) and solid (s) ultrasound signals, 
respectively [Shull, 2002; Kobayashi & Vanderby, 2007]. Recent efforts have correlated 
matrix content and mechanics in developing engineered cartilage constructs with positive 
success by applying reflective ultrasound [Rice et al., 2009]. In that work, the speed of 
sound (SoS) and slope of attenuation (SoA) were compared between developing cell-
biomaterial constructs and nondegrading hydrogel controls from 50 and 100 MHz 
ultrasound data. SoA was shown to be a better indicator of the density of accumulated 
matrix molecules than SoS, while SoS correlated better with mechanical modulus than 
SoA.  
These promising data have encouraged the incorporation of ultrasound sensors as 
described within two recent reports characterizing a novel bioreactor design for cell and 
tissue engineering [Mason et al., 2011; Popp et al., 2012]. This non-destructive approach 
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reduces the bench-top assessment modality to a practical tool for online, real-time 
evaluation of the developing analogous living system created within the bioreactor 
environment. As neotissue forms within the cell-seeded agarose constructs, it will be 
important to detect any critical changes to the mechanical properties in a nondestructive 
manner in order to optimize TE development. Overall, ultrasonic wave propagation offers 
a potential means to gather constituent content and mechanical metrics for characterizing 
the biokinetics of native and engineered cartilage. 
 
Section 4.09 Conclusion 
In this work, we explored the application of ultrasonic propagation velocity as a 
metric for comparing native cartilage explants and a hydrogel biomaterial as design 
specifications for ongoing cartilage tissue engineering. This approach has identified both 
the benefits of interfacing ultrasonic sensors with a novel bioreactor as well as the 
limitations of assaying hydrated materials, where the resulting wave propagation is 
dominated by the water content. A more refined acoustoelastic analysis will facilitate 
distinguishing the cell and matrix biokinetics as modeled previously. 
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Section 5.01 Preface 
This chapter contains material from a manuscript that was submitted to: 
International Scholarly Research Network (ISRN) Biomedical Engineering as a Research 
Paper (MS # 956362) in March 2013. The final version was published In May 2013. The 
work presented here was the 1st part of a two-series experiment on the influence of extra-
endocrine vitaD3 metabolism on the in vitro temporal bone development sequence. 
 
Section 5.02 Authors Contribution 
The work presented here was carried out in collaboration between all authors. 
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the biological 
methods and experiments, while SSK designed the mathematical modeling. SSM carried 
out the laboratory experiments, analyzed the data, interpreted the results and wrote the 
paper. SSK co-worked on associated data collection and their interpretation. SRW co-
designed the biological experiments. All authors have contributed to, seen and approved 
the manuscript. 
Section 5.03 Hypothesis 
The overall goal of these experiments was to demonstrate the extrahepatic 
metabolism of parental vitaD3 precursor to the active vitamin D metabolite 1,25OH2D3 
by osteoblast precursor cells in a dose-dependent manner. The global hypothesis was that 
the conversion of vitaD3 to 1,25OH2D3 would lead to an increase in alkaline phosphatase 
(ALP) activity associated with osteoblast ECM maturation and an increase ECM 
mineralization indicated by calcium deposition detected  by alizarin red stain  (ARS).  
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Section 5.04 Abstract 
Osteoblastic precursors experience distinct stages during differentiation and bone 
development, which include proliferation, extracellular matrix (ECM) maturation, and 
ECM mineralization. It is well known that vitamin D plays a large role in the regulation 
of bone mineralization and homeostasis via the endocrine system. The activation of 
vitamin D requires two sequential hydroxylation steps, first in the kidney and then in the 
liver, in order to carry out its role in calcium homeostasis. Recent research has 
demonstrated that human-derived mesenchymal stem cells (MSCs) and osteoblasts can 
metabolize the immediate vitamin D precursor 25-dihydroxyvitamin D3 (25OHD3) to the 
active steroid 1α,25-dihydroxyvitamin D3 (1,25OH2D3), and elicit an osteogenic 
response. However, reports of extrahepatic metabolism of vitamin D3 (vitaD3), the 
parental vitamin D precursor, have been limited. In this study, we investigated whether 
osteoblast precursors have the capacity to convert vitaD3 to 1,25OH2D3 and examined the 
potential of vitaD3 to induce 1,25OH2D3 associated biological activities in osteoblast 
precursors. It was demonstrated that the engineered osteoblast precursor derived from 
human marrow (OPC1) is capable of metabolizing vitamin D3 to 1,25OH2D3 in a dose-
dependent manner. It was also demonstrated that administration of vitaD3 leads to the 
increase in alkaline phosphatase (ALP) activity associated with osteoblast ECM 
maturation and calcium deposits, and a decrease in cellular proliferation in both 
osteoblast precursor cell lines OPC1 and MC3T3-E1. These findings provide a two-
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dimensional culture foundation for future three-dimensional engineered tissue studies 
using the OPC1 cell line. 
Section 5.05 Introduction  
An osteoblastic precursor cell line (OPC1), derived from human fetal bone tissue, 
was originally established to provide a consistent and reproducible culture system for 
evaluating bone development, cell/biomaterial interactions, and screening putative bone 
differentiating factors (Winn et al., 1999). In addition, OPC1 can be used to study the 
growth and differentiation of osteoprogenitors and offers the possibility of examining 
events associated with stem cell differentiation to osteoblasts. Proliferation and 
differentiation of osteoblasts is regulated by their respective microenvironment, which 
encompasses cells, growth factors and cytokines, and their extracellular matrix (ECM) 
[Atanga et al., 2011]. Osteoblasts are a main target for calcitropic hormones including 
vitamin D [Biswas & Zanello, 2009].  
Several studies have demonstrated changes in bone devlopment in response to the 
steroid hormone vitamin D, especially with regard to the inhibition of growth during the 
proliferation stage and the stimulation of osteogenic differentiation during the maturation 
and mineralization stages, albeit the outcomes appear to be variable and  dependent upon 
the stage of cellular maturation or differentiation at the time of hormone responsivness 
[Pockwinse et al., 1995; Lian & Stein, 1995]. Because OPC1 is a stable osteoblast 
precursor that has displayed consistent reproducible cultures, it is an ideal culture system 
to study the effects of vitamin D on bone development, and elucidate the extraendocrine 
metabolism of vitamin D in osteoblasts.  
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Vitamin D, also known as calciferol, refers to a collective group of fat-soluble 
pluripotent, seco-steroid metabolites that together carry out the known vitamin D-related 
functions. The classic understanding of vitamin D is the essential role it plays in the 
regulation and maintenance of calcium and phosphorous homeostasis and bone 
metabolism. Elucidating the steps required for the metabolism of vitamin D precursors, 
vitamin D3 (cholecalciferol) and 25-hydroxyvitamin D3 (25OHD3; calcidiol), to the active 
hormone 1α,25-dihydroxyvitamin D3 (1,25OH2D3; calcitriol) led to the discovery of 
regulatory cytochrome P-450 (CYP-related hydroxylases) involved in the activation and 
inactivation of vitamin D, and the nuclear vitamin D receptor (VDR) and its interactions 
with transcriptional machinery inside vitamin D target cells [Jones, Strugnel, & DeLuca, 
1998]. 1,25OH2D3 directly influences osteoblast binding to the VDR, which consequently 
elicits nuclear and extra-nuclear cellular responses related to the production and 
maintenance of the skeleton [Biswas & Zanello, 2009]. Once it was demonstrated that 
VDR and vitamin D regulatory CYPs were present in multiple tissues and cells not 
involved in the classic endocrine actions of vitamin D, it was acknowledged that its 
functions extended far beyond mineral homeostasis and bone metabolism. It is now 
recognized that vitamin D is associated with the regulation of many cellular process 
including proliferation, differentiation, and apoptosis in multiple tissues in a 
paracrine/autocrine manner [Brannon, 2012; Hobaus et al., 2013; Jones et al., 1998].  
Vitamin D, in the form of vitamin D3, is endogenously made from cholesterol in 
the skin when it is exposed to ultra-violet light (UVB). Alternatively vitamin D can be 
acquired by diet in either the vitaD3 (derived from animals) or vitamin D2 (derived from 
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plants) form. There are many metabolites or isomers of vitamin D. The active metabolite 
1,25OH2D3 and the immediate metabolic precursor to the active metabolite, 25OHD3, are 
among the most studied. Vitamin D3, the metabolic precursor to 25OHD3, itself is 
biologically inert, or inactive, in that it does not directly increase the active transport of 
calcium or mediate any of the other vitamin D-related activities in physiological 
concentrations unless it its metabolized to a more polar compound [Kumar, 1990]. 
  In the classic endocrine metabolic pathway of vitamin D, both endogenous and 
dietary vitamin D3 undergoes sequential steps of activation by being hydroxylated in the 
liver to 25OHD3 by CYP-related 25-hydroxylase (CYP27A1) and then to 1,25OH2D3 by 
25-hydroxyvitaminD3-1α-hydroxylase (CYP27B1) in the kidneys (Ahmed & Shoker 
2010; Norman, 1998; Jones et al. 1998). While early data suggested that the liver is the 
only significant site of 25-hydroxylation in vivo, there have been occasional reports of 
extrahepatic 25-hydroxylation of vitamin D3 (Jones et al., 1998; Hollick, 2010). Recently 
extrarenal metabolism of 25OHD3 to 1,25OH2D3 has been demonstrated definitively 
(Zhou et al., 2012; Hobaus et al., 2013). In vitro, many non-renal cells, including 
mesenchymal stem cells (MSCs), bone, cartilage, keratinocytes, placenta, prostrate, 
macrophages, lymphocytes, dendritic cells, and several cancer cell lines can convert 
25OHD3 to 1,25OH2D3 (Zhou et al., 2012). Several of these cell types have been shown 
to express both CYP27 hydroxylase enzymes required for the activation of vitamin D3, 
which may explain the occasional reports of extrahepatic 25-hydroxylation of vitamin D3 
[Lehman, 2008; Hollick, 2010; Jones et al.,1998].  
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The molecular effects of vitamin D are mediated through the intra-nuclear 
receptor VDR, which acts as a ligand-activated transcription factor for target genes when 
bound to 1,25OH2D3 [Seiffert et al., 2004]. 1,25OH2D3 has a high affinity for VDR and 
upon binding forms a heterodimer with the retinoid X receptor, which allows it to bind to 
the response/receptor element (VDRE) in the promoter regions of target genes [Flanagan 
et al., 2006; Brannon, 2012; Geng et al., 2011]. The genes include those associated with 
calcium homeostasis, immune response and maintenance of immune cells, cellular 
growth, differentiation, cell cycle arrest, apoptosis, and the enzymes required for their 
own metabolism [Chen et al., 2011; Flanagan et al., 2006; Boyan et al., 2009; Geng et al., 
2011]. 1,25OH2D3 influences many aspects of bone cell biology, and has been implicated 
in the regulation of both osteoblastic and osteoclastic activity affecting both resorptive 
and synthetic phases of bone remodeling [Atkins, et al., 2007]. In addition, 1,25OH2D3 
has been demonstrated to regulate osteoblast and chondrocyte gene transcription, 
proliferation, differentiation, and mineralization of ECM [Boyan et al., 2009; Atkins et 
al., 2007]. More than 30 tissues are known to have nuclear receptors for 1,25OH2D3, and 
it is known to regulate the function of more than 200 genes  [Flanagan et al., 2006; 
Hollick, 2010; Norman, 1998; Naeem, 2010]. Because of its role in proliferation and 
differentiation, it has been hypothesized that the local production of 1,25OH2D3 in 
extrarenal tissues serves to regulate growth and differentiation in an autocrine/paracrine 
fashion [Atkins et al., 2007; Lehmann & Meurer, 2003].  
Despite the increase in research over the last few decades, further investigation on 
vitamin D metabolism and regulation needs to be carried out in order to elucidate extra-
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endocrine metabolism and local production of 1,25OH2D3. While there has been an 
increase in the reports of extrarenal 1,25OH2D3 synthesis and occasional reports of 
extrahepatic 25-hydroxylation of vitamin D3, to our knowledge, there is no detailed 
analysis of extrahepatic vitamin D3 metabolism in osteoblast precursors. Furthermore, 
paracrine/autocrine regulation and gene expression that results in local changes in 
proliferation and differentiation need to be further investigated to understand the potential 
application of vitamin D for regenerative medicine. In this study, we investigated whether 
osteoblast precursors have the capacity to convert the parental vitamin D precursor, 
vitamin D3, to 1,25OH2D3 and examined the potential of vitamin D3 to induce 1,25OH2D3 
associated biological activities in osteoblast precursors.  
 
Section 5.06 Materials and Methods 
(i) OPC-1 and MC3T3-E1 Cell Cultures 
Vitamin D3 (cholecalciferol) and 1,25OH2D3 (calcitriol) were purchased and 
maintained in 10 mM and 10 µM stock solutions in ethanol, respectively (Sigma-
Aldrich, St. Louis, MO). All other reagents and chemicals were purchased from 
the same vendor unless otherwise indicated. Original OPC1 and MC3T3-E1 cell 
lines were cultured on-site (Department of Molecular & Medical Genetics, 
Oregon Health & Science University, Portland, OR). Cells were cultured at 
populations of 2.5 x 105 in 75 cm2 tissue culture flasks in alpha modified essential 
medium (α-MEM) with 5% fetal bovine serum (FBS). Once confluent, OPCs 
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were plated in 12-well plates after trypsin-ethylenediaminetetraacetic acid 
(EDTA) enzymatic removal and counted with 0.4% trypan blue (1:1) on a 
hemacytometer. Cultures were then prepared in duplicate at a seeding density of 
2.5 x 104 cells/well in the initial bone medium (designated as BM-) with 200mM 
L-Glutamine and antibiotics for at least 4 hours before creating experimental 
groups based on additive culture medium. Six types of medium-based groups 
were prepared. BM- provided a negative control (Group 1) and the additional 
groups included: BM- supplemented with 1 µM vitamin D3 (Group 2); BM- 
supplemented with 10 nM 1,25OH2D3 (Group 3); BM- supplemented with 
osteogenic factors (BM+) comprised of 10 mM β-glycerophosphate, 10nM 
dexamethasone, and 50 µg/ml of ascorbic acid phosphate (Wako Chemical, 
Osaka, Japan) represented the positive control (Group 4); BM+ supplemented 
with 1µM vitaD3 (Group 5); and BM+ supplemented with 10nM 1,25OH2D3 
(Group 6). Fresh medium was added every 1 to 3 days.  
 
(ii) Cell Proliferation 
OPC1 and MC3T3-E1 cell lines were evaluated for growth kinetics while 
maintained in the presence of vitamin D metabolites, vitaD3 and 1,25OH2D3, with 
(BM+) or without (BM-) osteogenic factors, at the indicated experimental group 
concentrations. Each sample set was cultured for at least two weeks in duplicate 
or quadruplicate. Every 2 to 5 days, following the addition of experimental media 
and at the end of each incubation period, cell proliferation was measured using 
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crystal violet solution (CVS, Sigma-Aldrich). Cultures were rinsed with 
Dulbecco’s phosphate buffered saline (DPBS) and fixed for 15 minutes in 95% 
ethanol. The fixed cells were rinsed several times with distilled water, and stained 
for 10 minutes with CVS. The CVS was then extracted from the cells after a 4 h 
incubation in 1% Triton X-100 at room temperature. The samples were then 
stored at -80°C until the end of each experimental period. Triton extracts were 
measured at 570 nm on a microplate reader (Cary 50, Varian Australia Pty. Ltd). 
Absorbance values were converted into cell numbers extrapolated from standard 
growth curves.  
 
(iii) Alkaline Phosphatase 
As described above, OPC-1 and MC3T3-E1 were treated with both vitaD3 and 
1,25OH2D3 in the BM- and BM+ experimental groups. Alkaline phosphatase 
(ALP) activity was measured every 3 to 4 days. At the end of the incubation, the 
cell layers were washed three times with DPBS, scraped off of the plates with 500 
µl DPBS and stored at -80°C until the end of each experimental period (2 to 3 
weeks). Each sample was subjected to three freeze-thaw cycles in order to lyse the 
cells. ALP activity in the cell lysates was measured using ρ-nitrophenyl phosphate 
liquid substrate system at 37°C for 30 minutes. Protein content was measured 
using a micro-volume spectrophometer system (Epoch, Biotek, Winooski, VT).  
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(iv) Matrix Mineralization 
A histochemical analysis of mineralization was evaluated utilizing an Alizarin 
Red S (ARS) assay. ARS staining is used to evaluate calcium-rich deposits by 
cells in culture, and is considered a functional in vitro endpoint reflecting 
advanced cell differentiation (Hoemann et al. 2009). In brief, after 10 to 15 days 
in culture, cells were fixed in 95% ethanol for 15 minutes, then rinsed thoroughly 
with distilled water and stained with 40 mM of ARS (pH = 4.1) at room 
temperature for 20 min with gentle shaking. The cell layers were efficiently rinsed 
with distilled water and observed both grossly and microscopically. For semi-
quantification, ARS was extracted from the cells after incubating for one hour in 
at room temperature in 10% volume to volume (v/v) acetic acid with gentle 
shaking, and then the residual dye was further extracted by scraping the cells and 
heating at 85°C on a heating block with a layer of mineral oil to prevent 
evaporation. The samples were neutralized with 10% (v/v) ammonium hydroxide 
and the extracts were read at a resolution of 405 nm on the microplate-reader. The 
samples were compared to a serially diluted ARS standard. The resulting data 
were normalized using cell numbers extrapolated from the CVS proliferation data.  
 
(v) Vitamin D3 Metabolism 
Vitamin D metabolism by OPC1 was performed in a dose-dependent manner 
over a 24-hour period. The conversion of 1,25OH2D3 from vitamin D was 
quantitatively measured using an enzyme-linked immuno sorbent assay (ELISA) 
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kit (Human1,25-dihydroxyvitamin D3 DVD/DHVD3, NB-E10878, Novatein 
Biosciences, Cambridge, MA). OPC-1 was plated in 6-well plates at a seeding 
density of 105 cells/well. Upon confluency, experimental media was added in 
duplicates when creating experimental groups slightly modified from those 
described in Section 2.1: base medium (BM-) provided a negative control (Group 
1): BM- supplemented with 10 nM 1m25OH2D3 as a positive control (Group 2); 
BM- supplemented with 10 nM vitaD3 (Group 3); BM- supplemented with 1 µM 
vitaD3 (Group 4); and BM- supplemented with 10 µM vitamin D3 (Group 5). The 
assay was carried out via manufacturer’s protocol.  
 
(vi) Statistical Analysis and Mathematical Modeling 
Statistical analyses were carried out using commercial software (Prism, Irvine, 
CA; JMP Pro v10, SAS Concepts, Inc., Cary, NC; Excel, Microsoft, Redmond, 
WA). Data were expressed as means ± standard error of the mean (SEM) of 
samples characterized in three two-week sample sets plated in duplicate or 
quadruplicate, and assayed in duplicate (n = 12 or n = 24, respectively). One-way 
and two-way analysis of variance (ANOVA) and linear regression statistically 
assessed the culture treatments through time and between experimental groups, 
with asterisks of *p<0.05, **p<0.01 and ***p<0.001 indicating varying levels of 
statistical significance. Bonferonni Post-test (direct comparisons with controls) 
and Dunnett’s Test (pairwise comparisons) were applied where appropriate. 
Through the ELISA assay protocol for examining the dose-response of the 
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metabolized form of vitamin D, the input dosage levels (x-values) were controlled 
and distributed at logarithmic concentration levels (in units of ng/ml). A log-base-
10 model was applied to the resulting response data (y-values in pmol/mg protein) 
in the form: 
 
y = m Log10 x        (1) 
 
Here, the coefficient (m) was identified as a fitting parameter optimizing the 
model’s representation of the collected data. The model was applied to the 
metabolized vitamin D concentration data. Least squares estimates were 
constructed for the log-coefficient via a quasi-Newton convergence method with 
commercially available software (Solver, Frontline Systems, Inc., Incline Village, 
NV; Excel, Microsoft, Redmond, WA). The model fit was again determined by 
minimizing the root mean square error (RMSE) between the actual and response 
concentrations. The correlation coefficient (R2) further assayed the strength of the 
modeled relationship.  
 
(vii) Microscopic Imaging  
Microscopic images were taken using an advanced transmitted light inverted 
microscope (EVOS-XL) and accompanying software (EVOS3), both 
commercially available (Advanced Microscopy Group, Bothell, WA). Images 
were processed using an open source, image-processing package (FIJI, ImageJ 
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v1.47d, National Institutes of Health, Bethesda, MD). To maintain consistency, 
each image was processed in the same manner including maintaining consistent 
light intensities during optical density measurements. The operations included the 
background subtraction command, mean filter, and local contrast (CLAHE 
commands: blocksize 100, bin 256, and maximum slope 2.50, respectively).  
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Section 5.07  Results 
(i) ALP Activity and Early Matrix Mineralization 
As described, in order to determine the optimal dose of vitaD3, OPC1 and 
MC3T3-E1 cells were cultured at a seeding density of 5.0 x 104 in quadruplicates 
with 1 or 10 µM vitaD3 in standard bone medium (BM-), or in a BM- vehicle 
control containing the equivalent amount of ethanol for 10 days in 12-well plates. 
After 10 days, two wells from each group were prepared for ALP assay, and two 
wells were stained with ARS to assess ECM calcium deposition. [the previous 
sentences are Methods, and should be moved to that section] OPC1 treated with 
vitamin D3 at concentrations of 1 or 10 µM had a statistically significant (p < 
0.001) increase in ALP activity compared to that of the control (Figure 5-1). 
There was no statistically significant difference (p  > 0.05) between experimental 
groups containing either 1 µM or 10 µM vitamin D3. There was also no 
statistically significant difference (p = 0.2388) in ALP activity between MC3T3-
E1 treated with either 1 µM or 10 µM vitamin D3 compared to that of the control, 
however in the wells treated with 10 µM vitamin D3 we observed a variable affect 
on ALP activity and an adverse affect on cell viability (not shown), which was 
observed microscopically throughout the experiment (Figures 2 and 3). There was 
not a significant increase in calcium deposition in ECM in either cell lines 
compared to the ethanol vehicle control (p  > 0.05).  
  
 
 
 
 
Figure 5-1. 
MC3T3-E1 after 10 days in culture after being 
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Alkaline phosphatase activity (ALP) of osteoblast precursor OPC1 and 
treated with or without vita
p = 0.2166) on ALP 
th either 1 µM or 10 µM vitaD3, however there was an 
p = 0.0026) in ALP activity between vita
 
 
D3 (BM- 
D3 
 Figure 5-2. Osteoblast precursor cell lines OPC1 (A
after 10 days in culture. OPC1 without treatment of vitamin D
a statistically significant amount of ARS per cell population (see 
either 1 µM vitamin D3 (B) or 10 
without vitamin D3 (ethanol control) (D), 1 
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-C) and MC3T3-E1 (D-F) stained with 
3  (ethanol control) (A) did not absorb 
Figure 3), than with treatment of 
µM vitamin D3 (C). Similar results were seen with MC3T3
µM vitamin D3 (E), and 10-µM vitamin D3 
 
ARS 
-E1 
(F).  
  
 
 
 
 
 
 
 
Figure 5-3. Semi-quantification of matrix mineralization was conducted by taking the 
optical density (resolution, 450 nm) of the ARS extracted from each treatment group 
(shown in Figure 2). Vitamin D
significant effect on the ECM mineralization of OPC1 (
0.1101) after 10 days, compared to the control group. 
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3 at both 1 µM and 10 µM did not have a statistically 
p = 0.2881) or MC3T3-E1 (
 
 
p = 
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(ii) Influence of Vitamin D3 and 1,25OH2D3 on Osteoprecursors 
(a) Antiproliferative Effects 
 
As described, OPC1 and MC3T3-E1 were cultured for two weeks with 
either 10-µM vitaD3 or 10 nM 1,25OH2D3 with (BM+) or without osteogenic 
factors (BM-), and then compared to BM- and BM+ ethanol vehicle controls. 
Proliferation kinetics was quantitatively compared after conducting a CVS assay 
as a function of time. The CVS proliferation assay indicated a statistically 
significant inhibition of cell proliferation in OPC1 treated with 10 µM vitaD3 in 
the same manner as cells treated with 10 nM 1,25OH2D3, compared to that of the 
BM- and BM+ ethanol controls (shown as absolute cell populations and 
percentages in Figures 5-4 and 5-5, respectively). Groups containing BM+ 
overall, had lower proliferation rates than with BM- groups, however groups 
treated with BM+ containing either vitaD3 or 1,25OH2D3 were significantly lower 
then the BM- groups. Growth kinetics of MC3T3-E1 cultured with BM+ and 
10µM vitaD3 was indistinguishable from cells cultured in BM+ containing 10nM 
1,25OH2D3 (shown as absolute cell populations and percentages in Figures 6 and 
7, respectively).  
  
 
 
Figure 5-4. Absolute 
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proliferation of OPC1 cells maintained in six types of tissue culture 
-week periods (n = 24). At day 5, the OPC1 cell counts in the wells 
etabolites ± osteogenic factors (BM+) were statistically lower then than 
-). OPC1 treated with BM+ and 1,25OH2D3 experienced the largest 
-proliferative effect. The effect of vitamin D3
 
 
 was similar to 
  
Figure 5-5. Percent proliferation of OPC1 cells maintained in six types of tissue culture medium 
over three two-week periods (
containing vitamin D metabolites ± osteogenic factors (BM+) were statistically lower then than 
the negative control (BM-). By day 10, OPC1 treated with BM+ and active 1,25OH
around 50% of the BM- cellular confluency. In both BM
cells proliferated in a manner very similar to those treated with 1,25OH
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n = 24). By 7 to 10 days, the OPC1 cell counts in the wells 
2D
- and BM+ groups, vitamin 
2D3.  
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D3 treated 
  
 
 
 
 
 
Figure 5-6. Absolute proliferation of MC3T3
culture medium in duplicates over three two
12). Two types of medium was used, one with osteogenic factors (BM+), and one without 
(BM-). At day 5, the MC3T3
± osteogenic factor were statistically lower then than 
E1 cells treated with BM+ and vitamin D
both experienced the largest statistically (
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-E1 cells maintained in six types of tissue 
-week periods, and assayed in duplicates (n = 
-E1 cell counts in the wells containing vitamin D metabolites 
the negative control (BM
3 were indistinguishable from 1,25OH
p < 0.001) anti-proliferative effect. 
 
-). MC3T3-
2D3, in that 
 
  
 
 
 
Figure 5-7. Percent proliferation of 
culture medium. At day 10, the OPC1 cell counts in the wells containing vitamin D 
metabolites ± osteogenic factors (BM+) were very statistically lower (***) then than the 
negative control (BM-) and remained 
day 10, MC3T3-E1 cells treated with BM+ and vitamin D
1,25OH2D3, as in the absolute proliferation, both experienced the most significant (
0.001) anti-proliferative effect. 
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MC3T3-E1 cells maintained in six types of tissue 
at around 50% of the BM- cellular confluency. By 
3 were indistinguishable from 
 
 
p < 
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(b) ECM Maturation 
 
Increased ALP activity was directly associated with osteoblast function and 
matrix maturation during the active stages of bone development (Figure 8). 
Treatment of OPC-1 cells with standard bone medium (BM-) and both vitaD3 and 
1,25OH2D3 stimulated a 2 to 3 fold increase in ALP activity after two weeks 
relative to the parallel control culture, while treatment with osteogenic medium 
(BM+) containing 1,25OH2D3 stimulated a 5 fold increase in ALP activity in 
comparison to BM- and a 20% increase in comparison with the BM+ control 
(Figure 9). However, treatment of MC3T3-E1 cells with BM- containing either 
vitaD3 or 1,25OH2D3 showed a slight increase in ALP Activity, while BM+ 
containing either vitamin D metabolite was increased by 20% when compared to 
the parallel control, and a 70 to 80% increase when compared to the BM- control 
(Figure 5-10).  
 
  
 
 
 
Figure 5-8. ALP activity of OPC1 and MC3T3
culture medium aggregated over three two
OPC1 ALP activity of 1,25OH
statistically greater when compared to the negative control (BM
treated with vitamin D3 
BM+ control containing ethanol vehicle. All cellular groups containing BM+ had a 
significantly higher ALP activity compared to the control within the MC3T3
MC3T3-E1 response to vitamin D
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-E1 cells maintained in six types of tissue 
-week periods (n = 12). After two
2D3 and osteogenic factors (BM+) treated cells were 
-). ALP activity of OPC1 
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Figure 5-9. ALP activity of OPC1 cells maintained in six types of tissue culture 
medium described over three two
ALP activity of 1,25OH
statistically greater than the negative control (BM
with vitamin D3 and BM+ was significantly higher 
BM+ control containing ethanol vehicle. 
 
 
 
 
123
 
-week periods (n = 12). After two-weeks, the OPC1 
2D3 and osteogenic factors (BM+) treated cells were 
-). ALP activity of OPC1 treated 
than BM-, but not higher than
 
 
 the 
  
 
  
 
Figure 5-10. ALP activity of MC3T3
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MC3T3-E1 ALP activity of 1,25OH
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(c) ECM Mineralization  
 
The ability to mineralize the ECM during bone development provides the 
functional niche of osteoblasts in vitro and in vivo (Halvorsen et al., 2001). OPC1 
groups cultured in BM+ containing vitaD3 (n = 8) or 1,25OH2D3 (n = 8) had a 
statistically larger amount of ECM calcium compared to the BM- (p < 0.001) and 
BM+ (p = 0.027) ethanol vehicle controls based on ARS measurements (Figure 
11). The optical density of the OPC1 cell culture (measured in normalized ARS), 
increased by 100% relative to the negative control (BM-) and by about 10% 
compared to the BM+ parallel control (Figure 13). OPC1 cells treated with BM+ 
and vitaD3 (39.68 ng/mg/106 cells ± 0.75, n = 8) were indistinguishable from cells 
cultured with BM+ and 1,25OH2D3 (39.69 mean ± 1.00, n = 8) (p<0.05). MC3T3-
E1 groups cultured in BM+ containing vitaD3 (n = 8) or 1,25OH2D3 (n = 8) had a 
statistical greater amount of ECM calcium compared with treatment groups with 
only BM- (p < 0.001). Meanwhile, cultures with BM+ and 1,25OH2D3 had a 
statistically greater amount of ECM calcium compared with the BM+ parallel 
control (p = 0.0055) (Figures 12 and 13).  
 Figure 5-11. Osteoblast precursor cell lines OPC1 stained with ARS after two weeks in 
experimental conditions. Images of OPC1 cells without either osteogenic factors (BM
D
 
(ethanol control) (A), BM
consistently did not absorb a statistically perceptible amount of ARS compared to groups 
containing osteogenic factors (BM+) (D
D3 (E), and BM+ with 10 µM vitamin D
calcium associated with ECM mineralization compared to the BM+ control (D
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- with 1 µM vitamin D3 (B), and BM- with 10 µM vitamin D
-F). However, cells cultured with BM+ and 1 
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).  
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 Figure 5-12. Osteoblast precursor cell line MC3T3
the experimental treatment groups. MC3T3
vitamin D
 
(ethanol control) (A), BM
(C), consistently did not absorb a significant amount of ARS compared to groups containing 
osteogenic factors (BM+) (D
significant compared to the negative 
control (D). However, cells cultured with BM+ and 10 nM 1,25OH
significant (p = 0.0055) amount of calcium associated with ECM mineralization compared to the 
BM+ control (D).  
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Figure 5-13. Semi
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-quantification of matrix mineralization of cultured experimental 
Figures 11 and 12). OPC1 treated with vitamin D
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in BM+ had a statistically significant (p = 0.0055) amount of 
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(iii) Endogenous 1,25OH2D3 Synthesis by OPC1. 
OPC1 cultures were tested for their ability to synthesize 1,25OH2D3 from the 
parental precursor vitaD3. For this dose-response assay, cells were cultured at 
high density in order to maximize the concentration of secreted 1,25OH2D3. Low 
serum conditions were also used and compared with a serum control to account 
for any potential influence of vitamin D metabolites present in the serum. OPC1 
cultured in the presence of vitaD3 produced a detectable level of 1,25OH2D3 that 
elevated with increasing concentration. The synthesis of 1,25OH2D3 in OPC1 
correlated logarithmically to the dosage of vitaD3 when applying the log-model of 
equation 1 (R2 = 0.9898, p = 0.0051, m = 7.23 ng/ml) (Figure 5-14).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 5-14.  
incubation with vitamin D
metabolism of precursor vitamin D
vitamin D3 was controlled and administered at logarithmic concentration levels. A log 
base-10 model was applied to the resulting response data. 
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Endogenous production of 1,25OH2D3 by OPC1 in response to 
3. A 1,25OH2D3/VDR ELISA was performed to analyze the 
3 to the hormonally active form. The dose of 
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Section 5.08 Discussion  
We investigated whether osteoblast precursors have the capacity to convert vitaD3 
to 1,25OH2D3 and examined the potential of vitaD3 to induce 1,25OH2D3 associated 
biological activities in osteoblast precursors. The active form of vitamin D, 1,25OH2D3, 
is generated from the parental precursor of vitamin D3which requires two sequential 
hydroxylation steps catalyzed by mitochondrial cytochrome P450 enzymes, CYP27A1 
and CYP27B1, respectively (Hewison et al., 2004). We found that OPC1 is capable of 
synthesizing 1,25OH2D3 by administering vitaD3 in a dose-dependent manner, and that 
the influences of vitaD3 on antiproliferation and osteoblast differentiation was very 
similar to 1,25OH2D3. It was also found that vitaD3 induced ALP activity and calcium 
deposition associated with ECM maturation and mineralization during early bone 
development in a manner that was indistinguishable from groups treated with 
1,25OH2D3. These findings have important implications for bone and vitamin D research 
because it provides further evidence that local production of active 1,25OH2D3 can occur 
in osteoprecursors and the local metabolism of vitaD3 can influence bone development.  
Several osteoblast culture systems have demonstrated that cells undergo a 
temporal developmental sequence that starts with a proliferation phase and results in fully 
mature osteocyte-like cells embedded in mineralized ECM (Pockwinse et al., 1995; 
Owen et al., 1991). There are three stages of in vitro bone development that have been 
characterized by morphology and gene expression. These are (1) a proliferation and ECM 
biosynthesis stage, (2) an ECM development and maturation stage noted by an increase in 
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ALP activity, and (3) a final stage of ECM mineralization in which hydroxyapetite is 
organized and deposited (Pockwinse et al., 1995; Owen et al., 1991; Lian & Stein, 1995). 
In the first stage, following initial cell-seeding, the cells actively proliferate for the first 
10 to 12 days of culture and several genes associated with ECM formation, including 
type I collagen and osteopontin, are actively expressed then gradually decline as 
proliferation rate decreases and ECM maturation begins. We report that both vitaD3 and 
1,25OH2D3 had similar effects on two osteoprecursor cell lines, which influenced the 
proliferation stage of bone development by significantly hampering the growth rate.  
Immediately following the decrease in proliferation, ALP activity is greatly 
increased. This post-proliferative period occurs between days 12 and 18, and it is during 
this time that the ECM matures and becomes competent for mineralization (Pockwinse et 
al., 1995; Lian & Stein, 1995). Here, ALP activity of untreated osteoprecursors steadily 
increased, while the groups containing osteogenic factors (BM+) and either vitaD3 or 
1,25OH2D3  increased more then 10 fold over a two week period of time. While the 
measurement of increased ALP expression is used as an osteogenic marker as an 
indication of osteoblast phenotype, its function still remains unclear. It has been 
postulated to increase concentration of inorganic phosphate, a concept known as the 
“booster hypothesis” (Golub & Boesze-Battaglia, 2007). During the third stage of bone 
development, ALP expression decreases and other genes associated with bone 
mineralization are expressed at maximal level (Owen et al., 1991; Lian & Stein, 1995; 
Golub & Boesze-Battaglia, 2007). These bone cell synthesized proteins include 
osteopontin (OP) and osteocalcin (OC) and are known to interact with the mineralized 
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ECM in vivo (Lian & Stein, 1995). OP is expressed in both the proliferation and 
mineralization periods, and down-regulated post-proliferatively during matrix maturation; 
however, during proliferation, OP expression reaches only about 25% of its maximal 
level which peaks between days 16 and 20 during mineralization. In contrast, the calcium 
binding protein OC, which binds to hydroxyapetite, is expressed only post-proliferatively 
with the onset of nodule formation, and is expressed maximally with ECM mineralization 
in vivo  and in vitro (Lian & Stein, 1995). We saw minimal calcium mineralization after 
two weeks in untreated cell cultures as well as calcium mineralization of the ECM in 
cultures that were treated with osteogenic factors (BM+) and vitaD3 or 1,25OH2D3. 
However, further studies need to be carried out for a longer duration to see maximal 
levels of ECM mineralization that is associated with bone development.  
The osteoprecursor cultures observed in the present work were non-confluent 
cultures with actively dividing cells. Because vitamin D has an anti-proliferative effect, it 
is important to look at its influence on osteoblast precursors after proliferation begins to 
decrease in order to get a better understanding of how vitamin D effects a confluent cell 
population. Both OPC1 and MC3T3-E1 cultures treated with vitaD3 or 1,25OH2D3 did 
not reach confluency during the 15 day culture period, while the control groups reached 
confluency at around 10 to 12 days after an initial seeding density of about 6,500 
cells/cm2. Confluent osteogenic cultures, including MC3T3-E1 cells and human bone 
marrow derived stromal cells (BMSCs), follow a two-stage developmental process 
including a 1 to 2 week initiation phase during which cells slowly proliferate, express 
ALP activity and other bone specific genes, and produce and assemble a collagen matrix, 
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and a second maturation phase occurring in weeks 2 to 3 in which ECM mineralization is 
observed (Hoemann et al., 2009). Mineralization has been demonstrated in BMSC 
cultures that achieve a minimal ALP activity (~0.25 nmol/min/µg protein or 1.2 
nmol/min/10,000 cells) at some point during the 2 to 3 week culture period, albeit some 
BMSC cultures can produce high-levels of ALP in vitro without ever mineralizing 
(Hoemann et al., 2009). Treatments applied here tended to speed up maturation at the 
expense of proliferation, hence confluencey would be achieved more slowly (or not at all, 
in this case) relative to control cultures. The effects of vitamin D on ALP activity and 
mineralization of ECM on confluent OPC1 cultures is currently under way.  
One limitation here is that because supra-physiological doses (≥ 10-7 M) of vitaD3 
(10 µM) and 1,25OH2D3 (10 nM) were used to achieve a maximal response, it is unclear 
how relevant our findings are to the action of lower vitaD3 levels within the physiologic 
range. In vivo, doses of vitaD3 as low as 10 µg (400 IU) have been shown to stimulate 
bone mineral augmentation in adolescents (Viljakainen , et al., 2006), and the 
administration of physiological doses of 1,25OH2D3 has been shown to cure vitamin D-
dependency rickets I (Vanhooke, et al., 2006). Our findings indicated, for an in vitro 
system, supra-physiological doses had a positive effect on bone maturation and 
mineralization and a negative response in cellular proliferation.  
Another limitation is that an insufficient amount of RNA was obtained from the 
groups containing vitaD3 and 1,25OH2D3 to permit simultaneous analysis by qRT-PCR of 
multiple primers. This was due to the fact that both vitaD3 and 1,25OH2D3 inhibited 
proliferation, which lead to a much smaller population size in comparison to the controls. 
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Advancements in the design of biomedical engineering technologies, especially that 
supporting regenerative medicine through cell and tissue engineering, include the use of 
precursor cell lines which can consistently be manipulated to develop neotissue. The 
OPC1 cell line investigated here maintained consistent proliferation, ECM synthesis, and 
boney maturation, albeit during an abbreviated two-dimensional study. Future 
investigations will recreate the culture scenarios in a three-dimensional, cell-biomaterial 
construct with concomitant mechanical stimulation through the application of a novel 
bioreactor (Mason et al., 2011). This approach will establish a surrogate living tissue 
model for pharmacokinetic assessment of the dose-response relationship building off of 
the foundation described here.  
 
ACKNOWLEDGMENTS  
The authors appreciate the generous support given by fellow laboratory members in the 
Department of Molecular and Medical Genetics, Oregon Health & Science University. 
Partial funding was provided by the National Institutes of Health (Grant No. P20 
MD003350) and the Collins Medical Trust. 
 
 
 
 
 
 
  
 
 
136
REFERENCES 
Ahmed, M. S., & Shoker, A. (2010). Vitamin D metabolites; protective versus 
toxic properties: molecular and cellular perspectives. . Nephrology Reviews , 2 (1). 
Ando, K., Lmai, S., Isoya, E., Kubo, M., Mimura, T., Shioje, S., et al. (2009). 
Effect of dynamic compressive loading and its combination with a growth factor on 
chondrocytic phenotype of 3-dimmensional scaffold-embedded chondrocytes. Acta 
Orthopaedica , 80 (60), 724-733. 
Appleman, T. P., Mizrahi, J., Elisseeff, J. H., & Seliktar, D. (2009). The 
differential effect of scaffold composition and architecture on chondrocyte response to 
mechanical stimulation. Biomaterials , 30, 518-525. 
Atala, A., & Lanza, R. P. (2002). Methods of Tissue Engineering. Philadelphia, 
PA: Elisevier. 
Atanga, E., Dolder, S., Dauwalder, T., Wetterwald, A., & Hofstetter, W. (2011). 
TNFa inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone 
, 49, 1090-1100. 
Atkins, G. J., Andersin, P. H., Findlay, D. M., Welldon, K. J., Vincent, C., 
Zannettino, A. C., et al. (2007). Metabolism of vitamin D3 in human osteoblasts: 
evidence of autocrine and paracrine activities of 1a,25-dihydroxyvitamin D3. Bone , 40, 
1517-1528. 
Bahney, C. S., Hsu, C. W., Yoo, J. U., West, J. L., & Johnstone, B. (2011). A 
bioresponsive hydrogel tuned to chondrogenesis of human mesenchymal stem cells. 
FASEB J . 
  
 
 
137
Barbero, A., & Martina, I. (2007). Tissue Engineering (2nd ed.). (H. Hauser, & M. 
Fussenegger, Eds.) Totowa, NJ: Humana. 
Barlic, A., & Kregar-Velikonja, N. (2008). Re-differentiation of human articular 
chondrocytes is not enhance by a rotary bioreactor system. Folia Biol , 54, 177-179. 
Berg, J. P. (1999). Vitamin D-binding protein prevents vitamin D deficiency and 
present itamin D for its renal a ctivation. Eur J of Endicrinology , 141, 321-322. 
Biswas, P., & Zanello, L. P. (2009). 1,25(OH)2D vitamin D3 induction of ATP 
secretion in osteoblasts. J Bone Miner Res , 24, 1450-1460. 
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. 
F., et al. (2008). Vitamin D and human health: lessons from vitamin D receptor null mice. 
Endocrine Reviews , 29 (6), 726-776. 
Boyan, B. D., Hurst-Kennedy, J., Denison, T. A., & Schwartz, Z. (2009). Cellular 
responses to 24R,25-dihydroxyvitamin D3 in bone and cartilage. Immun, Endoc & Metab 
Agents in Med Chem , 9, 137-142. 
Brannon , P. M. (2012). Key questions in vitamin D research. Scand J Clin Lab 
Invest , 73 (Suppl 243), 154-162. 
Brockbank, K. G. (2000). Tissue engineering constructs and comercialization. 
Austin, TX: Landes Biosciene. 
Cartnmell, S. H., Porter, B. D., Garcia, A. J., & Guldberg, R. E. (2003). Effects of 
medium perfusion rate on cell-seeded three-dimensional bone constructs in vitro. Tissue 
Eng , 9 (6), 1197-1203. 
  
 
 
138
Chen, G., Kim, S. H., King, A. N., Zhao , L., Simpson , R. U., Christensen, P. J., et 
al. (2011). CYP24A1 is an independent prognostic marker of survival in patients with 
lung carcinoma. Clin Cancer Res , 17, 817. 
Cheung, Y. K., Azeloglu, Shiovitz, D. A., Costa, K. D., Seliktar, D., & Sia, S. K. 
(2009). Microscale control of stiffness in a cell-adhesive substrate using microfluidics-
based lithography. Angew Chem Int Ed , 48, 7188-7192. 
Choi, J. B., Youn, I., Cao, L., Leddy, H. A., Cilchrist, C. L., Setton, L. A., et al. 
(2007). Zonal changes in the three-dimensional morphology of the chondron under 
compression: the relationship among cellular, pericellular, and extracellular deformation 
in articular cartilage. J Biomech , 40, 2596-2603. 
Chung, P. G., & Burdick, J. A. (2008). Engineering cartilage tissue. Adv Drug 
Delivery Rec , 60 (2), 243-262. 
Cooper, G. M. (2000). Signaling Molecules and Their Receptors. In G. M. Cooper, 
The Cell: A Molecular Approach (2nd ed.). Sunderlan, MA: Sinauer Associates. 
Flanagan, J. N., Young, M. V., Persons, K. S., Wang, L., Mathieu, J. S., Whilatch, 
L. W., et al. (2006). Vitamin D metabolism in human prostate cells: impications for 
prostate cancer chemoprevention by vitamin D. Anticancer Research , 26, 2567-72. 
Freed, L. E., Guilark, F., Guo, E., Gray, M. L., Tranquilo, R., Holmes, J. W., et al. 
(2006). Advanced tools for tissue engineering: scaffolds, bioreactors, and signaling. 
Tissue Engineering , 12 (12), 3285-3305. 
  
 
 
139
Geng, S., Zhou, S., & Glowacki, J. (2011). Effects of 25-hydroxyvitamin D3 on 
proliferation and osteoblast differentiation of human marrow stromal cells require 
CYP27B1/1a-hydroxylase. J of Bone and Miner Res , 26 (5), 1145-1153. 
Golub, E. E., & Boesze-Battaglia, K. (2007). The role of alkaline phosphatase in 
mineralization. Curr Opin Orthop , 444-448. 
Halvorsen , Y. C., Franklin, D., Bond, A. L., Hitt, D. C., Auchter, C., Boskey , A. 
L., et al. (2001). Extracellular matrix mineralization and soteoblast gene expression by 
human adipose tissue-derived stromal cells. Tissue Engineering , 7 (6), 729-741. 
Hardingham, T., Tew, S., & Murdoch. (2002). Tissue engineering: chondrocytes 
and cartilage. Arthritis Res , 4, S63-68. 
Hattori, K., Takakura, Y., Ohgushi, H., Habata, T., Uematsu, K., Yamauchi, J., et 
al. (2005). Quantitative ultrasound can assess the regeneration proess of tissue-engineered 
cartilage using a complex between adherent bone marrow cells and a three-dimensional 
scaffold. Arthritis Resarch and Therapy , 7 (3), R552-R559. 
Hein, A., & O'Brien, W. J. (1993). Current time-domain methods for assessing 
tissue motion by analysis from reflected ultrasound echos-a review. IEEE Transcactions 
on Ultrasonics, Ferroelectris and Frequency Control , 40 (2), 84-102. 
Hewison, M., Zehnder, D., Chskraverty, R., & Adams, J. S. (2004). Vitamin D and 
barrier function: a nove role for extra-renal 1a-hydroxylase. Molecular and Cellular 
Endocrinology , 215, 31-38. 
  
 
 
140
Hobaus, J., Thiem, U., Hummel, D. M., & Kallay, E. (2013). Role of calcium, 
vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anti-Cancer 
Agent in Medicinal Chemistry , 13 (1), 20-35. 
Hoemann, C. D., El-Gabalawy, H., & McKee, M. D. (2009). In vitro osteogenesis 
assays: influence of the primary cell source on alkaline phosphatase activity and 
mineralization. Pathologie Biologie , 57, 318-323. 
Hollick, M. F. (2010). Vitamin D. Boston, MA: Springer. 
Hosmer, D. W., & Lameshow, S. (2000). Applied Logistic Regression. New York, 
NY: Wiley. 
Jones, G., Strugnel, S. A., & DeLuca, H. F. (1998). Current Understanding of the 
molecualr actions of vitamin D. Physiological Reviews , 78 (4), 1193-1211. 
Kohles, S. S., Bowers, J. R., Vailas, A. C., & Vanderbery, R. (1997). Ultrasonic 
wave velocity measurement in small polymeric and cortical bone speciments. J Biomech 
Eng , 119 (3), 232-236. 
Kohles, S. S., Bradshaw, S., Mason, S. S., & Looft, F. J. (2011). A multivariate 
logistical model for identifying the compressive sensitivity of single rat tactiles receptors 
as nanobiosensors. J Nanotechnol Eng Med , 2 (1). 
Kohles, S. S., Kohles, D. A., Karp, A. P., Erlich, V. M., & Polissar, N. L. (2004). 
Time-dependent surgical outcomes following cauda equina syndrom diagnosis: 
comments on a meta-analysis. Spine , 29 (11), 1281-1287. 
  
 
 
141
Kohles, S. S., Wilson, C. G., & Bonassar, L. J. (2007). A mechanical composite 
sphers analysis of engineered cartilage dynamics. ASME J Biomech Eng , 129 (4), 473-
480. 
Kumar, R. (1990). Vitamin D metabolism and mechanisms of calcium transport. J 
Am Soc Nephrol , 1 (1), 30-42. 
Lanza, R., Langer, R., & Vacanti, J. (2007). Principles of Tissue Engineering. San 
Diego, CA: Elisever. 
Lehman, B. (2008). Role of vitamin D3 pathway in healthy and diseased skin - 
facts, contradictions and hypotheses. Experimental Dermatology , 18, 97-108. 
Lehmann, B., & Meurer, M. (2003). Extrarenal sites of calcitriol synthesis: the 
particular role of the skin. . Recent Results Cancer Res , 164, 237-245. 
Lian, J. B., & Stein, G. S. (1995). Develpment of the osteoblast phenotype: 
molecular mechanisms mediating osteoblast growth and differentiation. The Iowas 
Orthopaedic J , 15, 118-140. 
Liu, P., Oyahobi, B. O., Russell, R. G., & Scutt, A. (1999). Regulation of 
osteogenic differentiation of human bone marrow stromal cells: interaction between 
transforming growth factor-B and 1,25(OH)2 vitamin D3 in vitro. Calcif Tissue Int , 65, 
173-180. 
Mason, S. S., Kohles, S. S., & Zelick, R. D. (2011). Three-dimensional culture of 
cells and matrix biomolecules for engineered tissue development and biokinetic model 
validation. J Nanotechnol Eng Med , 2 (2), 025001-7. 
  
 
 
142
Naeem, Z. (2010). Vitamin D defficiency - an ingnored epidenmic. Int J Health 
Sci , 4 (1), V-VI. 
Owen, T. A., Aronow, M. S., Barone, L. M., Bettencourt, B., Stein, G. S., & Lian, 
J. B. (1991). Pleiotropic effects of vitamin D on osteoblast gene expression are related to 
the proliferative and differentiated state of the bone cell phenotype: dependency upon 
basal levels of gene expression, duration of exposure, and bone matrix competency in 
norma. Endocrinology , 1496-1504. 
Park, K., Min, B. H., Han, D. K., & Hasty, K. (2007). Quantitive anaylsis of 
temporal and spatial variation of chondrocyte nehavior in engineered cartilage during 
long-term culture. Annals Biomed Eng , 35 (3), 419-428. 
Pazanno, D., Mercier, K. A., Moran, J. M., Fong, S. S., DiBiaso, D. D., Rulf, J. X., 
et al. (2000). Comparison of chondrogenesis in static and perfused bioreactor culture. 
Biotechnol Prog , 16, 893-896. 
Pockwinse, S. M., Stein, J. L., Lian , J. B., & Stein, G. S. (1995). Developmental 
stage-specific cellular responses to vitamin D and glucocorticoids during differentiation 
of the osteoblast phenotype: interrelationship of morphology and gene expression by in 
situ hybridization. Experimental Cell Research , 216, 244-260. 
Ramage, G., Nuki, D., & Salter, M. (2009). Signaling cascades in 
mechanotransduction: cell-matrix interaction and mechanical loading. Scand J Med sci 
Sports , 19, 4757-4769. 
  
 
 
143
Saha, A. K., & Kohles, S. S. (2011). A cell-matrix model of anabolic and catabolic 
dynamics during cartilage biomolecule regulation. International Journal of Computers in 
Healthcare . 
Saha, A. K., & Kohles, S. S. (2010). A distinct catabolic to anabolic threshold due 
to single-cell nanomechanical stimulation in a cartilage biokinetics model. J Nanotechnol 
Eng Med , 1 (3), 031005. 
Saha, A. K., & Kohles, S. S. (2010). Periodic nanomechanical stimulation in a 
biokinetics model identifying anabolic and catabolic pathways associated withh cartilage 
matrix homeostasis. J Nanotechnol Eng Med , 1 (4), 041001. 
Schuurman, W., Gawlitta, D., Lein, T. J., Hoope, W. T., Riijen, M. H., Dhert, W. 
J., et al. (2009). Zonal chondrocyte subpopulations reacquire zone-specific characteristics 
durin in vitro redifferentiation. AJSM , 20 (10), 1-8. 
Seiffert, M., Rech, M., Meineke, V., Tilgen, W., & Rechrath, J. (2004). 
Differential biological effects of 1,25-dihydroyxy Vitamin D3 on melanoma cell lines in 
vitro. J of Steroid Biochem & Molec Bio , 89-90, 375-379. 
Tellisi, N., & Nureddin, A. (2007). Comparison of meshes, gels and ceramic for 
cartilage tissue engineering in vitro. Eur J Plast Surg . 
Tibbitt, M. W., & Anseth, K. S. (2009). Hydrogels as extracellular matrix mimics 
for 3D cell culture. Biotechnol Bioeng , 103, 656-669. 
Tortelli, F., & Cancedda, R. (2009). Three-dimensional cultures of osteogenic and 
chondrogenic cells: a tittue engineering approach to mimic bone and cartilage in vitro. 
Eur Cell Mater , 17, 1-4. 
  
 
 
144
Vanhooke, J. L., Prahl, J. M., Kimmel-Jehan, C., Mendelsohn, M., Danielson, E. 
W., Healy, K. D., et al. (2006). CYP27B1 null mice with LacX reporter gene display no 
25-hydroxyvitamin D3-1a-hydroxylase promote activity in the skin. PNAS , 103 (1), 75-
80. 
Viljakainen , H. T., Natri, A. M., Karkainen , M., Huttunen , M. M., Palssa, A., 
Jakobsen, J., et al. (2006). A positive dose-response effect of vitamin D supplementation 
on site-specific bone mineral augmentation in adolescent girls: a double-blinded 
randomized placebo-conrolled 1-year intervention. J Bone Miner Res , 21 (6), 836-44. 
Villanueva, I., Weigal, C. A., & Bryant, S. J. (2009). Cell-matrix interactions and 
dynamic mechanical loading influence chondrocyte gene expression and bioactivity in 
PEG-RGD hydrogels. Acta Biomaterialia , 5 (8), 2832-2846. 
Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., & Noel, D. (2009). 
Cartilage engineering: a crucial combination of cells, biomaterials, and biofactors. Trens 
Biotecnol , 19, 307-314. 
Walker, J. M., Myers, A. M., Scluchter, M. D., Goldberg, V. M., Caplan, A. I., 
Berilla, J. A., et al. (2011). Nondestructive evaluation of hydrogel mechanical properties 
using ultrasound. Annals of Biomedical Engineering , 39 (10), 2521-2530. 
Wilson, C. G., Bonassar, L. J., & Kohles, S. S. (2002). Modeling the dynamic 
composition of engineered cartilage. Arch Biochem Biophys , 408 (2), 246-254. 
Winn, S. R., Randolph, G., Uludag, H., Wong, S. C., Hair, G. A., & Hollinger, J. 
O. (1999). Establishing an Immortalized Human Osteoprecursor Cell Line: OPC1. J of 
Bone and Miner Res , 14 (10), 1721-1733. 
  
 
 
145
Yilmaz, B. C., Yilmaz, G., Yilmaz, N. S., Balli, E., & Tasdelen, B. (2010). 
Optimal transport time and conditions for cartilage tissue samples and expanded 
chondrocyte suspensions. Orthopaedics , 33 (1), 25. 
Zhou, S., Glowacki, J., Kim, S. W., Hahne, J., Geng, S., Mueller, S. M., et al. 
(2012). Clinical characterizatics influence in vito action of 1,25-dihydroxyvitamin D(3) 
in human marrow stromal cells. . J Bone Miner Res , Ahead of Print. 
Zuwei, M. A., Kotaki, M., Inani, R., & Ramakrishna, A. (2005). A potential of 
nanofiber matrix as tissue-engineering scaffolds. . Tissue Eng , 11 ((1-2)), 101-10. 
  
 
 
146
 
Chapter VI. INVESTIGATION THE REGULATION OF MRNA EXPRESSION 
INVOLVED IN EXTRA-ENDOCRINE VITAMIN D METABOLISM DURING OPC1 
BONE MATURATION AND MINERALIZATION 
 
Shelley S. Mason1 
Sean S. Kohles1 
Shelley R. Winn2 
Randy D. Zelick1 
 
1Department of Biology, Portland State University, Portland, Oregon; 2Department 
of Molecular and Medical Genetics, Oregon Health Science University, Portland, 
Oregon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
147
Section 6.01 Preface 
This chapter contains material from a manuscript that will be submitted for 
publication at a later date. The work presented here is the 2nd part of a two-series 
experiment on the influence of extra-endocrine vitaD3 metabolism on in vitro temporal 
bone development sequence. 
Section 6.02 Authors Contribution 
The work presented here was carried out in collaboration between all authors. 
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the methods and 
experiments, carried out the laboratory experiments, analyzed the data, interpreted the 
results and wrote the paper. SSK edited the manuscript. SRW co-designed the biological 
experiments. All authors have contributed to, seen and approved the manuscript. 
Section 6.03 Hypothesis 
The overall goal of this experiment was to demonstrate the extrahepatic metabolism 
of parental vitaD3 precursor to the active vitamin D metabolite 1,25OH2D3 by the 
osteoblast precursor cell line OPC1, and demonstrate the subsequent influence on bone 
maturation and mineralization. The global hypothesis was that the conversion of vitamin 
D3 to 1,25OH2D3 would lead to an increase in alkaline phosphatase (ALP) activity 
associated with osteoblast ECM maturation and an increase ECM mineralization 
indicated by calcium deposition detected alizarin red stain  (ARS). It was also 
hypothesized that the presence of vitaD3 would enhance the temporal bone 
developmental sequence of OPC1.  
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Section 6.04 Abstract 
Multipotential precursor cell lines derived from human bone marrow, capable of 
differentiating into cartilage or bone, may provide a useful tissue development model for 
studying the regulation and metabolism of putative growth and differentiation factors 
necessary for tissue regeneration. In mammals, the process of bone development depends 
on the proliferation and differentiation of osteoblast lineage cells, and the subsequent 
synthesis and mineralization of bone extracellular matrix (ECM). Vitamin D metabolites 
play a pivotal role in bone and mineral homeostasis, and are positive factors on bone 
development. Recently, it was demonstrated that human-derived engineered osteoblast 
precursor cell line, OPC1, derived from human bone marrow, can metabolize the parental 
precursor vitamin D3 (vitaD3) to the active  steroid 1α,25-dihydroxyvitamin D3 
(1,25OH2D3), and elicit an osteogenic response that results in the decrease in proliferation 
and increase of ECM synthesis during early bone development. In this study, we 
investigated whether vitaD3 influences bone ECM mineralization in the same manner as 
1,25OH2D3. In addition, we explored the influence of vitamin D metabolites, in 
combination with other commonly used osteogenic factors, ascorbic acid, β-
glycerophosphate, dexamethasone (dex) and bone morphogenetic protein-2 (BMP-2) on 
the osteoinduction of OPC1 during early bone development. It was demonstrated that 
OPC1 expresses the mRNA for the enzymatic equipment necessary to convert vitaD3 to 
1,25OH2D3, as well as the mRNA associated with the catabolic enzyme known to 
regulate the concentration of active 1,25OH2D3. It was also demonstrated that mRNA 
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expression for the vitamin D receptor (VDR) was influenced by both vitaD3 and 
1,25OH2D3. Differential results using vitamin D metabolites in combination with 
ascorbic acid, β-glycerophosphate, and either dex and/or BMP-2 were observed in ALP 
activity and calcium deposition, and mRNA expression of procollagen (proColI), 
osteocalcin (OC), and osteopontin (OP). Overall it was demonstrated that vitamin D in 
combination with osteogenic factors influence the temporal bone development sequence 
in a positive manner.  
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Section 6.05 Introduction 
Most of the load-bearing demand placed on the human body is transduced by skeletal 
tissue, and the skeleton’s capacity to articulate in various opposing directions is essential 
for mobility and locomotion [Buttery, et al., 2001]. Consequently, cartilage and bone 
defects due to trauma, disease, and developmental abnormalities results in severe 
disabling pain and immobility for millions of people worldwide [Mason, et al., 2011]. 
Multipotential precursor cell lines derived from human bone marrow, capable of 
differentiating into cartilage or bone, may provide a useful tissue development model for 
studying the regulation and metabolism of putative growth and differentiation factors 
necessary for tissue regeneration.  
There are several factors that need to be taken into consideration for in vitro model 
systems, such as cell source and acquisition, phenotypic stability, reproducibility, and the 
incorporation of appropriate signaling molecules. One of the challenges using 
mesenchymal stromal cells (MSCs)/progenitor cells isolated from bone marrow aspirates 
is isolation sufficiency and expansion, because of the relatively low frequency at which 
they occur in the marrow stroma (reported to be in the range of 1/10,000 cells to 
1/100,000 cells) [Hicok, et al., 1998; Buttery, et al., 2001; Huang et al., 2012]. In 
addition, MSCs have a finite capacity for self-renewal, and the potential to proliferate and 
differentiate diminishes with age [Buttery, et al., 2001]. In addition, MSC isolates tend to 
be heterogeneous, containing progenitor cells with varying levels of potency. 
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Osteoblastic precursor cell line (OPC1) is a conditionally immortalized cell line derived 
from human bone, and has been demonstrated to maintain phenotypic stability and a 
consistent pattern of differentiation for more than 70 passages, therefore it provides an 
ideal model for the study of osteoblast differentiation and bone development as an 
alternative to MSCs [Winn, et al., 1999]. OPC1 has been used in previous studies and has 
shown to provide a consistent and reproducible culture system for evaluating bone 
development [Mason, et al. 2013]. Recently, we were able to demonstrate the extra-
endocrine metabolism of vitaD3 to 1,25OH2D3 by OPC1, which resulted in decreased 
proliferation and increased ALP activity and calcium deposition associated with ECM 
bone maturation and mineralization. 
In the early 1900’s vitamin D was the fourth identified essential vitamin, thus 
named vitamin “D” by convention. It wasn’t until 50 years later that it was realized that 
vitamin D is metabolized and acts as a steroid hormone in an endocrine manner, a 
paradigm that has dominated the classic thought of vitamin D function until the end of 
the 20th century [Morris & Anderson, 2010]. Recently, it has been demonstrated that 
number of organ systems are influenced by vitamin D in an autocrine manner, that is 
1,25OH2D3 is being synthesized within those cells, and/or within adjacent cells (paracrine 
action). While the vitamin D endocrine system plays a principal role in the maintenance 
of calcium and phosphate homeostasis, extra-endocrine metabolism has been postulated 
to have cellular functions that include the regulation of proliferation, differentiation, and 
apoptosis in many target tissues [Brannon, 2012; Hobaus, et al., 2013; Jones, et al., 1998; 
Atkins, et al. 2007], including bone and cartilage.  
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VitaD3 is biologically inactive in physiological concentrations until it is 
sequentially hydroxylated and the polarity is increased. VitaD3 is activated by two-
sequential hydroxylations, first by the cytochrome P450 oxidase (CYP) 25-hydroxylase, 
CYP27A1 (mitochondrial) and CYP2R1 (microsomal), resulting in the metabolite 25-
hydroxyvitamin D3 (25OHD3), and then to the active metabolite, 1,25OH2D3, by 25-
hydroxyvitaminD3-1α-hydroxylase (CYP27B1) [Ahmed & Shoker 2010; Norman 1998; 
Jones, et al. 1998; Trump, et al., 2010].  
1,25OH2D3 is the most active form of vitamin D because of its high affinity for the 
intranuclear vitamin D receptor (VDR), in which it mediates its biological effects upon 
binding. VDR belongs to the nuclear hormone receptor family and serves as a ligand-
dependent transcription factor (TF) that controls the expression of vitamin D associated 
target genes which include those associated with calcium homeostasis, cellular 
proliferation and differentiation, cell division and cycle arrest, and apoptosis [Yamamoto, 
et al., 2013; Seiffert, et al., 2004; Flanagan, et al., 2006; Hollick, 2010; Naeem, 2010]. 
Upon 1,25OH2D3  binding, VDR forms a heterodimer with the retinoid X receptor, which 
allows it to bind to vitamin D receptor elements (VDRE) in the promoter regions of target 
genes [Flanagan, et al., 2006; Brannon , 2012; Geng, et al., 2011; Trump, et al., 2010]. 
Coupled with other TFs, this complex induces transcription of vitamin D responsive 
genes including those associated with the CYP-related enzymes required for vitamin D 
metabolism [Chen, et al., 2011; Flanagan, et al., 2006; Boyan, et al., 2009; Geng, et al., 
2011; Trump, et al., 2010].   
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The action of vitamin D is limited by the catabolic enzyme 24-hydroxylase 
(CYP24A1), which results in a compound that is more soluble and has a substantially 
lower affinity for VDR [Trump, et al., 2010; Ahmed & Shoker, 2010; Ambrecht, et 
al.,1998]. CYP24A1 has been shown to hydroxylate both 25OHD3 and 1,25OH2D3 to 
form 24,25OH2D3 and 1,24,25OH3D3, respectively [Flanagan, et al., 2006]. The main 
function of CYP24A1 is to regulate the circulating concentration of 1,25OH2D3 by 
inactivating it. The catabolic pathway of CYP24A1, collectively known as the C-24 
oxidation pathway, starts with the 24-hydroxylation of 25OH2D3 or 1,25OH2D3 followed 
by sequential steps of hydroxylation that lead to the progressive loss of biological activity 
until vitamin D is converted to the water-soluble biliary excretory form, calcitroic acid 
[Ahmed & Shoker, 2010; Jones et al., 1998; Pairse et al., 2006]. 1,25OH2D3 induces and 
mediates CYP24A1 via an autocatalytic loop through VDRE located in the promoter 
region of the CYP24A1 gene [Chen et al., 2011]. Generally, basal expression of 
CYP24A1 is extremely low but the gene is highly induced by 1,25OH2D3 [Geng, et al., 
2011; Atkins, et al., 2007]. Thus, the synthesis and degradation of 1,25OH2D3 is highly 
regulated, and the concentration is controlled at the cellular level.  
Vitamin D affects many aspects of bone cell biology, and has been implicated in 
the regulation of both osteoblastic and osteoclastic activity effecting both resorptive and 
synthetic phases of bone remodeling [Atkins, et al., 2007]. In addition, 1,25OH2D3 has 
been demonstrated to regulate osteoblast and chondrocyte gene transcription, 
proliferation, differentiation, and ECM maturation [Boyan, et al., 2009; Atkins, et al., 
2007]. VDR is nearly ubiquitously expressed, almost all cells respond to 1,25OH2D3 
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[Bouillon, et al., 2008], and it is known to regulate the function of more than 200 genes  
[Flanagan et al., 2006; Hollick, 2010; Norman, 1998; Naeem, 2010].  
In this study, OPC1 was used to study the differentiation of osteoprogenitors 
towards the osteoblast lineage and the events associated with bone development in the 
presence of vitamin D metabolites, vitaD3 and 1,25OH2D3, in combination with 
osteogenic factors ascorbic acid, β-glycerophosphate, dexamethasone and bone 
morphogenetic protein-2 (BMP-2). Because in vitro temporal bone development 
encompasses three stages, proliferation, bone ECM maturation, and mineralization, and 
vitamin D has been shown to significantly hamper OPC1 proliferation [Mason et al. 
2013], confluent cultures were used in order to investigate the influence on bone ECM 
maturation and mineralization.  
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Section 6.06 Materials and Methods 
(i) Materials 
Vitamin D3 (cholecalciferol) and (calcitriol) 1,25OH2D3 were purchased from 
Sigma-Aldrich (St. Louis, MO), and maintained in 10mM and 10µM stock 
solutions in ethanol respectively. All other reagents and chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. Tissue 
plastic-ware was obtained from USA scientific (Ocala, FL). OPC1 and rhBMP-2 
were a generous gift from Dr. S. R. Winn (Department of Molecular and Medical 
Genetics Laboratory, Oregon Health Science University, Portland, OR).  
(ii) Methods 
(a) OPC1 Cell Cultures 
 
Cells were cultured at 2.5 X 105 in 75-cm2 tissue culture flasks in alpha 
modified essential medium (α-MEM) with 5% fetal bovine serum (FBS). Once 
confluent, OPCs were plated in 12-well plates after trypsin-EDTA enzymatic 
removal and counted with 0.4% trypan blue (1:1) on a hemacytometer. Cultures 
were prepared in duplicate at a seeding density of 3.0 x 104 cells/well in a 
standard bone medium (BM-) of α-MEM supplemented with 5% FBS, 200mM L-
Glutamine, and antibiotics until 85-90% confluent prior to adding experimental 
medium. Nine types of medium were utilized in quadruplicates. BM- with 95% 
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ethanol (EtOH) in amount that equated the EtOH vehicle for vitamin D metabolite 
delivery provided a negative control (group 1) and the additional groups included: 
BM- supplemented with 1µM vitaD3 (group 2); BM- supplemented with 10nM 
1,25OH2D3 (group 3); BM- supplemented with osteogenic factors (BM+) 
comprised of 50 µg/ml ascorbic acid, 10mM β-glycerophosphate, 10nM 
dexamethasone (dex), and 50 µg/ml of ascorbic acid phosphate (Wako Chemical, 
Osaka, Japan) provided as a positive control (group 4); BM+ supplemented with 
1µM vitaD3 (group 5); and BM+ supplemented with 10nM 1,25OH2D3 (group 6). 
BM+ supplemented with rhBMP-2 (BMP+)  (group 7), BMP+ with 1µM vitaD3 
(group 8); and BMP+  supplemented with 10nM 1,25OH2D3 (group 9). Fresh 
medium was added every 1-2 days.  
 
(b) ALP activity associated with bone matrix maturation  
 
OPC-1 was treated with both vitaD3 and 1,25OH2D3 in BM-, BM+, and 
BMP+, in duplicate at the indicated concentrations. ALP activity was measured 
every 7 days. At the end of the incubation, the cell layers were washed with cold 
DPBS, and 500µl 0.1% triton-X in DPBS and stored at -80°C until the end of 
each experimental period. ALP activity in the cell lysates was measured using ρ-
nitrophenyl phosphate liquid substrate system at 37°C for 30 minutes. Protein 
content was measured using a micro-volume spectrophometer system (Epoch; 
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Biotek, Winooski, VT). For statistical analysis of ALP over time, a two-way 
ANOVA and Bonferonni posttest control comparison was performed.  
 
(c) Calcium deposition during bone matrix mineralization 
 
A hystochemical analysis of mineralization was evaluated utilizing an 
Alizarin Red S (ARS. ARS staining is used to evaluate calcium-rich deposits by 
cells in culture, and is considered a functional in vitro endpoint reflecting 
advanced cell differentiation [Hoemann et al. 2009]. In brief, every 7 days cells 
were fixed in 10% neutral buffered formalin for 15 min. followed by fixation in 
100% cold methanol.  Each well was rinsed thoroughly with cold DPBS, and 
stained with 40mM of ARS, pH 4.1, at room temperature (RT) for 20 min with 
gentle shaking. The cell layers were efficiently rinsed and observed both grossly 
and microscopically. For semiquantification, ARS was extracted from the cells 
after incubating for one hour in at RT in 10% (v/v) acetic acid with gentle 
shaking, and then the residual dye was further extracted by scraping the cells and 
heating at 85°C on a heating block with a layer of mineral oil to prevent 
evaporation. The samples were neutralized with 10% (v/v) ammonium hydroxide 
and the extracts were read at 405 nm on a microplate-reader (Cary 50; Varian 
Australia Pty. Ltd). The samples were compared to serially diluted ARS standard. 
The resulting data was normalized with total protein content measured using a 
micro-volume spectrophometer system (Epoch; Biotek, Winooski, VT). For 
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statistical analysis of ARS over time, a two-way ANOVA and Bonferonni posttest 
control comparison was performed. 
 
(d) Quantitative RT-PCR 
 
Established RT-PCR qualitative analysis techniques were used to 
characterize the presence of CYP24A1 [Zhou, et al., 2012], CYP27A1 [Seiffert, et 
al., 2004], CYP27B1 and VDR (see Table 6-1) [Seiffert, et al., 2004; Zhou, et al., 
2012], osteopontin (OP), procollagen I (proColI), and osteocalcin (OC) (see Table 
6-2) [Winn, et al., 1999]. The oligionucleotide RT-PCR primer sequences (see 
Table 6-3) were purchased from Intergrated DNA Technologies (Coralville, Iowa, 
USA). Briefly, mRNA was isolated using 500µl TRIzol (Life Technologies, 
Grand Island, NY, USA) per well of 12-well plates. Samples were collected every 
7 days and stored at -80°C. The mRNA was purified from TRIzol according to the 
manufacturer’s specifications and the concentration was determined by 
spectrophotometric absorbance (Epoch; Biotek, Winooski, VT) of light at 260nm 
and 280 nm (A260/A280) in µg/ml. The cDNA was synthesized from 2µg of mRNA 
using a high capacity cDNA reverse transcriptase kit from Applied Biosystems 
(Life-Technologies, Grand Island, NY, USA) according to manufacturer’s 
instructions. Aliquots of the total cDNA were amplified in each PCR using fast 
SYBR® green master mix from Applied Biosystems (Life-Technologies, Grand 
Island, NY, USA) with the primers listed in Table 1 and performed in a Rotor-
Gene Q RT-PCR thermocycler (Qiagen, Germantown, Maryland, USA), for 45 
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cycles (30s denaturation at 95°C, 45s annealing at 58°C, and 60s extension at 
72°C). Quantification and analysis was carried out using Rotor-Gene Q Operating 
Software and Microsoft Excel (Microsoft Corp. Seattle, WA, USA). 
 
 
 
 
 
 
 
Vitamin D Associated 
Biomarker  
Function 
CYP24A1 The gene that encodes the mitochondrial protein that initiates 
the degradation of vitamin D metabolites 25OHD3 and 
1,25OH2D3 to calcitroic acid [Schlingmann et al. 2011]. 
CYP27A1 The gene that encodes the mitochondrial protein involved in 
the metabolism of vitamin D3 to 25OHD3 [Sawada et al. 2000]. 
CYP27B1 The gene that encodes the mitochondrial protein responsible 
for the hydroxylation of  the vitamin D metabolite 25OHD3 to 
1,25OH2D3 [Jones, 2013]. 
VDR The gene that encodes the nuclear hormone receptor for 
vitamin D. Downstream targets of this nuclear hormone 
receptor are known to be involved with mineral metabolism, 
proliferation, differentiation, apoptosis, and immune response 
[Freedman, 1999]. 
Table 6-1.  Vitamin D biomarkers associated with vitamin D metabolism. 
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Osteoblast Marker Function 
Alkaline Phosphatase (ALP) A hydrolase involved in bone ECM maturation and 
mineralization, postulated to increase inorganic 
phosphate concentration. ALP is thought to be 
regulated by 1,25OH2D3 [Boyan et al. 1989]. 
Osteocalcin (OC), bone gamma-
carboxyglutamate protein (BGLAP) 
A noncollagenous protein found in bone that binds 
Ca2+ and  hydroxyapatite, is vitamin D-responsive, 
related to bone mineralization, and involved in the 
recruitment and differentiation of osteoclasts. OC 
synthesis has been shown to be stimulated by 
1,25OH2D3 [Beresford et al. 1984].  
Osteopontin (OP), secreted 
phosphoprotein 1 (SPP1) 
A noncollagenous extracellular 
glycophosphoprotein found in bone that binds to 
hydroxyapatite, and plays a role in osteoblast 
adhesion, migration, cell survival, and bone 
remodeling  [Standal, Borset, & Sundan, 2004].  
Procollagen Type I (proColI) Synthesized prior to collagen type I, the principal 
structural protein of bone ECM. 
Table 6-2. Osteoblast biomarkers associated with bone development. 
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(e) Statistical Analysis 
 
Statistical analysis was carried out using Prism (Irvine, CA, USA) and 
Microsoft Excel Software. Data were expressed as means ± SEM of samples 
characterized in three two-week sample sets plated in duplicate or quadruplicate, 
and assayed in duplicate (n=12 or n=24 respectively). A two-tailed ANCOVA 
with a Bonferonni posttest control comparison and non-linear regression 
(polynomial quadratic function) was used for statistical analysis of treatment over 
time, with *p<0.05, **p<0.01 and ***p<0.001 as significantly and very 
significantly different, respectively.  
Primer Set Forward Reverse 
CYP24A1 5’ – GCA GCC TAG TGC AGA TTT – 3’ 5’ – ATT CAC CCA GAA CTG TTG – 3’ 
CYP27A1 5’ – GGC AAG TAC CCA GTA CGG – 3’ 5’ – AGC AAA TAG CTT CCA AGG – 3’  
CYP27B1 5’ – TGT TTG CAT TTG CTC AGA – 3’ 5’ – CCG GGA GAG CTC ATA CAG – 3’ 
VDR 5’ – CCA GTT CGT GTG AAT GAT GG – 3’ 5’ – GTC GTC GGT GAA GGA – 3’ 
OC 5’ – CTG GCC ACT GCA TTC TGC – 3’ 5’ – AAC GGT GGT GCC ATA GAT GCG– 3’ 
OP/SPP1 5’ – AAA TAC CCA GAT GTG GC – 3’ 5’ – AAC CAC ACT ACC TCG GC – 3’ 
ProColI 5’ – TGA CGA GAC CAA GAA CTG – 3’  5’ – CCA AAG TCA CCA AAC CTA CC – 3’  
Table  6-3. Oligionucleotide primers use in quantitative real-time RT-PCR. 
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(f) Microscopic Imaging 
 
 Microscopic images were taken using an advanced transmitted light 
inverted EVOS-XL microscope and accompanying software (EVOS3) from 
Advanced Microscopy Group (AMG, Bothell, WA, USA). Images were 
processed using FIJI, an Open Source image-processing package based on 
ImageJ. To maintain consistency, each image was processed in the same manner. 
The operations included the background subtraction command, mean filter and 
Enhance Local Contrast (CLAHE; blocksize 100, bin 256, max. slope 2.50), 
respectively.  
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Section 6.07 Results 
(i) Influence of vitamin D metabolites and osteogenic factors on OPC1 bone 
matrix maturation. 
  Increased ALP activity is associated with osteoblast function and the 
matrix maturation stage of bone development. ALP activity was found to be 
significantly (P<0.01) higher in groups cultured in standard bone medium (BM-) 
containing vitaD3 by week two of culture, and significantly higher (P<0.001) in 
groups containing either vitaD3 or 1,25OH2D3 by week three compared to the 
BM- ethanol vehicle control (see Figure 6-1A). For groups in osteogenic medium 
(BM+) both vitamin D metabolites displayed significantly (P<0.001) higher ALP 
activity compared to the BM+ EtOH control in both the second and third week 
(see Figure 6-1B). All groups cultured in BM+ were significantly (P<0.001) 
higher the groups cultured in BM- during the three week culture period, and 
reached maximal ALP, while groups in BM- did not reach maximal ALP activity.  
Groups cultured in BM+ containing rhBMP (BMP+) showed a significant 
increase (P<0.001) only in the second week compared to the BMP+ EtOH 
control, and by week three all groups displayed low levels of ALP activity (see 
Figure 6-1C). While groups cultured in BM+ continued to increase in ALP 
activity throughout the three-week culture period, BM+ reached a peak in 
between week 1 and 3, and began to decline in between week 2 and 3.  
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Figure 6-1. Temporal alkaline phosphatase activity of OPC1 treated with 
(A) ethanol vehicle control in standard bone medium (BM-), BM- containing 
10µM vitamin D3, and BM- with 1,25OH2D3; (B) ethanol control in 
osteogenic medium (BM+) containing ascorbic acid, β-glycerophosphate, 
and dexamethasone, BM+ containing 10µM vitamin D3, and BM+ with 
1,25OH2D3; (C) ethanol control in BM+ containing rhBMP (BMP+), BMP+ 
containing 10µM vitamin D3, and BM- with 1,25OH2D3. Cellular isolates 
were collected on day 7, 14, and 21 during the differentiation time course. 
Treatment with both vitamin D metabolites significantly (P<0.01) influenced 
OPC1 ALP activity in all medium groups.  
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(ii) Influence of vitamin D metabolites and osteogenic factors on OPC1 bone 
matrix  mineralization.  
The primary function of osteoblasts is to produce and maintain mineralized 
bone ECM. For samples cultured in BM- with or without vitamin D metabolites, 
vitaD3 and 1,25OH2D3, calcium deposition was significantly  (P<0.001) greater in 
cultures containing either vitamin D metabolites compared with the BM- ethanol 
control   (see Figure 6-2). OPC1 cultured in BM+ with or without vitamin D 
metabolites showed a significantly (P<0.001) higher amount of calcium 
deposition throughout the three week culture period compared to that of cultures 
in BM-, and cultures containing either vitaD3 or 1,25OH2D3 were significantly 
(P<0.001) higher than the BM+ EtOH control by the third week of culture time 
(see Figure 6-3). Cultures containing rhBMP (BMP+) showed a significant 
(P<0.001) amount of calcium deposition compared to that of the groups cultured 
in BM- throughout the three-week culture period. The presence of vitaD3 in 
BMP+ medium showed a significant (P<0.01) amount of calcium deposition 
compared to that of the BMP+ EtOH control, and slightly significant (P<0.05) in 
the presence of 1,25OH2D3 (see Figure 6-4).  
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Figure 6-2. Calcium deposition stained with alizarin red stain (ARS) (A) of OPC1 cultured in 
BM- and vitamin D metabolites vitaD3 and 1,25OH2D3. After microscopic analysis, ARS was 
extracted from each culture well, and read on a microplate reader (B). By week three of 
culture time, there was a significant (P<0.001) amount of calcium deposition detected by 
ARS in cells treated with either vitaD3 or 1,25OH2D3 compared to that of the ethanol control.  
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Figure 6-3. Calcium deposition stained with ARS (A) of OPC1 cultured in BM+ and vitaD3 or 
1,25OH2D3. After microscopic analysis, ARS was extracted from each culture well, and read on a 
microplate reader (B). By week three of culture time, there was a significant (P<0.001) amount of 
calcium deposition detected by ARS in cells treated with either vitaD3 or 1,25OH2D3 compared to 
that of the ethanol control. There was a significant (P<0.001) amount of calcium deposition 
compared to all BM- groups (see Figure 6-2).  
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Figure 6-4. Calcium deposition stained with ARS (A) of OPC1 cultured in BM+ containing 
rhBMP-2 (BMP+) and vitaD3 or1,25OH2D3. After microscopic analysis, ARS was extracted 
from each culture well, and read on a microplate reader (B). In the second week of culture 
time, the BMP+ EtOH control had a significant amount of calcium deposition in comparison 
with the treatment groups. By week three of culture, there was a significant (P<0.01) amount 
of calcium deposition detected by ARS in cells treated with either vitaD3 or 1,25OH2D3 
compared to that of the ethanol control. There was a significant (P<0.001) amount of calcium 
deposition compared to all BM- groups (see Figure 6-2).  
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(iii) Expression of Vitamin D Associated mRNA in OPC1.  
CYP27A1 and CYP27B1 are hydroxylases demonstrated to be involved in the 
metabolism of vitaD3 to 25OHD3, and convert 25OHD3 to 1,25OH2D3 
respectively. OPC1 expressed both CYP27A1 (Figure 6-5A) and CYP27B1 
(Figure 6-5B) in response to the presents of vitaD3, relative to the BM- EtOH 
control.  Significant (P<0.001) increases occurred within the first 72 hours of 
treatment (treatment added on day 4 of culture), but decreased dramatically by the 
second week in the continuous presents of vitaD3 (see Figure 6-5A and 6-5B). In 
the groups containing osteogenic factors (BM+ and BMP+) the expression of 
CYP27A1 was higher than in the BM- group treated with vitaD3, however in 
groups treated with BMP+, CYP27B1 expression was lower than in the BM- and 
BM+ groups treated with vitaD3. OPC1 expressed CYP24A1 and VDR mRNA in 
response to vitaD3 and 1,25OH2D3 (see Figure 6-5C and 6-5D). In the first week 
all groups treated with vitamin D metabolites had a significant (P<0.001) increase 
in CYP24A1 and VDR expression relative to the BM- control, however BM- 
cultures treated with vitamin D expressed a much higher amount of CYP24A1 
mRNA relative to BM- control, compared to the cultures containing osteogenic 
factors. After continuous presents of vitamin D, in the second week of culture 
time, CYP24A1 expression decreased for the BM- groups, but increased in groups 
containing BM+ and BMP+. All groups treated with vitaD3 and 1,25OH2D3 had 
significant (P<0.001) VDR mRNA expression relative to the BM- control during 
the first week of culture time which decreased by the second week.   
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Figure 6-5. Induced mRNA expression of (A) CYP27A1, (B) CYP27B1, (C) CYP24A1, and 
(D) VDR in OPC1 by vitaD3 and 1,25OH2D3 in standard bone medium (BM-) and medium 
containing osteogenic factors (BM+ and BMP+). Total RNA was isolated and examined by 
quantitative RT-PCR. Data was normalized to GAPDH.  
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(iv) Expression of Osteogenic mRNA in OPC1 
Procollagen type I  (proColI) precedes the production of ColI, a major 
component of bone ECM, has been shown to be enhanced during early osteoblast 
differentiation, while OC and OP are identified with later stages of osteoblast 
differentiation and bone development. Real-time PCR analysis showed a 
significant (P<0.001) increase in proColI mRNA expression during the first week 
of OPC1 culture in all groups relative to the BM- control, and a higher increase 
with treatment groups containing either vitaD3 or 1,25OH2D3 (see Figure 6-6A). 
There was no significant expression of proColI mRNA in the second week in any 
of the culture groups. In contrast to the expression of proColI, OP mRNA 
expression was not seen in the first week of culture time in any of the groups and 
increased in both second and third week of culture relative to the BM- control (see 
Figure 6-6B). The BMP+ control without vitamin D displayed the highest OP 
mRNA expression relative to the BM- control. Similar to OP mRNA expression, 
expression of OC mRNA was highest in the BMP+ control group, but was 
increased in all groups relative to the BM- control (see Figure 6-6C). However, in 
contrast to OP mRNA expression, OC expression was increased in the first week, 
and continued to increase during the three-week culture period.  
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Section 6.08      Discussion  
In this study, an engineered osteoblast precursor cell line, OPC1, was used to examine 
the effect of vitamin D metabolites, vitaD3 and 1,25OH2D3, on the maturation and 
mineralization of culture expanded cells during bone development. In comparison to the 
untreated cells, vitamin D metabolites in combination with ascorbic acid, β-
glycerophosphate, dex and/or BMP-2, produced more calcium deposition and showed a 
greater increase in ALP over time. Cultures containing osteogenic factors varied in ALP 
activity depending on the present of rhBMP-2. In addition to ALP activity and calcium 
deposition, mRNA expression of proColI, OC, and OP were analyzed over the three-
week culture period, as well as the mRNA expression of genes associated with vitamin D 
action and metabolism.  
Osteoblasts are bone-forming cells derived from multipotential progenitor cells 
within the bone marrow stroma that also are capable of committing to other mesenchymal 
lineages, including fibroblasts, myoblasts, chondrocytes, adipocytes, and osteoblasts 
[Hicok, et al., 1998; Swolin-Eide, 2002]. Once precursors have committed to a specific 
lineage, tissue specific molecules are expressed. Phenotypical characteristics of an 
osteoblast include the synthesis and mRNA expression of prColI preceded by ColI, OC, 
OP, VDR, increased ALP activity, and the ability to mineralize ECM. When osteoblast 
precursors commit to the osteoblastic lineage, the osteoblasts express bone matrix protein 
genes at different expression levels depending on the maturation level of the cells 
[Komori, 2010]. For example, immature mesenchymal cells and preosteoblasts weakly 
express ColI and ColII, while immature osteoblasts express OP, and bone sialoprotein 
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(BSP), and mature osteoblasts strongly express OC [Komori, 2010].  Mature osteoblasts 
become osteocytes when they are embedded into the bone matrix and express dentin 
matrix protein 1 (DMP-1).  
In vitro human osteoblasts respond to exogenous 1,25OH2D3 by decreasing their rate 
of proliferation while increasing their expression of mRNA of osteogenic biomarkers 
such as OC and OP.  While it has been known that circulating vitamin D is derived from 
the kidneys, recently a number of studies have demonstrated the extra-renal synthesis of 
1,25OH2D3 from 25OHD3 in skin, liver, lymph nodes, activated monocytes/macrophages, 
dendritic cells, and osteoblasts [Atkins, et al., 2007].  In contrast to extra-renal 
metabolism of 25OHD3 to 1,25OH2D3, there have been occasional reports of extra-
hepatic metabolism of vitaD3, but no detailed analysis until now. Recently, we 
demonstrated that OPC1 could metabolize vitaD3 to 1,25OH2D3 in a dose-dependent 
manner, and in this experiment, we were able to demonstrate the upregulation of mRNA 
expression of vitamin D associated hydroxylases CYP27A1, CYP27B1, and CYP24A1, 
as well as VDR in response to vitaD3. It was also demonstrated that vitaD3 influenced the 
expression of osteogenic mRNA proColI, OC, and OP in the same manner as 1,25OH2D3.  
In addition to the effects of vitamin D on OPC1, vitamin D in combination with 
common osteogenic factors, ascorbic acid, β-glycerophosphate, dex, and BMP-2 was 
investigated. It was demonstrated that in combination with these osteogenic factors, 
matrix maturation and mineralization was significantly increased. However, there were 
differential results in bone maturation associated with ALP activity seen in cultures 
treated with BMP+ (see Figure 6-1C). ALP expression is associated with bone cell 
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phenotype, and in heavily mineralized cultures, cellular levels of ALP decline [Lian & 
Stein, 1992]. OPC1 cultured with BMP+ with or without vitamin D metabolites 
demonstrated an increase in mineralization, and consequently with the mRNA expression 
of OC and OP, proteins that are known to increase with the accumulation of 
mineralization, compared to BM- and BM+ groups with or without vitamin D 
metabolites. These results indicate that rhBMP-2 had a major influence on OPC1 bone 
mineralization, that may exceed the influence of vitamin D. A major limitation to this 
results, was that BMP+ cultures were so heavily mineralized that by day 17 of culture 
time, the monolayer began to detach from the culture vessel.   
 It has been demonstrated that using dex, BMP-2, and 1,25OH2D3 enhance a more 
differentiated osteoblast phenotype [Jorgensen, et al., 2004], however in this study, OP 
and OC mRNA expression in groups treated with vitaD3 or 1,25OH2D3 and BMP+ was 
slightly lower then the BMP+ control, but higher then the osteogenic medium containing 
vitamin D metabolites and no BMP (BM+) (see Figure 6-6B and 6-6C). This may be 
because we used a higher dose of 1,25OH2D3, which would also explain the very 
significant increase in catabolic enzyme mRNA expression of CYP24A1 seen in the 
second week of culture (see Figure 6-5). In addition, it could be postulated that as a 
regulator of ECM mineralization, vitamin D dampened the effects of BMP. Many in vitro 
vitamin D studies investigating the anti-proliferative and pro-differentiative effects of 
vitamin D are short-term and use a supra-physiological dose, howver, for long-term 
cultures using vitamin D as an osteognenic factor, it may be beneficial to use a dose that 
is more closely resmbles the phsyiological dose.  
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It has been long recognized that long-term or excessive use of glucocorticoid 
(GC) excess, whether from endogenous hypersecretion or iatrogenically, manifests 
adverse skeletal effects such as osteoporosis [Walsh, et al., 2001]. In human subjects 
receiving long-term GC treatment, bone loss is associated with the decrease in overall 
bone formation rate and in the mean thickness of the walls on newly synthesized 
trabecular bone, a pattern consistent with the decrease in number and/or activity of 
osteoblasts rather than the increase in number and/or activity of osteoblasts [Walsh, et al., 
2001]. Paradoxically, several studies have demonstrated that treating cells derived from 
human bone with GCs promotes osteogenic differentiation, and has been proposed as a 
standard supplement for the ex vivo expansion of cells with osteogenic potential for use in 
tissue reconstruction and repair [Walsh, et al, 2001]. Dexamethasone (dex) is a GC that is 
commonly used as an inducer of bone marrow stromal cell differentiation, which reliably 
stimulates the development of many, but not all, phenotypic features of human 
osteoblasts [Jorgensen, et al., 2004]. However, GCs have deleterious effects in vivo, 
resulting in inhibition of osteoblast function. Bone morphogenetic protein-2 (BMP-2) is 
another inducer of osteoblast differentiation, and is essential for postnatal bone 
formation. BMP-2 has been used to induce osteoblast differentiation in vitro in many 
human and animal models, and is believed to provide a more physiologic stimulus than 
dex, however it appears to enhance a more mature osteoblast characteristic  [Jorgensen, et 
al., 2004], as was seen here.  
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APPENDICES 
 
A. Modeling of OPC-1 and MC3T3-E1 Cell Proliferation 
 
(i) Growth Model Application. 
 An exponential cell growth model was applied to characterize the normalized 
proliferation as a percentage of the initial cell population through culture time, 
C(t), such that: 
 
        (1) 
 
Where the experimental input includes the initial cell population (Ci = 100%) 
and culture time, t, in days. The result of the fitting procedure produces a 
characteristic growth rate constant similar to a time constant, . This fitting 
metric provides a quantitative value by which to compare cell population growth 
curves, where lower values represent a shorter culture time leading to a 
maximum cell count [Wilson et al., 2002; Kohles et al., 2007].  
The model was applied to the aggregate cell population data for the OPC-1 
and MC3T3-E1 cells as well as to the individual test group data for each cell 
type. This approach constructed least squares estimates of the growth time 
C(t) = Cie t τ
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constants via a quasi-Newton convergence method with commercially available 
software (Solver, Frontline Systems, Inc., Incline Village, NV, and Excel, 
Microsoft, Redmond, WA). The model fit was determined by minimizing the 
root mean square error (RMSE in similar units) between the actual and modeled 
cell population percentages for each dataset. The correlation coefficient (R2) 
assayed the strength of the modeled relationship.  
The aggregate plots contain all repeated measures data as well as the model 
curves. The test group curves are presented in rank order of their respective time 
constants. Statistical influences of the test group culture combinations were 
further explored with repeated measures analysis of co-variance (MANCOVA).  
 
 
Table A-1: Proliferation modeling metrics summary 
Test Group  (days) RMSE (%) R 
OPC-1 MC3T3-
E1 
OPC-1 MC3T3-
E1 
OPC-1 MC3T3-
E1 
Aggregate 4.49 3.87 209 453 0.77 0.67 
BM-Control 3.86 3.39 199 597 0.91 0.74 
BM+Control 3.96 3.56 242 479 0.85 0.76 
BM-VitaD3 4.61 3.72 128 297 0.89 0.86 
BM+VitaD3 5.19 5.28 161 262 0.73 0.49 
BM-1,25OH2D 4.80 3.54 119 210 0.89 0.94 
BM+1,25OH2D 5.50 5.94 103 249 0.85 0.32 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1. OPC-1 Aggregate Data, cell population over time. 
 
Figure A-2: OPC-1 Isolated Test Group Data, cell population over time. 
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Figure A-3. MC3T3
 
Figure A-4 MC3T3
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-E1 Aggregate Data, cell population over time.  
-E1 Isolated Test Group Data, cell population over time.
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B. Supplemental Material and Methods: Cartilage Engineering (Chapters 3 
and 4) 
(ii) Materials and Reagents 
 
Chondrocyte/Cartilage Culture Medium.  
Dulbecco’s modified essential medium/Ham’s F-12 (DMEM/F12) 10% 
10% Fetal Bovine Serum (FBS) 
200 mM L-Glutamine  
1% antibiotic/antimycotic solution (AB/AM).  
 
Liberase Blendzyme III (Roche Diagnostics, Madison, WI) 
Reconstitute 5mg vial in 2ml PBS (2.5mg/ml) 
Place vial on ice to rehydrate the enzyme 
Gently agitate the vial at 2-8ºC until enzyme is dissolved  
Store unused stock solution in single used aliquots at -15 20ºC.  
 
Collagenase (Sigma-Aldrich) 
Cell or tissue dispersal 0.5-2.5mg/ml  
Cartilage dispersal is 1-2mg/ml  
solubilized in calcium-free DPBS 
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(iii) Methods 
(a) Harvesting  Cartilage Tissue 
 
Tissue is excised from articular cartilage of bovine metacarophalangeal 
joints within 8 hours of slaughter. After dissection, chondrocytes are 
isolated from tissue fragments by mechanically disaggregation and 
enzymatic digestion. Freshly isolated chondrocytes cultured are expanded in 
2D monolayers and /or seeded within a 3D biomatieal scaffold according to 
conventional cell culture techniques.  
Procedure: 
1. Obtain several calf hooves that include the first joint 
(metacarpophalangeal joint or fetlock) above the hoof. 
2. Wash and scrub each hoof with water and antibacterial soap to 
remove all traces of dirt from the skin and the hoof. 
3. Once all dirt is removed and water runs clear, generously spray the 
specimen with 70% ethanol.  
4. Using a no. 23 disposable scalpel, make a lengthwise incision and 
dissect away the skin, taking care not to pierce the joint capsule. 
Wash the skinned limb with water, than generously spray with 70% 
ethanol.  
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5. Place the skinned limb upright, anterior side forward, inside the 
hood, and on top of an absorbent protective sheet (see Figure A-
5A). Flex the limb back at the joint. 
6. Make a horizontal incision through the anterior side of the joint 
capsule, taking care not to cut into cartilage (see Figure A-5B), and 
continue the incision around the side until the joint is exposed on 
three sides. Carefully sever the internal ligament and open the joint 
fully (see Figure A-5C), and wash away the clear viscous synovial 
fluid with sterile PBS. If blood is visible in the joint capsule when it 
is opened, the joint should be discarded, as it may be necrotic or 
contaminated with microorganisms. 
7. Using a sterile no. 15 disposable scalpel, obtain shavings from the 
metacarpophalangeal chondylar surface (see Figure A-5D). Follow 
the curve of the joint as closely as possible so as to obtain long, 
uniformly shaped shavings, ideally in one or two long pieces per 
joint surface. Long pieces are especially desirable when cartilage is 
to be sectioned into chips. If uniformity of cartilage shavings is not 
critical (i.e., if chips are to be enzymatically digested to release 
chondrocytes for culture), it can also be excised from other surfaces 
within the joint to increase the overall yield of chondrocytes. 
Excessive oozing blood from the shavings indicates that the 
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incision was deep and included bone, which (unlike cartilage) is 
vascularized. 
8. As the cartilage is scrapped off the joint, transfer the shavings to a 
petri-dish containing 0.1% collagenase and 2.5% AB/AM in cold 
PBS to prevent sticking and contamination. Shavings from each 
hoof should be placed in a separate dish to minimize the possibility 
of cross-contamination. 
9. Wash the shavings three times with 2.5% AB-AM in cold PBS and 
immerse washed tissue in growth media containing 1-2.5% 
AB/AM. 
10. Add 30 ml of sterile growth medium  to each sample 
11. [OPTIONAL] To allow timely detection of microbial 
contamination, it has been suggested to incubate chips for 24-48 hrs 
before digestion. Microbial contamination typically presents as 
cloudy medium (bacteria) or visible mold. 
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Figure A-5. Dissection of cartilage from the bovine 
metacarpophalangeal joint. (A) The skins is removed, exposing 
the outer joint capsule. (B) An incision through the anterior 
surface of the join capsule is made which spares the cartilage 
within. (C) After the joint has been opened and exposed, a scalpel 
is used to excise articular cartilage by shaving along the curved 
surface of the exposed joint. (D) The same joint with some of the 
cartilage removed, revealing the underlying bone [Liebman and 
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(b) Mechanical Disaggregation of Tissue.  
 
Mincing or chopping tissue in liquid medium releases cells from the 
supporting matrix. Most disaggregation procedures begin with a mechanical 
step to reduce the tissue to small fragments, providing a larger surface area 
for exposure to the digesting enzymes and facilitating penetration of 
enzymes into the tissue [Harris et al.; 2006]. Soft tissues can be minced 
finely with scissors and harder tissues chopped with scalpels. Further 
release of cells from minced tissue is achieved by vigorous pipetting of the 
smaller fragments in the suspending fluid, creating shear forces strong 
enough to separate cells from the fragments.   
Procedure:  
1. Place the freshly harvest cartilage tissue into the glass petri dish and 
moisten its surface with a small volume of 5% AB/AM in calcium-
free Hank’s buffered salt solution (HBSS).  
2. Using sterile dissecting scissors or scalpels mince the tissue into 
small fragments. (Note 1: It is easier to cut or mince the tissue if the 
volume is kept small because the fragments then stay on the surface 
of the dish and cannot float away from the dissecting instruments. 
Note 2: Mince soft tissue with scissors and chop harder tissue with 
two opposed scalpel blades.) 
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3. Tilt the dish to an angle of ~30° from the horizontal and allow the 
medium and released cells to wash down into the angle of the dish. 
Use a sterile pastette to aspirate the cell suspension and transfer it to 
a sterile culture tube.  
4. Add a  small volume of HBSS to the dish with a pastette and wash 
it over the fragments and surface to release and recover more cells.   
5. Repeat the last three steps two more times, aiming to reduce the 
tissue fragments ~1-2 mm across. Pool the released cells from each 
stem. Keep the fragments for further digestion. 
6. Centrifuge the cell suspension at 1000 rpm for 5 min. (Note: If the 
cell suspension is of low viability it may be enhanced by keeping 
the recovered cell at 4 °C. Released cells may be of low viability 
because damaged cells separate more easily from the surrounding 
matrix and the physical forces involved damage cells. However, 
some tissues are disaggregated effectively with mechanical 
methods.) 
7. Decant the supernatant from the cell pellet and resuspend the cells 
in 10 ml of storage medium. Store in refrigerator at 4 °C. (Note: the 
volume of medium added should be increased to 20 ml if the cell 
pellet is >5ml.) 
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(c) Enzymatic Digestion of Cartilage Tissue 
 
Isolation of chondrocytes is a two-step procedure: digestion of cartilage 
tissue and isolation of cells from the tissue digest. Freshly harvested 
cartilage tissue is rinsed several times and transferred to a digestion vessel 
after weighing. For tissue weighing <300 mg w use a 50-ml tube as the 
digestion vessel and for a larger amount of tissue use a 225-ml spinner flask 
[Atala and Lonza, 2002].  
Trypsin Digestion. Trypsin damages cells if exposure is prolonged and 
care must be taken to minimize this when devising tissue-specific 
protocols. Trypsinization can be carried out at 37°C (warm trypsinization) 
or at 4 °C (cold trypsinization). DNA released from damaged cells 
becomes viscous and its presence impairs the recovery of free cells. 
DNAse is therefore included at low concentrations to digest DNA and 
reduce viscosity. Serum contains trypsin inhibitors and these must be 
washed away from the tissue before digestion is started. Conversely, the 
action of trypsin is neutralized by the addition of serum.  
 
0.25% Trypsin 
1ml of 2.5% stock solution  
9ml cation-free DPBS or HBSS 
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0.4% DNAse Type I 
                  0.4g per ml cation-free DPBS or HBSS 
Filter-sterilize through a sterile 0.22 µm filter membrane 
 Store as 1 ml aliquots in sterile containers at -20 °C. 
 
0.25% Trypsin/0.004% DNAse 
Thaw out 1 ml aliquot of DNAse 
Add to 100 ml 0.25% trypsin  
 
Procedure:  
1. Rinse the minced fragments from mechanical disaggregation in 3 X 
10 ml washes of HBSS to remove trypsin inhibitors in the serum 
and discard the washings.  
2. Transfer the minced tissue mince from the petri dish to the conical 
flask containing a sterile magnetic stirrer bar. Add 10 volumes of 
0.25% trypsin/0.004% DNAse (pre-warmed to 37°C) to 1 volume 
of tissue.  
3. Re-cap the flask with the aluminum foil lid and place on the stirrer. 
Set the stir speed to keep the fragments in suspension; there should 
be a small vortex with no frothing.  
4. Carry out trypsinization for 20-30 minutes.  
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5. Remove the flask from the stirrer and allow the larger undigested 
fragments to settle. Remove the foil cap and carefully decant the 
enzyme solution containing released cells into a universal container. 
This can be done by using a sterile filter (70 µm) large enough to 
contain the left over fragments (should appear more gelatinous then 
solid) or by using a long-form pastette or 10 ml pipette. For the 
latter, tilt the flask and allow the fragments to settle in the angle of 
the flask and aspirate the cell suspension from the fragments. 
6. Add an equal volume of serum-containing medium to neutralize the 
effects of trypsin. 
7. Centrifuge the cell suspension at 1000 rpm for 5 min and resuspend 
the cells in medium. Label T1 and store at 4°C. 
8. Add fresh pre-warmed 0.25% trypsin/0.004% DNAse to the flask 
and repeat the last two steps two times (T2 and T3). (Note: 
trypsinization is complete when only fluffy white connective tissue 
remain.) 
9. Pool freshly isolated cells and calculate cell number  and viability 
using 0.4% trypan blue and hemacytometer. 
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Collagenase Digestion. Literature suggests a large range of collagenase 
concentrations (0.1-0.5%) depending on the collagenase used. The 
digestion time can range from 4 to 24 hours depending on brand. 
Collagenase and dispase (neutral protease) are less harmful to cells then 
trypsin and digestion with these enzymes can be carried out in the 
presence of serum. Contaminating fibroblasts are more likely in 
collagenase digest because it is more effective against the connective 
tissue matrix in which fibroblasts are found; this may be less irrelevant if 
cells are not to be cultured because there is no opportunity for fibroblast 
overgrowth. Collagenase Type I and IV are mainly used for tissue 
disaggregation, though crude collagenase is sometimes recommended 
because it contains small amounts of non-specific proteases, which 
contribute to matrix break-down [Harris et al. 2006]. 
 
Collagenase (Crude, Type I or IV)  
Dissolve in HBSS (10X Stock Solution) 
Filter sterilize  
Dispense into 1ml aliquots  
Store at -20°C. high.  
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Procedure:  
1. Transfer fragments from mechanical disaggregation and/or 
trypsinization into a culture flask using either a sterile spatula or 
teaspoon. Use a size of flask appropriate to the volume of tissue (aim 
to add ~10 volumes of enzyme per 1 volume of tissue fragments).  
2. Incubate the flask horizontally in a 37°C incubator overnight. Note: 
Different media have different buffering capacities and the metabolic 
activity and the incubation period need to be taken into consideration 
when deciding about the medium to use. Phenol red is used as a pH 
indicator and the buffering system is based on bicarbonate 
concentration. Hanks = 0.35 g/l: Earle's =2.2 g/l; Dulbecco's = 3.75 g/l. 
HBSS is suitable when metabolic activity and CO2 production is low 
and a low buffering capacity is sufficient. Earle's is used when 
tissue/cells are metabolically active and a higher buffering capacity is 
needed; most culture media are based on Earle's salts. 
3. The following day use a wide-bore pastette to aspirate the fragments 
several times and release loosened cells. Check the flask under an 
inverted phase-contrast microscope for cell release; continue digestion 
if cell yield is low and/or cells can still be seen within the tissue 
fragments. Note: If the medium becomes viscous, add DNAse at 
0.004%.  
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4. Decant the cells from the tissue using a sterile pastette or use a sterile 
filter to separate the cells and media from the tissue. 
5. Centrifuge the cells, discard the supernatant, and resuspend the cell 
pellet in culture medium.  
6. Rinse and repeat at least 3 times to ensure no residual collagenase is 
present. It is best to rinse the cells with DPBS the first couple of times, 
and add 1ml of PBS the last time, resuspend in 1ml PBS and take 100 
µl for cell count and viability.  
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(d) 3D Culture Seeded in Biomaterial Scaffold 
 
Scaffolds play a critical role in the reorganization of neotisues. The majority 
of mammalian cell types are anchorage-dependent, and will die if an 
adhesive substrate is not provided. The scaffold must provide a suitable 
substrate for cell attachment, cell proliferation, differentiated function, and 
cell migration [Khang et al. 2007].   
 
Polyethylene Glycol (PEG) Biomaterial Scaffold. Degradable synthetic 
PEG-based hydrogels can be used as an inert structural platform due to its 
hydrophilicity and resistance to protein absorption [Raeber, Lutolf, & 
Hubbell, 2005].  
 
PEG-Diacrylate (PEGDA) 
1.0 g  PEGDA 
10 ml 1% AB/AM in DPBS 
 
Procedure: 
1. Allow PEGDA and PBS to come to room temperature.  
2. Under Aseptic conditions prepare PEGDA hydrogel solution by 
mixing in 1ml sterile PBS with penicillin (100 u/ml) and 
streptomycin (100 mg/ml) to 0.1g PEGDA for a 10% (w/v) 
solution.  
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3. Invert the solution several times to dissolve. The solution will be 
clear and slightly viscous.  
4. The photo-initiator, 1-hydroxycyclohexyl phenyl ketone (Sigma 
Aldrich), is added and mixed thoroughly to make a final 
concentration of 0.05% (w/w). It is best to make this a separate 
solution and add to the PEGDA/PBS from step 1.  
5. Immediately before photo-encapsulation, cells are re-suspended in 
polymer solution. 100 ml of cells-PEGDA solution containing 
~106 cells are transferred to mold and exposed to 365 nm light 
(long wave) for 5-15 min to form hydrogel. Make sure the UV 
light is in close proximity to the hydrogel solution.  
6. Hydrogels are removed from their molds and incubated up to 21 
days in chondrogenic medium containing 5% FBS.  
7. Unused PEGDA solution can be stored at -20ºC for up to one 
month. Protect from light.  
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(e) Cartilage Staining with Safranin-O, Fast Green and Toluidine Blue.  
 
Toluidine blue, Safranin-O and Fast Green can be used to easily detect 
aggrecan and type II collagen in cartilage. Toluidine blue and Safranin-O 
are cationic stains (basic dyes) that stain acidic proteoglycan present in 
cartilage tissues. Toluidine blue, also called metachromatic dye, shows 
subtle color changes depending on the tertiary structure of the sample. 
Cytoplasm stains light blue, nuclear region dark blue, and mast cell purple. 
Safranin-O, which binds to glycosaminoglycan and shows an orange color, 
is often used to stain articular cartilage. Fast green, the contrast stain of 
Safranin-O, is a sulfate-group containing acidic substrate, which binds 
strongly to the amino group on protein and thereby strongly stains the 
noncollagen sites. 
 
0.1% Toluidine Blue O  (Sigma-Aldrich) 
0.1g Toluidine Blue/100 ml distilled water 
 
0.1% Safranin (Sigma-Aldrich) 
0.1g Safranin/100ml distilled water 
 
0.1% Fast Green (Sigma-Aldrich) 
0.1g  Fast Green/100ml distilled water 
  
 
 
 
225
 
 
Procedure (cells): 
1. Remove culture medium for culture 
2. Add 500µl of fixation solution per ml of culture (~1x106 cells/ml) and let 
stand at room temperature for 10 minutes to fix the cells. 
3. Remove the fixation solution from each sample after diluting it with 2-4 
ml of sterile PBS. Wash each sample twice with 2-4ml of sterile PBS and 
remove the final wash.  
4. Add 500-µl of 1% Acetic acid to each sample, allow to react for 10-15 
seconds and then remove the 1% Acetic acid.  
5. Add 500-µl of stain solution (Toluidine, Safranin, or Green) and let stand 
at room temperature for 5 minutes to stain the cells. 
6. Wash 3 times with sterile PBS. Adjust the color level by altering the 
number of washes.  
7. Microscopic observation may be done in the presence of PBS.  
 
 
 
 
 
 
  
 
 
 
 
 Procedure (tissue sections):
1. Prepare sections or paraffin
deparafinization:
2. Add 100-200µl of fixation solution to each tissue section for 1 
minimum. Remove the fixation solution. 
3. Add 200µl of 1% acetic acid to each tissue section, allow to react for 10
15 seconds 
4. Add a 200µl aliquot of stain solution (0.1% of Safranin, Toluidine, or Fast 
Green) to each tissue section and let stand at room temperature for 5 
minutes to stain the tissue. Remove stain solution. 
5. Add absolute ethanol for destai
appropriate level. 
6. Perform dehydration, clearing and mounting. 
fixation solution and stain depending on the size of the tissue section. 
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 sections. Paraffin sections require 
 
 
then remove acetic acid.  
 
ning. Destain until the color reaches the 
 
Adjust the volume of 
 
– 4 hours 
-
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C. Supplemental Materials and Methods: Bone Development and VitaD3 
Metabolism (Chapters 5 and 6) 
(iv) Materials and Reagents 
 
1mM VitaD3 Stock Solution 
3.85mg vitaD3 (MW 384.6) [C9756, Sigma-Aldrich] 
10ml Ethanol 
store at -20°C until use 
 
10uM 1,25OH2D3 Stock Solution  
10 µg vile 1,25OH2D3 (MW 416.64) [D1530, Sigma-Aldrich] 
2.4 ml ethanol  
Store at -20°C until use 
 
rhBMP-2 (stock 0.5µg/ml) 
(50ng/ml) 5µl/50ml media 
(100ng/ml) 10µl/50ml media 
 
Standard Bone Medium (BM-)   
500 ml α-MEM 
25-ml FBS (5%) 
5-ml antibiotic/antimycotic (1%) 
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2.5ml L-Glut 
 
5X Osteogenic Medium (BM+)  
250 ml BM(-) 
Dissolve 2.7 g  β-glycerophosphate 
Dissolve 0.025 g ascorbate-2-phosphate  
Add 50µl 1mM Dexamethasone (in ethanol)  
Sterile Filter 
 
Osteogenic medium (BM+)  
20 ml 5X BM(+) 
80 ml BM(-) 
 
BM(+) + rhBMP-2 
20µl rhBMP 
100ml BM(+) 
 
BM(-) + 1 µM VitaD3 
100 ml BM(-) 
100 µl 1mM vitaD3 Stock Solution 
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BM(+) + 1 µM VitaD3 
100ml BM(+) 
100ul 1mM vitaD3 Stock Solution 
 
BM(+) + rhBMP-2 + 1 µM VitaD3  
100 ml BM(+) + rHBMP-2 
100 µl 1-mM vitaD3 Stock Solution 
 
BM(-) + 10 nM 1,25OH2D3  
100 ml BM(-) 
100 µl 10-µM 1,25OH2D3 Stock Solution 
 
BM(+)+ 10 nM 1,25OH2D3 
100 ml BM(+)  
100 µl 10-µM 1,25OH2D3 Stock Solution 
 
BM(+) + rhBMP-2 + 10 nM 1,25OH2D3 
100ml BM(+) + BMP 
100 µl 10-µM 1,25OH2D3 Stock Solution 
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(v) Methods 
(a) Cell Culture.  
 
Culture OPC-1 into 12 well plates at an initial seeding density of 25,000 
cells per well, or 6 well plates at a seeding density of 100,000 cell per well. 
Maintain in standard bone medium (BM-) consisting of α-MEM, 5% fetal 
bovine serum (FBS), 200mM L-Glutamine, and antibiotics/antimycotics for 
at least 4 hours (preferably overnight) following trypsinization (0.025% 
trypsin-EDTA).  Remove standard growth medium and replace with 1 mL 
of appropriate medium; e.g., duplicates or quadruplicates of: 
a. BM(-) with 100l 95% ethanol (Control) 
b. BM(+) with 100 l 95% ethanol (Control) 
c. BM(+) + rhBMP-2 with 100ul 95% ethanol (control) 
d. BM(-) with 1 µM 25OHD 
e. BM(+) with 1 µM 25OHD 
f. BM (+) + rhBMP-2 with 1 µM 25OHD 
g. BM(-) with 10 nM 1α,25OHD 
h. BM(+) with 10 nM 1α,25OHD 
i. BM (+) + rhBMP-2 with 10 nM 1α,25OHD 
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(b) Vitamin D. 
 
 VitaD3 is soluble in ethanol at 50 mg/ml. Stock solutions are prepared at 
1mM (3.85 mg/10ml 95% EtOH) and kept at -20°C. Add 100 µl stock 
solution to 100 mL of medium to obtain 1 µM vitaD3 for the experimental 
group. Add 100 µl of ethanol to the control medium (BM- and BM+ without 
vitamin D). 1,25OH2D3 is diluted into medium from 10 µM stock solutions 
prepared in ethanol (4.2 µg/ml). For 1 vile of 1,25OH2D3 containing 10 µg 
add 2.38 ml of ethanol and store at -20°C until use. Add 100µl to 100 ml of 
medium for experimental group.  
 
(c) Feeding/Sample Collection Schedule.  
 
Maintain cultures with the feeding schedule outlined below.  Medium is 
replaced every 1-2 days with freshly diluted 10 nM dexamethasone, 5 mM 
β-glycerophosphate, and 50-µg/mL ascorbate-2-phosphate. From Day 2 
onwards, cells (that require vitamin D) are cultured in the continuous 
presence of 1 µM 25OHD, and/or 10 nM 1,25OH2D3. Because of the 
sensitivity to light, vitamin D has to be freshly diluted whenever the media 
is replaced.  
D1: Cell lines are plated in 12 well cell culture plates at an initial 
seeding density of 25,000 cells per well in BM(-).  
D2: BM(-) from D1 is removed and 1 mL of appropriate medium is 
added to each well.  
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D3, D7, D(end): Every 3 to 4 days supernatant and cells are 
collected/prepared for crystal violet (CV) proliferation assay, alkaline 
phosphatase (ALP) assay, qRT-PCR, and on the last day of the sample 
set alizarin red S (ARS) assay. Supernatant is stored at   -20°C and cells 
are scraped from the bottom of the wells and stored in PBS containing 
0.1% triton X-100 at -80°C. Prior to use, cell lysates are freeze/thawed 
(3X) or sonicated. Cells from the other well are lysed with TRIzol and 
prepared for PCR and stored at -80°C until qRT-PCR is conducted. For 
CV and ARS, wells are fixed and stained prior to sample collection.  
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(d) Alkaline Phosphatase (ALP) Assay (Based on Lowry Method) 
 
 ALP is a membrane bound enzyme that is often used as a marker for 
osteogenic assay. This is a colorimetric assay in which the colorless para-
nitrophenol phosphate (ρNPP) turns yellow as it is cleaved to para-
nitrophenol + phosphate. The cell number is normalized by measuring 
protein.  
 
2-Amino-2 Methyl-1-Propanol (AMP) 
For working solution, 1.5 M balanced to pH 10.25 with HCl, Prepare 
50ml; store in 4C frig (good for 1 month). 7.18ml/50ml and 
3.59ml/25ml.  
 
ρ-Nitrophenyl Phosphate (ρNPP) 
 For working solution, 20mM, prepare 50ml, store in 4C and protect 
from light. Good for 1 month. 263.10mg/50ml, 131.55mg/25ml. 
[N7653, liquid pNPP system; Sigma-Aldrich] Ready to use. Already 
has magnesium chloride buffer system in it.  
 
MgCl2 (100% MgCl2)  
For working solution, 10mM; prepare 25ml; store in 4C. Good for 7 
days. 0.2ml 1M/25ml.  
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1M NaOH 
For working solution, prepare 50 or 25ml depending on number of 
samples; mix fresh each day; maintain at room temperature. 1g/25ml.  
 
Ultrapure water or 0.05% Triton X-100 
 Use the one your sample is suspended in.  
 
Buffer Solution (AMP-ρNPP-MgCl2) 
For working solution, prepare fresh solution from above. Prepare each 
day and maintain at room temperature. Combine AMP, pNPP, and 
MgCl2 in a 1:1:1 ratio.  
 
ρ-Nitrophenyl Standard (ρNP) 
Combine 1 part stock with 9 parts ultrapure (1:10 dilution). Make 500ul 
aliquots and store in 4C.  
 
Procedure 
1. Label microcentrifuge tubes appropriately.  
2. Remove media from each well and transfer to sterile labeled 
microcentrifuge tubes. Freeze tubes.  
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3. Carefully wash each well with 0.25 ml EBSS (calcium and 
magnesium free). Remove and fill each well again with 0.25-ml EBSS.  
4. Replace medium with 0.25ml of 0.025% trypsin (37°C). Cap the 
tubes, mix well, vortex and freeze for at least 60min in -80°C or until 
assayed.  
5. Tubes for ALP assay should contain at least 50 µl of FBS 
containing medium to inactivate the trypsin. Once the cells come off 
the plastic of the well, pipette up and down to generate homogenous 
cell dispersion and place in tubes. Wash each well with 0.25ml of 
EBSS (calcium and magnesium free) and collect into the same tubes.  
6. Pellet cells by centrifugation for 5min. Remove supernatant and 
discard. Resuspend the pellet in 300ul of the APase buffer.  
7. Prepare reagents for APase assay according to the Lowry method. 
The APase buffer solution should be kept in 37°C water bath until use. 
Prepare 1M NaOH (4 pellets NaOH with 10 ml ultrapure). Mix tubes 
well, and load test wells in duplicate in 96-well plate with 100 µl of 
sample starting with D1. 
8. Load 100 µl/test well with APase buffer solution (only to samples). 
Note the time carefully as the test is time dependent. Place multi-well 
plate in 37°C incubator. For reactive samples, check reaction color after 
5 min. To stop the enzyme reaction, add 100 µl of the 1 N NaOH to the 
test samples as needed. Be careful not to allow the test reaction to 
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proceed too long (and become too yellow) as the plate reader will 
measure an absorbance at 405 nm up to 3.5, but not higher.  
9. While the plate is in the incubator, make the standard solutions for 
the modified standards. To each standard add 500 µl of ultrapure water. 
In descending order, add 250, 245, 240, 230, 220, and 210 µl of the 
APase buffer to each tube. Finally add 0, 5, 10, 20, 30, and 40 µl of the 
pNP stock solution to each tube, cap the tubes and mix each adequately. 
In triplicate, add 100 µl of each solution to A1, B1, C1,…to A6, B6, C6 
for an increasing concentration of ρNP. Immediately add 100 µl of the 
1M NaOH to each standard well to stop the reaction. After 100 µl of the 
1M NaOH has been added to all of the test samples and the standards 
have been loaded, the plate can be read on the multiplate reader at 405 
nm.  
Table A-2. ALP standards. 
Tube 1 2 3 4 5 6 
H2O 500ul 500ul 500ul 500ul 500ul 500ul 
APase 250ul 245ul 240ul 230ul 220ul 210ul 
pNP 0 5ul 10ul 20ul 30ul 40ul 
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(e) Alizarin Red S Assay (ARS).  
 
ARS is used to evaluate ECM mineralization and calcium deposits from 
cells in culture. ARS can be extracted from a stained monolayer and 
assayed. This method is for the recovery and semiquantification of ARS in a 
stained monolayer based on acetic acid extraction and neutralization with 
ammonium hydroxide followed by colorimetric detection at 405nm. 
 
Alizarin Red S [A5533, Sigma; MW 342.26g/mol] 
40mM prepare in dH2O  
1.369g ARS in 100ml dH2O 
pH adjusted to 4.1 using 10% (v/v) NaOH  
 
Procedure: 
1. Remove medium and rinse cell layers with PBS.  
2. Fix cells with ice cold 70% ethanol for 1 hour at 4°C, or Fix cells in 
10% neutral buffered formalin for 5-10 minutes.  
3. Rinse with distilled water and air dry.  
4. Add 1ml of 40mM ARS (pH 4.1) per well and incubate at room 
temperature for 20 min with gentle shaking.  
5. Aspirate the unincorporated dye from each well.  
6. Wash each well 4X with 1ml dH2O while shaking for 5 min.  
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7. Remove excess water by leaving the plates at an angle for 2 min. 
Aspirate again and then store plates at -20°C.  
8. Stained monolayers are visualized by phase microscopy using an 
inverted microscope.  
9. For quantification of staining: add 800ul 10% (v/v) acetic acid to 
each well and incubate at room temperature for 30 min with 
shaking.  
10. Scrape cell from plate and transfer (with 10% (v/v) acetic acid) to a 
1.5ml microcentrifuge tube.  
11. Vortex for 30 sec.  
12. Overlay slurry with 500ul mineral oil. 
13. Heat to 85°C for 10 min, and transfer to ice for 5 min. Tubes should 
not be opened until fully cooled.  
14. Centrifuge at 20,000g for 15min.  
15. Remove 500ul of supernatant and add to new 1.5ml microcentrifuge 
tube.  
16. Add 200ul of 10% (v/v) ammonium hydroxide to neutralize.  
17. Aliquot 150 µl in duplicate or triplicate into a 96 well plate (Opaque 
walled transparent bottom plates). Read at 405nm. 
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Tube Standard (Concentration of 
Alizarin Red S stain) 
Alizarin Red 
Stain 
Solubilization 
Solution 
A 1 mg/ml 50 ul Stock  950 ul 
B 500 ug/ml 500 ul of A 500 ul 
C 250 ug/ml 400 ul of B 500 ul 
D 100 ug/ml 500 ul of C 600 ul 
E 50 ug/ml 500 ul of D 500 ul 
F 25 ug/ml 500 ul of E 500 ul 
G 10 ug/ml 400 ul of F 600 ul 
H 5 ug/ml 500 ul of G 500 ul 
I 0 ug/ml 0 ul 500 ul 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  A-3. Alizarin Red Standard Curve.  
 
  
 
 
 
240
(f) Crystal Violet Proliferation Assay. 
 
This is a simple assay useful for obtaining information about the relative 
density of cells adhering to multi-well cluster dishes. The dye in this assay, 
crystal violet, stains DNA. Upon solubilization, the amount of dye taken up 
by the monolayer can be quantitated in a spectrophotometer or plate reader.  
Procedure  
1. Remove culture medium from wells.  
2. Wash plate gently with PBS warmed at least to room temperature: 
(0.2ml/96 well plate, 0.5ml/48 well plate, 1ml/24 well plate, 2ml/12 
well plate, or 3ml/ 6 well plate) 
3. Carefully remove PBS and fix in ethanol by adding 95% ethanol 
per well and incubate at RT for 10 min. (50µl/96 well plate, 
100µl/48 well plate, 200µl/24 well plate, 500µl/12 well plate, 
750µl/6 well plate) 
4. Add crystal violet solution. Incubate 10 min at room temperature 
(50µl/96 well plate, 100µl/48 well plate, 200µl/24 well plate, 
500µl/12 well plate, 750µl/6 well plate).  
5. Wash wells extensively with dH2O to remove excess stain.   
6. Add 1% SDS or 0.2% Triton X in dH2O and agitate. (50µl/96 well 
plate, 100µl/48 well plate, 200µl/24 well plate, 500µl/12 well plate, 
750µl/6 well plate). 
7. Read absorbance of each well at 570nm. 
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(g) Quantitative Reverse Transcriptase RT-PCR 
 
RNA extraction with TRIzol 
1. Rinse cell monolayer with ice cold PBS once.  
2. (homogenization) Lyse cells directly in a culture dish by adding 1 
ml of TRIZOL reagent per 3.5 cm diameter dish and scrapping with 
cell scrapper. The amount of TRIZOL reagent added is based on the 
area of the culture dish (1ml per 10cm2) and not on the number of 
cells present. An insufficient amount of TRIZOL reagent may result 
in DNA contamination of the isolated RNA. 
3. Pass the cell lysate several times through a pipette and vortex 
thoroughly.  
4. Incubate the homogenized sample for 5 minutes at RT to permit the 
complete dissociation of nucleoprotein complexes.  
5. Centrifuge to remove cell debris and transfer the supernatant to new 
tube. It is recommended to freeze in Trizol at least 1 hour at -80°C 
after incubating at RT. This is a potential stopping point. Samples 
can be kept at -80°C indefinitely because RNA is stable in Trizol 
and TrIzol inactivates after 5 minutes. Thaw samples on ice. 
6. (Phase Separation) Add 0.2ml of chloroform per 1 ml of TRIZOL 
reagent. Cap sample tubes securely.  
7. Vortex samples vigorously for 15 seconds and incubate at RT for 2 
to 3 minutes. 
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8. Centrifuge the samples at no more than 12,000 x g for 15 minutes at 
2-8°C.  
9. Work on ice from this point on. Following centrifugation, the 
mixture separates into lower red, phenol chloroform phase, an 
interphase, and a colorless aqueous phase. RNA remains 
exclusively in the aqueous phase carefully without disturbing the 
interphase into a fresh tube. Leave behind a small amount of clear 
phase; do NOT pick up any pink phenol-chloroform phase; use 
pipette tips with a large hole to prevent this from happening. 
Measure the volume of the aqueous phase. (The volume of the 
aqueous phase is about 60% of the volume of TRIZOL reagent used 
for homogenization). Incubate 1+hr at -80°C. This is another 
potential indefinite stopping point.  
10. (RNA Precipitation) Precipitate the RNA from aqueous phase by 
mixing with isopropyl alcohol (IPA). Use 0.5ml of IPA per 1ml of 
TRIZOL reagent used for the initial homogenization. 
11. Incubate samples at 15 to 30°C for 10 minutes and centrifuge for no 
more than 12,000 x g for 10 minutes at 2 to 4°C. The RNA 
precipitate, often invisible before centrifugation, forms a gel-like 
pellet on the side and bottom of the tube.  
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12. (RNA Wash) Remove the supernatant completely. Wash the RNA 
pellet once with 75% ethanol. Adding at least 1ml of 75% ethanol 
per 1 ml of TRIZOL Reagent used for the initial homogenization.  
13. Mix the samples by vortexing and centrifuge at no more than 7,500 
x g for 5 minutes 2 to 8°C. Repeat above washing procedure once. 
Remove all leftover ethanol.  
14. Air-dry or vacuum dry or vacuum dry RNA pellet for 5-10 minutes. 
So not dry the RNA pellet by centrifuge under vacuum. It is 
important not to let the RNA pellet dry completely as this will 
greatly decrease its solubility.  
15. Partially dissolved RNA samples have an A260/A280 ration <1.6. 
Dissolve RNA in DEPC-treated water by passing solution a few 
times through a pipette tip.  
16. The pellet should be resuspended in 12.5-15µl of Nuclease-free 
water/DEPC-treated water. Incubate at RT for 2-3 min then place 
on ice.  
17. (RNA Quantification) Spectrophotometric analysis: dilute 1µl of 
RNA with 39µl of DEPC-treated water (1:40 dilution). Using 10µl 
microcuvette, take OD at 260nm and 280n, to determine a sample 
concentration and purity. The A260/A280 ratio should be above 
1.6. Apply the convention that 1 OD at 260 equals 40µg/ml RNA. 
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Nanodrop quantification: quantify total RNA using a Nanodrop. 
Store total RNA indefinitely at -80°C.  
 
 
